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ABSTRACT OF DISSERTATION 
 
 
 
 
NICOTINIC RECEPTOR MODULATION OF DOPAMINE TRANSPORTERS 
 
 
The current project examined the ability of nicotine to modulate dopamine 
transporter (DAT) function.  Initial experiments determined the dose-response for 
nicotine to modulate dopamine (DA) clearance in rat striatum and medial 
prefrontal cortex (MPFC) using in vivo voltammetry and determined if this effect 
was mediated by nicotinic receptors (nAChRs).  In both striatum and MPFC, 
nicotine increased DA clearance in a mecamylamine-sensitive manner, indicating 
nAChR-mediation.  The effect of acute nornicotine on DAT function was also 
determined.  In contrast to nicotine, nornicotine in a dose-related manner 
decreased striatal DA clearance in a mecamylamine-sensitive manner, indicating 
nAChR mediation.  To determine if tolerance developed to the nicotine effect 
nicotine, separate groups of rats were injected once daily for 5 days with nicotine 
or saline.  DA clearance in striatum and MPFC was determined 24 hrs after the 
last injection.  Nicotine increased DA clearance only 10-15% in the group 
repeatedly administered nicotine, demonstrating that tolerance developed.  To 
determine if nicotine altered striatal DAT efficiency, following nicotine injection, 
  
 
DAT density and maximal velocity of [3H]DA uptake was determined using 
[3H]GBR12935 binding and saturation analysis of [3H]DA uptake in rat striatum, 
respectively.  Nicotine did not alter the Bmax or Kd of maximal binding of 
[3H]GBR12935 binding.  However, an increase in Vmax was observed at 10 and 
40 min following nicotine injection, suggesting that nicotine increases DAT 
efficiency.  To determine if systemic nicotine enhanced DAT function via an 
action at nAChRs on striatal DA terminals, [3H]DA uptake was determined in 
striatum in vitro in the absence or presence of nicotine in the buffer.  Nicotine did 
not alter the Vmax for [3H]DA uptake in vitro, suggesting that the nicotine-induced 
increase in DAT function observed in vivo is mediated by nAChRs on DA cell 
bodies or another site which indirectly alters DAT function.  To determine if the 
increase in DAT efficiency was due to increased surface expression of striatal 
DAT, biotinylation and Western blot analyses were performed.  Nicotine did not 
alter striatal DAT, suggesting that the nicotine-induced increase in DA clearance 
in vivo and DAT efficiency in vitro is not the result of increased trafficking of this 
protein to the cell surface.    
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Chapter One 
 
Introduction and Background 
 
I.  Drug Abuse and Reward 
The brain is a complex organ made up of various structures that interact 
with each other through neuronal networks.  Drugs of abuse have many different 
effects on neuronal circuitry and can modulate how information is carried 
throughout the brain.  Psychostimulants, such as nicotine, cocaine and 
amphetamine, modulate two primary circuitry pathways, the mesolimbic and 
nigrostriatal pathways.  Figure 1 represents a sagittal section through a rat brain.  
The mesolimbic system has cell bodies in the ventral tegmental area (VTA) and 
sends projections to the nucleus accumbens and the medial prefrontal cortex 
(MPFC).  The nigrostriatal pathway has cell bodies in the substantia nigra (SN) 
and sends projections to the striatum.  The mesolimbic and nigrostriatal 
pathways are dopaminergic pathways, i.e., dopamine (DA) is the 
neurotransmitter contained in the neurons in this pathway.   
 
Previous research on the neurobiology of reward and drug addiction has 
focused on the mesocorticolimbic and nigrostriatal DA systems, emphasizing the 
role of the nucleus accumbens, MPFC and striatum.  The accumbens shell, 
which is innervated by dopaminergic projections from the VTA, and its associated 
neurocircuitry are believed to encode primary appetitive stimuli associated with 
unconditioned drug reward (Wise and Bozarth, 1987; Robbins and Everitt, 1996; 
Bardo, 1998; Koob, 1999; Di Chiara, 2000; Kelley and Berridge, 2002), including 
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reward produced by nicotine (Fibiger and Phillips, 1987; Corrigall et al., 1992, 
1994; Balfour and Benwell, 1993; Mansvelder and McGehee, 2002; Mathieu-Kia 
et al., 2002).  More recently, focus has been placed on the involvement of the 
striatum and MPFC in reward and reinforcement.  The MPFC, which includes the 
anterior cingulate cortex and is innervated by dopaminergic projections from the 
VTA, is believed to encode secondary conditioned stimuli associated with 
environmental cues paired with drug, leading to reward expectancy, which is 
recognized as important to the process of addiction and relapse to drug use 
(Berridge and Robinson, 1998; Shima and Tanji, 1998; Kelley, 1999; Di Chiara, 
2000; Kelley and Berridge, 2002; Peoples, 2002; Cohen et al., 2004; Di Chiara et 
al., 2004; Rose and Behm, 2004; Brody et al., 2004).  Integration of the 
motivational information from the MPFC occurs at least in part in striatal 
cholinergic neurons, which are innervated by dopaminergic projections from the 
substantia nigra, leading to the initiation and execution of movement in reward 
expectancy and detection of reward (Martin-Soelch et al., 2001). 
 
 Ia.  Animal Models of Reward 
According to the DSM-IV, drug abuse is defined as an individual who uses 
a drug despite the knowledge that that drug may be harmful to them.  Abuse is 
different from drug dependence/addiction in that an addicted individual has an 
obsessive preoccupation with a drug, i.e., the drug is the most important 
relationship the individual has.  Animal models have been developed to examine 
the abusive or rewarding properties of drugs.  Conditioned place preference is a 
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paradigm in which an environmental stimuli is paired with a reward such as food 
or drug.  This results in a preference of the animal for the environment that was 
paired with the reward, even in the absence of the reward.  Therefore, one can 
determine the rewarding properties of a drug by evaluating the animal’s 
preference for the environment associated with reward.  Drug self-administration 
is the “gold-standard” for measuring the rewarding properties of a drug.  In this 
paradigm, animals are trained to press a lever to receive a drug reward.  Fixed-
ratio (FR) self-administration is a reinforcement schedule that will vary the 
number of lever presses required to receive a reward.  For example, an FR1 
means that one lever press will result in one infusion of drug whereas an FR5 
schedule requires 5 lever presses to receive one infusion of drug. The number of 
lever presses can be increased within a session (progressive ratio schedule) 
which will require the animal to work harder to receive the reward.  The point at 
which an animal will no longer increase the number of bar presses to receive 
drug is known as the break point, indicating that the level that the animal will 
work for the drug, indicating the amount of reward associated with it.   
 
II.   Diseases and Disorders  
Tobacco smoking and depressive disorders are highly comorbid 
(Glassman et al., 1993; Covey et al., 1997; Covey, 1999; Pomerleau et al., 2000; 
Cardenas et al., 2002).   Nicotine has been reported to have antidepressant 
properties in depressed individuals (Glassman, 1993; Salin-Pascual and 
Drucker-Colin, 1998; Balfour and Ridley, 2000; Picciotto et al., 2002) and in 
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animal models of depression (Tizabi et al., 1999; Vazquez-Palacios et al., 2004).  
Such evidence has led to the self-medication hypothesis of nicotine dependence, 
such that individuals may use tobacco, at least in part, to ameliorate depression 
(Markou et al., 1998; Balfour and Ridley, 2000; Hughes et al., 2003; Popik et al., 
2003).  The self-medication hypothesis is further strengthened by the observation 
that antidepressants, bupropion and perhaps others, serve as an efficacious 
smoking cessation pharmacotherapies (Hurt et al., 1997; Jorenby et al., 1999; 
Cryan et al., 2003a,b; Ferry and Johnston, 2003; Haustein, 2003; Richmond and 
Zwar, 2003; Hall et al., 2004), although the mechanism of action in this regard is 
not clear.  Clinical depression is generally accepted as associated with 
dysfunction of monoaminergic neurotransmitter systems.  Most effective 
antidepressants inhibit monoamine transporter function, increasing the 
extracellular concentrations of DA, norepinephrine and/or serotonin.  Many 
antidepressants, including bupropion (Wellbutrin®), inhibit monoamine 
transporters, but also act as nicotinic receptor antagonists (Richelson and 
Pfenning; 1984; Nomikos et al., 1989; Ascher et al., 1995; Fryer and Lukas, 
1999; Slemmer et al., 2000; Li et al., 2002; Miller et al., 2002a,b; Gumilar et al., 
2003; Damaj et al., 2004).  Smokers treated with bupropion while trying to quit 
smoking have been shown to have a decrease in symptoms of depression 
(Lerman et al., 2004).   
 
The use of nicotine replacement as a cessation therapy is based on 
activation of nicotinic receptors resulting in DA release, and potentially nicotine’s 
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ability to modulate DAT function. Treatment of smokers with a transdermal 
nicotine patch has been shown to increase positive affect, whereas nicotine 
administration by a nasal spray did not have any impact on affect (Strasser et al., 
2005), which demonstrates the importance of not only type of treatment but route 
of administration.  Furthermore, the presence of a DAT polymorphism (SLC6A3), 
in cigarette smokers, has been associated with an increase in stress-induced 
craving associated with smoking (Erblich et al., 2004).  That is exposure to a 
stressor results in an increased craving for a cigarette, and the stress-induced 
craving is higher in smokers with the SLC6A3 DAT polymorphism.  One 
possibility is that both transporters and nicotinic receptors contribute to 
antidepressant alleviation of depression as well as to smoking cessation.  
Understanding functional interactions between DAT and nicotinic receptors may 
provide a mechanistic basis and more thorough comprehension of the 
relationship between depression and nicotine dependence.   
 
A number of neurological diseases result in an alteration in the number of 
nicotinic receptors in striatum and SN, e.g., Parkinson’s disease and 
schizophrenia.  In Parkinson’s disease, there is a selective loss of nigrostriatal 
DA neurons with a concomitant loss of presynaptic nicotinic receptors on DA 
nerve terminals in striatum (Wonnacott et al., 1997).  In post mortem striatal 
tissue from Parkinson’s patients, there is a decrease in the number of 
[3H]nicotine binding sites (Court et al., 2000; Guan et al., 2002).  Furthermore, a 
decrease in the number of α3/α6 nicotinic receptors in monkey brain has been 
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shown after nigrostriatal damage (McCallum et al., 2005), as well as a loss of 
nicotine binding in the substantia nigra (Perry et al., 1995).  Following chronic 
tobacco use in humans, there is an increase in the number of nicotine binding 
sites in the brain (Perry et al., 1999).  Furthermore, people who smoke tobacco 
are reported to have a lower incidence of Parkinson’s disease (Morens et al., 
1995; Baron, 1986; Gorell et al., 1999; Quik and Kulak, 2002).  Both tobacco 
smoke and nicotine have been shown to be protective against MPTP 
neurotoxicity, which is an animal model for Parkinson’s (Parain et al., 2003).  
Therefore, therapies that increase the number of nicotine binding sites or 
nicotinic receptors may be beneficial in the treatment of Parkinson’s disease.   
 
Schizophrenic patients have a higher incidence of tobacco smoking 
compared to the general population (Hughes et al., 1986; Lohr and Flynn, 1992; 
Dalack et al., 1998; Esterberg and Compton, 2005).  A lack of sensory gating is 
observed in schizophrenics and this may involve desensitization of nicotinic 
receptors (Griffith et al., 1998).  In striatum, nicotine binding sites are increased 
in schizophrenic patients (Court et al., 2000).  Interestingly, hypoactivity is 
observed in the dopaminergic neurons in prefrontal cortex in schizophrenic 
patients (Davis et al., 1991), suggesting that different brain regions and 
potentially different nicotinic receptor subtypes in these brain regions may be 
involved in schizophrenia.  In schizophrenic smokers, nicotine administration 
improved delayed recognition memory, visuospatial working memory and 
continuous performance test scores (Myers et al., 2004; Sacco et al., 2005).  
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More recently, schizophrenic patients with a 113 base pair allele of the α7 
nicotinic receptor gene were found to be more likely to smoke and smoke heavily 
(De Luca et al., 2004). In addition, a polymorphism in the α7 nicotinic receptor 
gene (CHRNA7) was found to be linked to the auditory gating deficit common in 
the schizophrenic patient population (Freedman et al., 1997).  Consistent with its 
proposed involvement in sensory gating, selective α7 nicotinic receptor agonists 
and partial agonists such as tropisetron have been shown to restore auditory 
gating deficits in rodent models of schizophrenia (Stevens et al., 1998; O'Neill et 
al., 2003; Hajós et al., 2005; Koike et al., 2005; Siegel et al., 2005).  Not only 
nicotinic receptors, but also inhibition of monoamine transporters by bupropion 
has been shown to improve the auditory gating deficits in a mouse model of 
schizophrenia (Siegel et al., 2005). 
 
III.  Dopamine 
Dopamine (Figure 2) is a neurotransmitter in the central nervous system.   
Figure 3 shows a schematic representation of a DA nerve terminal.  The first step 
in the synthesis of DA is the conversion of tyrosine to 3, 4-
dihydroxyphenylalanine (DOPA) in the DA nerve terminal by the enzyme tyrosine 
hydroxylase.  Tyrosine is an amino acid that is transported across the blood brain 
barrier and then into DA neurons by amino acid transporters.  DOPA is then 
converted to DA by DOPA decarboxylase in the nerve terminal. Tyrosine 
hydroxylase is the rate-limiting enzyme of DA synthesis.  Once DA is 
synthesized, it can be stored in synaptic vesicles in preparation for release from 
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the terminal into the synapse.  Following stimulation and depolarization of the 
nerve terminal, synaptic vesicles fuse to the synaptic membrane and release DA 
into the synaptic cleft by a process called exocytosis.  After release, DA can be 
metabolized by catechol-O-methyl transferase or monoamine oxidase in the 
synapse, bind to presynaptic D2 DA autoreceptors located presynaptically, 
activate postsynaptic D1 and D2 DA receptors, or be transported back into the 
terminal by the DA transporter (DAT; Cooper et al., 2003).  D1 and D2 DA 
receptors are the most abundant DA receptors in striatum.  The D1 DA receptor 
has one known subtype, D5, which acts similarly to D1 in that it stimulates 
adenylate cyclase activity, but D5 has a 10-fold higher affinity for DA than does 
D1.  D1 is located throughout the brain including striatum and cortex.  However, 
D1 is more abundant in striatum than cortex.  D5 is also only located in 
hippocampus, thalamus and hypothalamus.  The D2 DA receptor family also has 
two receptor subtypes, D3 and D4.  Similar to D2 receptors, D3 and D4 both 
inhibit adenylate cyclase activity.  However, D3 has a 100-fold higher affinity for 
the DA receptor agonist quinpirol, and D4 has an order of magnitude higher 
affinity for the atypical antipsychotics such as clozapine.  D2 is located in both 
striatum and cortex and is also more abundant in striatum than cortex.  Both D3 
and D4 receptors have very little expression in the striatum or MPFC.  Once back 
inside the terminal, DA can be re-stored in vesicles or metabolized by 
monoamine oxidase located in the cytoplasm to provide the metabolite 
dihydroxyphenyacetic acid (DOPAC).   
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In smokers, nicotine dose-dependently increases neuronal activity in 
cingulate cortex, MPFC, striatum and accumbens assessed using functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET) 
(Stein et al., 1998; Barrett et al., 2004).  Recently, in an fMRI study examining 
decision-making and monetary reward, activity in the striatum was correlated with 
short-term reward (Haruno et al., 2004).  These data suggest that the striatum is 
heavily involved in reward-based behavioral learning.  Changes in striatal neural 
activity and blood flow have been observed following rewarding experiences in 
studies using humans (Delgado et al., 2000; Knutson et al., 2000; Elliot et al., 
2003; O’Doherty et al., 2004; Tanaka et al., 2004; Tricomi et al., 2004), monkeys 
(Kawagoe et al., 2003; Watanabe et al., 2003; Yamada et al., 2004), and rats 
(Schmitzer-Torbert and Redish, 2004).  The changes in neural activity may be 
related to the magnitude of reward that is received (Cromwell and Schultz, 2003).  
Recently, injection of a kappa-opioid antagonist into mouse striatum was shown 
to result in a decrease in cocaine-induced conditioned place preference, also 
indicating the involvement of the striatum in the rewarding properties of cocaine 
(Zhang et al., 2004).   
 
IV.   The Dopamine Transporter (DAT) 
Brain monoamine transporters are expressed almost exclusively in 
neurons that contain their cognate transmitter.  Immunolocalization studies reveal 
the presence of DAT, the norepinephrine transporter and the serotonin 
transporter on their respective cell bodies, axons and terminals (Nirenberg et al., 
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1996; Hersch et al. 1997; Hoffman et al., 1998; Sesack et al. 1998; Schroeter et 
al., 2000; Mengual and Pickel, 2004).  As shown in Figure 4, DAT is a twelve 
transmembrane protein with both the carboxy and amino termini located 
intracellularly.  Translocation of DA by DAT across the membrane is coupled with 
the cotransport of two Na+ ions and one Cl- ion down their electrochemical 
gradients, generating a small inward current (Kanner and Schuldiner, 1987; 
Rudnick and Clark, 1993).  Moreover, the DA neuron membrane potential 
influences DAT function, such that hyperpolarization increases the velocity of DA 
transport by DAT and depolarization decreases DA transport velocity (Sonders et 
al., 1997).   DA is also removed from the extracellular space by metabolism and 
diffusion, the latter factor playing a larger role in brain regions with sparse 
dopaminergic innervation and lower DAT density, such as the MPFC (Sesack et 
al., 1998).  These transporter proteins are located presynaptically and may be in 
close apposition to nicotinic receptors, suggesting the potential for their functional 
interaction.  Psychostimulants and antidepressants interact with these 
transporters (Barker and Blakely, 1996).  For example, amphetamine reverses 
monoamines transporters evoking monoamine release, whereas cocaine and 
antidepressants inhibit transporter function.  Since nicotine is a psychostimulant 
with antidepressant properties, it is reasonable to hypothesize that nicotine may 
interact with or modulate transporter function. 
 
DAT is a major pharmacological target for psychostimulant action.  
Psychostimulants inhibit DAT function and increase synaptic DA concentrations 
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(Horn 1990).  Cocaine and amphetamine alter the expression of cell surface DAT 
protein (Saunders et al. 2000; Daws et al. 2002; Little et al. 2002).  In cell 
expression systems, cocaine increases cell surface expression of DAT, whereas 
amphetamine decreases DAT localization on the cell surface.  The ability of 
nicotine to modulate the cell-surface expression of DAT has not been examined.  
As many psychostimulants alter DAT localization as their mechanism of action, 
studies examining the ability of nicotine to modulate DAT localization are 
warranted.  DAT is regulated by activation of protein kinase C, which decreases 
the maximal velocity (Vmax) of DA uptake and decreases DAT cell surface 
expression in cell expression systems and in brain (Melikian et al. 1994; 
Copeland et al. 1996; Melikian et al. 1996; Huff et al. 1997; Vaughan et al. 1997; 
Zhang et al. 1997; Pristupa et al. 1998; Daniels and Amara 1999; Melikian and 
Buckley 1999; Chi and Reith 2003).  Little is known about the effect of nicotine on 
transporter function and trafficking, as well as the underlying cellular mechanisms 
regulating these processes.   
 
           IVa.    DAT Regulation through Trafficking  
Studies suggest that monoamine transporters are regulated by several 
mechanisms, including constitutive internalization and recycling (i.e., trafficking), 
involving transporter phosphorylation and protein-protein interactions (Zahniser 
and Doolen, 2001; Kahlig and Galli, 2003; Loder and Melikian, 2003; Torres et 
al., 2003; Melikian, 2004).  Psychostimulants and second messengers alter 
phosphorylation, function and trafficking of these transporters (Gnegy et al., 
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2004; Kahlig et al., 2004).  For example, DAT surface expression in cell lines is 
acutely sensitive to amphetamine and cocaine, which decrease and increase 
DAT surface levels, respectively (Saunders et al., 2000; Daws et al., 2002; Little 
et al., 2002; Zahniser and Sorkin 2004).  Protein kinase C activation in native 
preparations and cell systems decreases surface distribution of DAT (Vaughan et 
al., 1997; Zhang et al., 1997; Zhu et al., 1997; Daniels and Amara, 1999; 
Melikian and Buckley, 1999; Loder and Melikian, 2003), whereas protein kinase 
A and calcium-calmodulin kinase II activation results in upregulation of DAT at 
the cell surface (Page et al., 2004).  Transporters undergo internalization and 
recycling, which may involve dynamin-clathrin mediated pathways and multiple 
protein-protein interactions, such as interaction with syntaxin-1A, PP2A, PICK1, 
ERK and synuclein (Zahniser and Doolen, 2001; Torres et al., 2003; Lee et al. 
2004; Melikian, 2004; Valjent et al., 2005).  Furthermore, psychostimulants can 
modulate DAT function by phosphorylation of DAT.  For example, amphetamine 
activates protein kinase C and mitogen activated protein kinase which enhances 
amphetamine stimulated DA release through DAT (Park et al., 2003; Johnson et 
al., 2005).  DAT can also be modulated by interneuronal signaling such as nitric 
oxide (Kiss et al., 2004), which can inhibit DAT function.  Nitric oxide is able to 
diffuse between different neurons and thus provides a mechanism for other 
neurotransmitter systems to modulate DAT. 
 
  
13 
V.   Nicotine 
Nicotine (Figure 2) is the most common drug of abuse and tobacco 
dependence the leading preventable cause of death in the USA (Surgeon 
General’s Report, 1988; Jaffe, 1990; USDHS, 2001).  Despite the deleterious 
effects of tobacco, ~23% of the US population continues to use tobacco 
(Trosclair et al., 2002).  About 70% of smokers want to quit, ~40% make an 
attempt to quit, however, only ~5% are successful at cessation for a period of 3-
12 months (Trosclair et al., 2002).  Nicotine, the most abundant alkaloid in 
tobacco (Bush et al., 1993), has intrinsic rewarding properties, which are 
believed to be responsible for tobacco dependence (Koob, 1992; Corrigall et al., 
1992; Stolerman and Jarvis, 1995; Di Chiara, 2000; Balfour, 2002; Mathieu-Kia et 
al., 2002; Garrett et al., 2003).  Volunteers who habitually smoke and are tobacco 
deprived will self-administer nicotine (Henningfield and Goldberg, 1983; Harvey 
et al., 2004; Johnson et al., 2004).  Indicative of its reinforcing properties, nicotine 
is self-administered in animal models using both fixed-ratio schedules (Goldberg 
et al., 1981; Henningfield and Goldberg, 1983; Cox et al., 1984; Corrigall and 
Coen, 1989; Corrigall et al., 1992, 1994; Sannerud et al., 1994; Donny et al., 
1998, 2003; Rose and Corrigall, 1997; Shoaib et al., 1997; Valentine et al., 1997; 
Rasmussen and Swedberg, 1998; Caggiula et al., 2001, 2002; Suto et al., 2001; 
LeSage et al., 2002, 2003; Fu et al., 2003; Paterson et al., 2004) and 
progressive-ratio schedules (Donny et al., 1999; Bruijnzeel and Markou, 2003).  
While the maintenance of smoking is believed to be due to the reinforcing 
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properties of nicotine, it is also possible that people continue to smoke to avoid 
the withdrawal symptoms instead of for reinforcement. 
 
Some of the rewarding properties of nicotine are considered beneficial 
such as mood elevation, arousal and learning and memory enhancement 
(Clarke, 1987; Pomerleau and Pomerleau, 1992).  The mechanisms underlying 
the reinforcing properties of nicotine are not well understood, but are important 
for understanding the initiation and maintenance of tobacco smoking behavior.  
Although the mechanisms underlying nicotine’s reinforcing properties are not well 
understood, the mesocorticolimbic and nigrostriatal DA systems are believed to 
be involved.  For example, activation of the immediate early gene, c-fos, in the 
anterior cingulate cortex, nucleus accumbens and striatum has been 
demonstrated in nicotine self-administering rats (Pagliusi et al., 1996; Merlo-Pich 
et al., 1997).  Additionally, cortical c-fos has been shown to be activated following 
exposure to environmental cues associated with repeated nicotine administration 
(Schroeder et al., 2001).  The latter results from animal studies are consistent 
with findings showing that in tobacco smokers, nicotine dose-dependently 
increases neuronal activity in the cingulate cortex, frontal lobe and nucleus 
accumbens, as determined using functional MRI (Stein et al., 1998).   
 
Elucidating the mechanism of nicotine action and determining the effects 
of chronic nicotine administration are of importance in understanding the initiation 
and maintenance of tobacco smoking behavior and in overcoming the difficulties 
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habitual smokers experience in extinguishing this behavior.  As previously 
discussed, evidence for the reinforcing properties of nicotine includes studies 
reporting nicotine self-administration by many species on various reinforcement 
schedules (Goldberg et al., 1981; Henningfield and Goldberg, 1983; Cox et al., 
1984; Corrigall et al., 1992, 1994; Sannerud et al., 1994; Donny et al., 1996) and 
nicotine-induced conditioned place preference in rats (Fudala et al., 1985; Shoaib 
et al., 1994; Risinger and Oakes, 1995).  Studies clearly indicate that under an 
FR5 schedule as well as when nicotine is given to an animal contingently, 
nicotine is avidly self-administered by rats (Corrigall and Coen, 1989; Corrigall et 
al., 1992, 1994; Donny et al., 1996).  Also, nicotine self-administration, both 
fixed- and progressive-ratio, is decreased in animals and humans by 
mecamylamine and other nicotinic receptor antagonists indicating nicotinic 
receptor involvement (Meltzer and Rosecrans, 1981; Stolerman et al., 1973, 
1984; Corrigall et al., 1994a; Rose et al., 1994; Mansbach et al., 2000; Shoaib et 
al., 1997, 2002, 2003; Markou and Paterson, 2001; Glick et al., 2002; 
Mansvelder and McGehee, 2002; Bruijnzeel and Markou, 2003; Rauhut et al., 
2002, 2003).   
 
Concomitant with the intrinsic reinforcing effects of nicotine, there is strong 
evidence indicating that nicotine stimulates locomotor behavior.  In drug-naïve 
rats, acute nicotine administration produces an initial depressant effect on activity 
followed by hyperactivity lasting 1 hour or longer (Clarke and Kumar, 1983; 
Clarke, 1990).  With chronic nicotine administration, tolerance develops to the 
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transient hypoactive phase (Stolerman et al., 1973, 1974; Collins et al., 1988, 
1990; Martin et al., 1990), whereas sensitization develops with respect to the 
hyperactive phase (Clarke and Kumar, 1983; Ksir et al., 1985, 1987; Clarke et 
al., 1988; Fung and Lau, 1988; Schoaib and Stolerman, 1992; Benwell and 
Balfour, 1992; Ksir, 1994; Stolerman et al., 1995).  Mecamylamine blocks both 
the hypoactive and hyperactive phases following acute nicotine injection and also 
blocks the development of behavioral sensitization occurring following chronic 
nicotine administration (Clarke and Kumar, 1983). Drugs of abuse, including 
nicotine, amphetamine and cocaine, have been suggested to produce their 
locomotor stimulant and reinforcing effects by activating the nigrostriatal and 
mesolimbic DA systems, respectively (Fibiger and Phillips, 1987; Corrigall et al., 
1992, 1994; Balfour and Benwell, 1993).  This pathway regulates cognitive and 
emotional behaviors (Simon et al., 1980) and is particularly sensitive to the acute 
effects of psychostimulants (Roberts and Koob, 1983; Wise and Bozarth, 1987; 
Self and Nestler, 1995). Furthermore, chronic nicotine exposure increases the 
maximal binding (Bmax) of nicotinic receptors (Collins et al., 1990; Bhat et al., 
1991, 1994; Marks et al., 1992; Sanderson et al., 1993), demonstrating nicotine-
induced upregulation of nicotinic receptors.  
 
VI.  Nicotinic Receptors 
Extracellular DA concentrations are increased following nicotine 
stimulation of nicotinic acetylcholine receptors in the cell body and terminal 
regions of the mesocorticolimbic and nigrostriatal systems.  Nicotinic receptors 
  
17 
are a family of ligand-gated transmembrane ion channels that are activated 
physiologically by acetylcholine (Figure 2) and pharmacologically by nicotine.  
Both acetylcholine and nicotine activate all known nicotinic receptor subtypes, 
whereas mecamylamine noncompetitively inhibits all known subtypes (Varanda 
et al., 1985; Loiacono et al., 1993; Peng et al., 1994).  Mecamylamine (Figure 2) 
is a nonselective, noncompetitive nicotinic receptor antagonist that blocks the 
opening of nicotinic receptors by binding in the pore of the receptor (Varanda et 
al., 1985; Loiacono et al., 1993; Peng et al., 1994).  Nonselective antagonists are 
not specific for a certain subtype of receptor, in the case of mecamylamine, it 
inhibits all nicotinic receptor subtypes.  Noncompetitive antagonists are 
antagonists that do not compete for the agonist binding site on the receptor, but 
act at an allosteric site on the protein removed from the agonist recognition site.  
Therefore, noncompetitive inhibition cannot be overcome by increasing the 
agonist concentration.  While much is known about the function of nicotinic 
receptors, the specific subunit composition of native nicotinic receptors in brain 
has not been elucidated.  Therefore, native nicotinic receptors in brain are only 
putatively designated.   
 
Once these receptors are activated, they undergo a transition from the 
closed, resting conformation to an open state, conducting cations (Na+, K+, Ca++) 
through the channel down their electrochemical gradients, causing rapid 
depolarization of the target cell (McGehee and Role, 1995; Role and Berg, 1996; 
Alkondon et al., 1997; Dani et al., 2001).  Heteropentameric nicotinic receptors 
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require two molecules of acetylcholine or nicotine to bind in order for the ion 
channel to open, whereas, homopentamers can bind up to five molecules of 
acetylcholine or nicotine.  
 
As shown in Figure 5, nicotinic receptors are pentameric structures 
composed of nine different alpha (α2 - α10) and three different beta (β2 – β4) 
subunits, with a general stoichiometry of 2α and 3β (Luetje et al., 1990; Anand et 
al., 1991; Cooper et al., 1991; Deneris et al., 1991; Luetje and Patrick, 1991; 
Role, 1992; Sargent, 1993; Elgoyhen et al., 1994; McGehee and Role, 1995; 
Elgoyhen et al., 2001).  α7 nicotinic receptors are homopentamers thus 
containing 5 different α7 subunits.  Amino acid sequencing determined that 
nicotinic receptor subunits have four membrane spanning regions (M1-M4).  The 
M2 region from each of the five subunits is believed to form the wall of the pore in 
the assembled functional receptor (Galzi and Changeux, 1995).  Mutation of the 
M2 region has been shown to alter the Ca++ permeability of α7 nicotinic receptors 
(Bertrand et al., 1992).  The alpha subunits are identified by a pair of adjacent 
cysteine residues in the amino terminal domain, and are thought to be the 
agonist binding subunits (Jensen et al., 2005).  The beta subunit appears to be a 
codeterminant of the functional properties of the receptor (Cachelin and Rust, 
1995; Jensen et al., 2005).  While much is known about the function of nicotinic 
receptors, the specific subunit composition of native nicotinic receptors in brain 
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has not been elucidated.  Therefore, native nicotinic receptors in brain are only 
putatively designated (indcated by an asterisk).   
 
Hybridization cloning has revealed a surprising degree of subtype diversity 
among neuronal nicotinic receptors (Luetje et al., 1990; Luetje and Patrick, 1991; 
Deneris et al., 1991; Role, 1992; Sargent, 1993; Elgoyhen et al., 1994; McGehee 
and Role, 1995).  The α2, α3 and α4 subunits form functional receptors with 
either β2 or β4 when coexpressed in Xenopus oocytes.   In contrast, α7, α8 and 
α9 form functional homo-oligomers in oocytes (Couturier et al., 1990; Séquéla et 
al., 1993; Elgoyhen et al., 1994; Gerzanich et al., 1994; Peng et al., 1994; Briggs 
et al., 1995, 1998; Chavez-Noriega et al., 1997; Rothlin et al., 1999). α7 nicotinic 
receptors are highly permeable to Ca++ and have fast desensitization kinetics in 
the presence of agonist.  The α5, α6 and β3 subunits do not form functional 
receptors on their own or in combination with another single subunit in oocytes.  
However immunoprecipitation studies indicate that in vivo, α5 complexes with α3 
and β4, and more recently, that α3 combines with α4β2 and α4β4, suggesting 
that more than two different subunits may assemble together forming a receptor, 
which greatly increases the potential diversity of native nicotinic receptors 
(Conroy et al., 1992; Keyser et al., 1993; Vernallis et al., 1993; Ramirez-Lattore 
et al., 1996; Forsayeth et al., 1995; Wang et al., 1996; Campos-Caro et al., 1997; 
Forsayeth and Kobrin, 1997).  The functional significance of subtype diversity is 
still unknown; however, both native and cloned subtypes are pharmacologically 
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distinct in their response to both nicotinic agonists and antagonists (Luetje and 
Patrick, 1995; Luetje et al., 1990; Role, 1992; Luetje, 1993; Amar et al., 1993; 
Sargent, 1993; Cachelin and Rust, 1995; Decker, 1995). 
 
Heteromeric α4β2* nicotinic receptors are most abundant in brain, and 
second most abundant are homomeric α7* nicotinic receptors (Whiting and 
Lindstrom, 1986; Wada et al., 1989; Morris et al., 1990; Schoepfer et al., 1990; 
Anand et al., 1991; Flores et al., 1992; Lukas et al., 1999).  The subunits display 
different, but overlapping, patterns of expression in brain (e.g., β2 mRNA 
expression is prominent in the cerebellum, which exhibits no α4 hybridization; 
Wada et al., 1989).  mRNA for nine subunits (α2–α7 and β2–β4) of nicotinic 
receptors have been identified in SN and VTA dopaminergic neurons (Klink et al., 
2001, Zoli et al., 2002; Azam et al., 2002; Wooltorton et al., 2003), indicating that 
potentially a large number of heteromeric nicotinic receptor subtypes of 
pentameric structure may be expressed by these neurons.  
 
Nicotinic receptors are localized on presynaptic terminals and cell bodies 
of VTA and SN DA neurons (Schwartz et al., 1984; Clarke and Pert, 1985; 
McGehee and Role, 1995; Wonnacott, 1997; Quik et al., 2005); and evidence 
indicates that nicotinic receptor subtypes at cell body and terminal locations differ 
pharmacologically (Reuben et al., 2000; Champtiaux et al., 2003).  In striatal 
synaptosomes, nicotine has a lower affinity for nicotinic receptors than 
acetylcholine, and acetylcholine has equal affinity to epibatidine (a nicotinic 
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receptor agonist; Reuben et al., 2000).  However, in a dendrosomal preparation, 
nicotine has equal affinity to epibatidine (Reuben et al., 2000), suggesting that 
the nicotinic receptors in the terminal regions differ from those in the cell body 
regions.  Furthermore, α6β2* receptors have been shown to be located on DA 
terminals, whereas nonα6(α4β2)* receptors represent the majority of functional 
receptors on DA cell bodies (Champtiaux et al., 2003).  The selective α6 nicotinic 
receptor antagonist, α-conotoxin MII, has been shown to decrease nicotine-
evoked DA release, suggesting the involvement of the α6 subunit in nicotine-
evoked DA release (Salminen et al., 2004).  Both the α-conotoxin MII sensitive 
and resistant nicotinic receptor subtypes required the β2 subunit, however only 
the α-conotoxin MII sensitive subtype required the β3 subunit; whereas the α-
conotoxin MII resistant subtypes required α4.  These data suggest that the 
primary subtypes involved in DA release are the α6β3β2* and α4β2* subtypes 
(Salminen et al., 2004).  Importantly, α-conotoxin MII inhibits nicotine-evoked 
[3H]DA overflow by only 50%, implicating involvement of at least two different 
nicotinic receptor subtypes in this response (Zoli et al., 2002; Salminen et al., 
2004; Azam and McIntosh 2005).  It is likely that the difference in pharmacology 
between the nicotinic receptors in the cell body regions and the nerve terminal 
regions indicates that these receptors play different physiological roles. 
 
VII. Nicotine Modulation of DA System Function  
The pharmacological effects of nicotine are complex.  Nicotine can 
stimulate release of many different hormones including prolactin, vasopressin 
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and adrenocorticotropin (Cam et al., 1979; Conte-Devolx et al., 1981; Andersson 
et al., 1983; Mendelson et al., 2003; Sun et al., 2005).  Furthermore, nicotine 
increases blood pressure and heart rate (Benowitz et al., 1982; Benowitz et al., 
1988; Kadoya et al., 1994; Fattinger et al., 1997), and increases cerebral blood 
flow (Kodaira et al., 1992; Stein et al., 1998; Ernst et al., 2001; Rose et al., 2003; 
Domino et al., 2004).  To add to the complexity of nicotine dependence, genetics 
as well as socioeconomic status play important rolls in the development of 
dependence to cigarette smoking (Boomsma et al., 1994; Breslau et al., 2001; 
Berrettini and Lerman, 2005).   Nicotine not only releases DA as described 
above, but also releases other neurotransmitters such as norepinephrine and 
serotonin (Yoshida et al., 1980; Toth et al., 1992; Sharp and Matta, 1993; Yu and 
Wecker, 1994; Rao et al., 2003; Shearman et al., 2005).  While nicotine has 
many different effects, the current project will focus on the effects of nicotine on 
the DA system.    
 
Nicotine-evoked DA release is observed at nicotine concentrations (0.1-
0.8 μM) within the range found in smokers’ blood (Russell et al., 1980; Kogan et 
al., 1981).  Nicotine increases DA release in striatum, nucleus accumbens and 
MPFC in vitro (Giorguieff-Chesselet et al., 1979; Arqueros et al., 1978; Westfall, 
1974; Westfall et al., 1983; Chesselet, 1984; Rowell et al., 1987; Rapier et al., 
1988, 1990; Fung, 1989; Westfall et al., 1989; Izenwasser et al., 1991; Grady et 
al., 1992, 1994; Harsing et al., 1992; Rowell and Hillebrand, 1994; Schulz et al., 
1993; El-Bizri and Clarke, 1994; Rowell, 1995; Sacaan et al., 1995; Teng et al., 
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1997; Puttfarcken et al., 2000; Wonnacott et al., 2000; Zhou et al., 2001; Grady 
et al., 2002; Mogg et al., 2002; Wilkins et al., 2002; Grinevich et al., 2003; Crooks 
et al., 2004; Dwoskin et al., 2004; Rice and Cragg, 2004; Zhang and Sulser,  
2004).   Nicotine also increases DA release in striatum, accumbens and MPFC in 
vivo (Imperato et al., 1986; Damsma et al., 1989; Brazell et al., 1990; Toth et al., 
1992; Benwell et al., 1993, 1995; Bassareo et al., 1996; Marshall et al., 1997; 
Maisonneuve and Glick, 1999; Di Chiara, 2000; Fu et al., 2000; Sziraki et al., 
2002; Tizabi et al., 2002; Bednar et al., 2004; Brody et al., 2004b; Rahman et al., 
2004).  Systemic nicotine administration also markedly increases the firing rate of 
mesolimbic DA neurons recorded extracellularly (Grenhoff et al., 1986).    
 
 
Importantly, nicotinic receptors localized to cell bodies mediate nicotine-
induced DA release locally (somatodendritic), as well as at terminals (Clarke et 
al., 1988; Corrigall et al., 1994; Nisell et al., 1994a,b 1995; Fu et al., 2000; Sziraki 
et al., 2002; Tizabi et al., 2002; Champtiaux et al., 2003; Rahman et al., 2003; 
Laviolette and van der Kooy, 2003).  Nicotine-evoked DA release is inhibited by 
mecamylamine and/or di-hydro beta-erythroidine (a competitive nicotinic receptor 
antagonist; DHβE), and is Ca++ dependent (Westfall et al., 1987; Rapier et al., 
1990; Grady et al., 1992; El-Bizri and Clarke, 1994; Nisell et al., 1994; Crooks et 
al., 1995; Sacaan et al., 1995; Rowell, 1995; Teng et al., 1997).  Pre-exposure of 
striatal slices or synaptosomes from mice or rats with nicotine results in 
functional desensitization, such that subsequent nicotine exposure produces a 
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diminished [3H]DA release (Rapier et al., 1988; Grady et al., 1994; Rowell and 
Hillebrand, 1994; Rowell, 1995).  The desensitization induced by nicotine is 
reversible, and is observed even with pre-exposure concentrations which 
produce no detectable stimulation of [3H]DA release.  
 
Controversy exists regarding the exact subunit composition of nicotinic 
receptor subtypes mediating nicotine evoked DA release, and great effort is 
focused on elucidating specific nicotinic receptor subtypes involved. Using 
electrophysiology, a hypertonic sucrose solution allows for measurement of the 
size of the readily releasable pool of vesicles from synaptosomes (Turner, 2004).  
Repeated application of nicotine to the synaptosomes increased DA release by 
increasing the size of the readily releasable pool of vesicles.  This effect is 
inhibited by α-bungarotoxin, suggesting a role for the α7* nicotinic receptor 
subtype in nicotine-evoked DA release (Turner, 2004).  Subtype assignment of 
native nicotinic receptors mediating nicotine evoked DA release has been based 
largely on inhibition of agonist-induced response by subtype selective 
antagonists defined by inhibitory activity in cell systems expressing nicotinic 
receptor subtypes of known composition (Grady et al., 2002; Zoli et al., 2002; 
Everhart et al., 2004; Azam and McIntosh, 2005), by results from studies using 
nicotinic receptor subunit knockout mice (Picciotto et al., 1998; Champtiaux et al., 
2002, 2003; Whiteaker et al., 2002; Marubio et al., 2003), and by in situ 
hybridization and single cell polymerase chain reaction of mRNA in DA cell 
  
25 
bodies (Deneris et al., 1989; Wada et al., 1989; Le Novere et al., 1996; 
Charpantier et al., 1998; Klink et al., 2001; Azam et al., 2002).    
 
Initially, specific subunit combinations of nicotinic receptors mediating 
nicotine-evoked DA release (Imperato et al., 1986; Vezina et al., 1992; Nisell et 
al., 1996, 1997; Teng et al., 1997; Zhou et al., 2001) were thought to be the 
α3β2* (Schulz and Zigmond, 1989; Luetje and Patrick, 1991; Grady et al., 1992; 
Cartier et al., 1996; Kaiser and Wonnacott, 2000) and α4β2* (Grady et al., 1992; 
Rapier et al., 1990; Kulak et al., 1997; Kaiser and Wonnacott, 2000; Sharples et 
al., 2000) nicotinic receptor subtypes.   More recently, the selective α6 nicotinic 
receptor antagonist, α-conotoxin MII, has been shown to decrease DA release, 
suggesting the involvement of the α6 subunit in nicotine-evoked DA release 
(Salminen et al., 2004).  As previously discussed, DA neurons express α3 - α7 
and β2 - β4 mRNAs (Deneris et al., 1989; Wada et al., 1989; Le Novere et al., 
1996; Charpantier et al., 1998; Klink et al., 2001; Azam et al., 2002) resulting in a 
number of nicotinic receptor subtypes and subunit combinations that may be 
involved in nicotine-evoked DA release. For example, α -conotoxin MII is a 
nicotinic receptor antagonist, which inhibits electrophysiological responses in 
Xenopus oocytes expressing α3/α6 and α6/α4 nicotinic receptors containing 
either β2 or β4 subunits (Luetje et al., 1990; Cartier et al., 1996; Kuryatov et al., 
2000; Luetje, 2004).  Importantly, α-conotoxin MII inhibits nicotine-evoked [3H]DA 
overflow by only 50%, implicating involvement of at least two different nicotinic 
receptor subtypes (Zoli et al., 2002; Salminen et al., 2004; Azam and McIntosh 
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2005).  Immunoprecipitation of nicotinic receptors from DA terminals as well as 
electrophysiological studies in DA neurons from various nicotinic receptor 
knockout mice suggest the involvement of α4β2*, α6β2*, α6α4β2* nicotinic 
receptors in DA release (Champtiaux et al., 2003).  Furthermore, striatal lesion 
with 6-OHDA determined that possibly α3-, α4- or α5-containing nicotinic 
receptors were present on DA terminals and could be involved in nicotinic 
receptor modulation of DA release (Zoli et al., 2002).  α-Conotoxin MII binds with 
high affinity to immunopurified α6β2 nicotinic receptors (Zoli et al., 2002; 
McIntosh et al., 2004), which is eliminated in α6-knockout mice, but not in α3- or 
α4-knockout mice (Champtiaux et al., 2002; Whiteaker et al., 2002; Marubio et 
al., 2003); suggesting that α-conotoxin MII is a selective antagonist for α6 
containing receptors.  Nicotine does not evoke DA release in microdialysis 
experiments using α4-knockout mice (Marubio et al., 2003), indicating that α4 
nicotinic receptors are critical for DA release, at least in ventral striatum. 
However, the latter study also reported that basal DA release in α4-knockout 
mice was significantly greater than in the wild-type, suggesting that α4-knockout 
resulted in a compensatory response (altered tonic activity).  Evidence is also 
emerging suggesting that different DA neurons can be categorized based upon 
the expression of particular nicotinic receptor subtypes with varying compositions 
of nicotinic receptor subunits (Azam et al., 2002).  Chronic nicotine administration 
to β2 nicotinic receptor knockout mice did not increase locomotor activity, which 
is suggested to be a DA dependent behavior.  Thus the β2 subunit plays an 
important role in DA-dependent behavior (King et al., 2004). Thus, we are only 
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beginning to obtain a comprehensive understanding of the heterogeneous 
population of nicotinic receptors that mediate nicotine-evoked DA release and 
DA-dependent behaviors. 
 
VIII.   Nicotine Modulation of DAT  
Extracellular DA concentrations are the net result of exocytotic DA release 
from presynaptic terminals and reuptake of DA into presynaptic terminals 
(clearance) via DAT. Nicotine-induced stimulation of nicotinic receptors results in 
depolarization of the plasma membrane (Calabresi et al., 1989), which would be 
expected to decrease DAT function and decrease DA clearance, thereby 
increasing extracellular DA concentrations.  Many psychostimulants act at DAT 
as part of their mechanism of action.  Thus, studies determining the effect of 
nicotine on DAT function are important to pursue. 
 
Recently, α4 nicotinic receptor subunit knockout mice have been shown to 
have a decreased DAT function compared to wild type mice (Parish et al., 2005).  
These data suggest that nicotinic receptors may be involved in modulating basal 
DAT function.  Furthermore, nicotine (0.4 mg/kg) has been reported to increase 
DA clearance (enhance DAT function) in the nucleus accumbens in anesthetized 
rats (Hart and Ksir, 1996).  The latter results also contrast findings in vitro in 
which nicotine and another nicotinic agonist, 1,1-dimethyl-4-phenyl-piperazinium, 
have been reported to decrease [3H]DA uptake into chopped striatum and PC12 
cells, respectively (Izenwasser et al., 1991; Huang et al., 1999).   However, these 
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in vitro findings have not been replicated (Kramer et al., 1989; Carr et al., 1989; 
Rowell and Hill 1993; Zhu et al., 2003).   
 
The observation that nicotine enhances DAT function in nucleus 
accumbens in vivo (Hart and Ksir, 1996) is unexpected considering the 
electrogenic nature of the transporter.  As described previously, translocation of 
DA by DAT across the membrane is coupled to the cotransport of two Na+ ions 
and one Cl- ion down their electrochemical gradients, generating a small inward 
current (Kanner and Schuldiner, 1987; Rudnick and Clark, 1993; Hitri et al., 
1994).  Moreover, the DA neuron membrane potential influences DAT function, 
such that hyperpolarization increases the velocity of DA transport by DAT and 
depolarization decreases DA transport velocity (Sonders et al., 1997).  As such, 
nicotine-induced stimulation of nicotinic receptors, which results in depolarization 
of the plasma membrane (Calabresi et al., 1989), would be expected to decrease 
DAT function and decrease DA clearance, thereby increasing extracellular DA 
concentrations.  Recently DAT has been shown to act as a channel, not just as a 
transporter (Carvelli et al., 2004).  This would suggest that DAT has another role 
and can itself modulate membrane potential.   
 
With respect to nicotinic receptor modulation of DAT function, nicotine has 
also been reported to enhance amphetamine-evoked [3H]DA release from MPFC 
slices incubated in assay buffer in the absence of calcium (Drew et al., 2000).  
These assay conditions precluded nicotine-evoked exocytotic DA release, 
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suggesting the involvement of DAT in the nicotine-induced augmentation of the 
response to amphetamine.  Surprisingly, nicotine did not enhance amphetamine-
evoked [3H]DA release in striatum or nucleus accumbens (Drew et al., 2000), 
indicating that this effect was specific to MPFC.  The observed nicotine 
enhancement of the effect of amphetamine in MPFC was inhibited by nicotinic 
receptor antagonists, mecamylamine and DHβE, but not by α-bungarotoxin, 
indicating that specific, non α7 containing, nicotinic receptor subtypes are 
involved (Drew et al., 2000).  The latter findings suggest that nicotinic receptors 
may modulate DAT function under physiological conditions, i.e., in the presence 
of extracellular calcium, at least in MPFC.  Thus, determining the ability of 
nicotine to modulate DAT function in striatum and MPFC, areas involved in 
reward, is important for understanding the rewarding properties associated with 
tobacco smoking and nicotine self-administration. 
 
IX.   Specific Aims and Hypotheses: 
The work presented in this dissertation was based on the formation of four 
specific aims: 1) Determine the dose-response relationship for systemic nicotine 
to modulate DAT function in striatum and MPFC via a nicotinic receptor-mediated 
mechanism; 2) Determine the effect of repeated peripheral nicotine 
administration on DAT function in striatum and MPFC to assess differential brain-
region specific nicotine-induced regulation of DAT using in vivo voltammetry; 3) 
Determine if an increase in DAT efficiency is responsible for the nicotine-induced 
increase in DAT function; and 4) Determine if increased trafficking of DAT from 
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internal sites to the presynaptic terminal membrane accounts for the increase in 
DA clearance in response to nicotine administration. 
 
Specific Aim 1  
Hypothesis #1 
Nicotine will increase DA clearance in the striatum and MPFC in a dose-
dependent manner, and this increase in clearance will be mediated by nicotinic 
receptors. 
 
 Hypothesis #2 
Nornicotine, similar to nicotine, will increase DA clearance in the striatum via a 
nicotinic receptor-mediated mechanism. 
 
Specific Aim 2 
Hypothesis #3 
Repeated nicotine administration will further enhance the nicotine-induced 
increase in DA clearance in striatum and MPFC. 
 
Specific Aim 3 
Hypothesis #4 
Systemic pretreatment with nicotine will increase DAT function in striatal 
synaptosomes in vitro, similar to the increase in DA clearance observed in 
striatum in vivo. 
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Hypothesis #5 
The effect of nicotine to increase the Vmax of [3H]DA uptake in striatum is 
mediated by nicotinic receptors located on DA nerve terminals in striatum.  
 
Hypothesis #6 
Systemic administration of nicotine will increase the number of DAT sites in 
striatum as measured by radioligand binding. 
 
Specific Aim 4 
Hypothesis #7 
Systemic administration of nicotine will increase the trafficking of DAT to the 
neuronal cell surface in striatum. 
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Figure 1.  Sagittal slice through a rat brain.  Straight lines represent 
dopaminergic pathways and dotted lines indicate cholinergic projections.   
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Figure 2.  Structures  
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Figure 3.  Cartoon representation of a DA nerve terminal.  Adapted from 
Cooper, Bloom and Roth; The Biochemical Basis of Neuropharmacology. 
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Figure 4.  Diagram of a dopamine transporter.  DAT has 12 
transmembrane domains with intracellular amino and carboxy termini. 
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 Figure 5.  Representation of a neuronal nicotinic acetylcholine receptor.   
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Chapter Two 
Nicotine Increases Dopamine Transporter Function In Vivo in Striatum and 
Medial Prefrontal Cortex via a Nicotinic Receptor-Mediated Mechanism 
 
I.  Introduction 
Previous research on the neurobiology of reward and drug addiction has 
focused on the mesocorticolimbic and nigrostriatal DA systems, emphasizing the 
role of the nucleus accumbens, MPFC and striatum.  The accumbens shell, 
which is innervated by dopaminergic projections from the ventral tegmental area, 
and its associated neurocircuitry are believed to encode primary appetitive stimuli 
associated with unconditioned drug reward (Wise and Bozarth, 1987; Robbins 
and Everitt, 1996; Bardo, 1998; Koob, 1999; DiChiara, 2000; Kelley and 
Berridge, 2002).  The MPFC, which includes the anterior cingulate cortex and is 
innervated by dopaminergic projections from the ventral tegmental area, is 
believed to encode secondary conditioned stimuli associated with environmental 
cues paired with drug, leading to reward expectancy, which is recognized as 
important to the process of addiction and relapse to drug use (Berridge and 
Robinson, 1998; Shima and Tanji, 1998; Kelley, 1999; DiChiara, 2000; Kelley 
and Berridge, 2002; Peoples, 2002).  Integration of the motivational information 
from the MPFC occurs at least in part in striatal neurons, which are innervated by 
dopaminergic projections from the nigra, leading to the initiation and execution of 
movement in reward expectancy and detection of reward (Martin-Soelch et al., 
2001).  
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Nicotine is the most common drug of abuse and tobacco dependence the 
leading preventable cause of death in the USA (Surgeon General’s Report, 1988; 
Jaffe, 1990).  Nicotine, the most abundant alkaloid in tobacco, has intrinsic 
rewarding properties, which are believed to be responsible for tobacco 
dependence (Koob,1992; Corrigall et al., 1992; Stolerman and Jarvis, 1995; 
Garrett et al., 2003).  The mechanisms underlying the reinforcing properties of 
nicotine are not well understood, although the mesocorticolimbic and nigrostriatal 
DA systems are believed to be involved.  For example, c-fos activation of the 
anterior cingulate cortex, nucleus accumbens and striatum has been 
demonstrated in nicotine self-administering rats (Pagliusi et al., 1996; Merlo-Pich 
et al., 1997), and cortical c-fos has been shown to be activated following 
exposure to environmental cues associated with repeated nicotine administration 
(Schroeder et al., 2001).    The latter results from animal studies are consistent 
with findings showing that in tobacco smokers, nicotine dose-dependently 
increased neuronal activity in the cingulate cortex, frontal lobe and nucleus 
accumbens, as determined using functional MRI (Stein et al., 1998).   
 
Extracellular DA concentrations are increased following nicotine 
stimulation of nicotinic acetylcholine receptors in terminal regions of the 
mesocorticolimbic and nigrostriatal systems.  mRNA for nine subunits (α2–α7 
and β2–β4) of nicotinic receptors have been identified in substantia nigra and 
ventral tegmental dopaminergic neurons (Klink et al., 2001, Zoli et al., 2002; 
Azam et al., 2002; Wooltorton et al., 2003), indicating that potentially a large 
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number of heteromeric nicotinic receptor subtypes of pentameric structure may 
be expressed by these neurons.  Specific subunit combinations of nicotinic 
receptors mediating nicotine-evoked DA release (Imperato et al., 1986; Vezina et 
al., 1992; Nisell et al., 1996, 1997; Teng et al., 1997; Zhou et al., 2001) have not 
been elucidated conclusively.     
 
Extracellular DA concentrations are the net result of exocytotic DA release 
from presynaptic terminals and reuptake of DA into presynaptic terminals 
(clearance) via the DAT.   DA is also removed from the extracellular space by 
metabolism and diffusion, the latter factor playing a larger role in brain regions 
with sparse dopaminergic innervation and lower DAT density, such as the MPFC.  
DAT is the major presynaptic terminal protein regulating extracellular DA 
concentrations and is a presynaptic target for psychostimulant drugs of abuse, as 
well as for several antidepressant agents.  Psychostimulants, such as 
amphetamine, increase extracellular DA concentrations by reverse transport of 
DAT (Liang and Rutledge, 1992; Sulzer et al., 1995).  Cocaine inhibits DAT 
function, which results in increased extracellular DA concentrations (Kuhar et al., 
1991).  The antidepressant and tobacco use cessation agent, bupropion, inhibits 
DAT function, but also is a nicotinic receptor antagonist (Hurt et al., 1997; 
Slemmer et al., 2000; Miller et al., 2002).  Surprisingly, nicotine (0.4 mg/kg) has 
been reported to increase DA clearance (enhance DAT function) in the nucleus 
accumbens in anesthetized rats (Hart and Ksir, 1996).  The latter results also 
contrast findings in vitro in which nicotine and another nicotinic agonist, 1,1-
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dimethyl-4-phenyl-piperazinium, have been reported to decrease [3H]DA uptake 
into chopped striatum and PC12 cells, respectively (Izenwasser et al., 1991; 
Huang et al., 1999).   However, these in vitro findings have not been replicated 
(Kramer et al., 1989; Carr et al., 1989; Rowell and Hill 1993; Zhu et al., 2003).   
 
The observation that nicotine enhances DAT function in nucleus 
accumbens in vivo (Hart and Ksir, 1996) is not expected considering the 
electrogenic nature of the transporter.  Translocation of DA by DAT across the 
membrane is coupled to the cotransport of two Na+ ions and one Cl- ion down 
their electrochemical gradients, generating a small inward current (Kanner and 
Schuldiner, 1987; Rudnick and Clark, 1993).  Moreover, the DA neuron 
membrane potential influences DAT function, such that hyperpolarization 
increases the velocity of DA transport by DAT and depolarization decreases DA 
transport velocity (Sonders et al., 1997).  As such, nicotine-induced stimulation of 
nicotinic receptors, which results in depolarization of the plasma membrane 
(Calabresi et al., 1989), would be expected to decrease DAT function and 
decrease DA clearance, thereby increasing extracellular DA concentrations.   
 
With respect to nicotinic receptor modulation of DAT function, nicotine has 
also been reported to enhance amphetamine-evoked [3H]DA release from MPFC 
slices incubated in assay buffer in the absence of calcium (Drew et al., 2000).  
These assay conditions precluded nicotine-evoked exocytotic DA release, 
suggesting the involvement of DAT in the nicotine-induced augmentation of the 
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response to amphetamine.  Surprisingly, nicotine did not enhance amphetamine-
evoked [3H]DA release in striatum or nucleus accumbens (Drew et al., 2000), 
indicating that this effect was specific to MPFC.  The observed nicotine 
enhancement of the effect of amphetamine in MPFC was inhibited by nicotinic 
receptor antagonists, mecamylamine and dihydro-β-erythroidine, but not α-
bungarotoxin, indicating that specific nicotinic receptor subtypes are involved.  
The latter findings suggest that nicotinic receptors may modulate DAT function 
under physiological conditions, i.e., in the presence of extracellular calcium, at 
least in MPFC.   
 
The goal of the present study was to test the first hypothesis that nicotine 
will increase DA clearance in the striatum and MPFC in a dose-dependent 
manner, and this increase in clearance will be mediated by nicotinic receptors.  
The dose-response relationships for nicotine enhancement of DAT function were 
characterized in striatum and MPFC.  Furthermore, nicotinic receptor mediation 
was determined by assessing mecamylamine inhibition of the nicotine effect on 
DAT function in both striatum and MPFC.  Under physiological conditions, 
clearance of exogenously applied DA was assessed with msec resolution using 
in vivo voltammetry, a technique which has been previously shown to reliably 
evaluate DAT function (Cass et al., 1992).    
 
II. Methods 
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IIa.  Materials.   S(-)-Nicotine ditartrate (nicotine), 3-hydroxytyramine 
hydrochloride (dopamine, DA), mecamylamine HCl (mecamylamine) and sodium 
phosphate dibasic were purchased from Sigma/RBI (Natick, MA).  Sodium 
phosphate monobasic, sodium chloride, ascorbic acid and urethane were 
purchased from Fisher Scientific (Pittsburgh, PA).  Nafion perfluorinated ion-
exchange resin was purchased from Aldrich Chemical Co. (Milwaukee, WI).  
Dental wax was purchased from Patterson Dental Supply, Inc. (Louisville, KY).  
Dental acrylic was purchased from CMA Microdialysis (Acton, MA).  Epoxylite 
and PX grade Graphpoxy were purchased from Epoxylite Corp. (Irvine, CA) and 
Dylon Industries, Inc. (Cleveland, OH), respectively.  Carbon fibers of 30 μm 
diameter were purchased from Textron, Inc. (Lowell, MA), and 28 gauge lacquer-
coated copper wire was purchased from Radio Shack (Lexington, KY). 
 
IIb.  Animals.  Male Sprague Dawley rats (200 – 250 g) were obtained 
from Harlan Laboratories (Indianapolis, IN) and were housed two per cage with 
free access to food and water in the Division of Lab Animal Resources at the 
College of Pharmacy, University of Kentucky.  Experimental protocols involving 
the animals were in strict concordance with the NIH Guide for the Care and Use 
of Laboratory Animals and were approved by the Institutional Animal Care and 
Use Committee at the University of Kentucky. 
 
IIc.  In vivo Electrochemical Measurements.  Rats were anesthetized 
with urethane (1.25 - 1.5 g/kg, i.p.) and placed into a Kopf stereotaxic frame 
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(David Kopf Instruments, Tujunga, CA).  Body temperature was maintained at 37 
°C with a heating pad coupled to a rectal thermometer (Harvard Apparatus, 
Holliston, MA).  The scalp was reflected, and a section of the skull and dura 
overlying the frontal cortex were removed.  At a location remote from the 
recording site, a small hole was drilled in the skull above the posterior cortex for 
placement of two Ag/AgCl reference electrodes, which were cemented into place 
with dental acrylic. 
 
Electrochemical electrodes were prepared and electrochemical 
experiments conducted using previously described methods (Cass et al., 1992; 
Gratton et al., 1989). Electrochemical recording electrodes contained a single 
carbon fiber (33 μm diameter) in a pulled glass capillary (4 mm outer diameter, 
0.80 mm wall diameter) sealed with Epoxylite.  Graphite epoxy resin and a 28 
gauge lacquer-coated copper wire were inserted into the glass capillary to 
establish electrical contact with the carbon fiber.   The exposed carbon fiber 
extended 50-150 μm beyond the tip of the glass capillary.  Electrodes for some 
experiments were purchased from Quanteon (Lexington, KY).  To enhance 
selectivity for DA, the carbon fiber electrode was coated with Nafion polymer (5% 
solution, 6 - 8 coats) and cured by heating at 250 °C for 5 min.  Electrodes were 
calibrated in vitro to determine the sensitivity and selectivity for DA.  Calibration 
curves were generated using a range of DA concentrations (1.0 – 10 μM, at 22 
°C in 0.1 M PBS solution, pH 4.0).  Electrodes showed good sensitivity to DA and 
were relatively insensitive to ascorbic acid, such that the mean selectivity ratio of 
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DA/ascorbic acid was 594 ± 57 to 1 (n = 108).  Subsequently, each carbon fiber 
electrode was attached to a single barrel micropipette (tip diameter of 10-15 μm) 
with dental wax.  The tips of the electrode and micropipette were positioned 250 - 
300 μm apart.  The electrode micropipette assembly is shown in Figure 6.  
Micropipettes were prepared from monofilament glass (1.0 mm O.D., 0.58 mm 
I.D.) using a vertical pipette puller (Model 720, David Kopf Instruments, Tujunga, 
CA).  Single barreled micropipettes were filled with DA (200 μM, in 154 mM NaCl 
and 100 μM ascorbic acid, pH 7.4) immediately prior to conducting the 
experiment.  The concentration of DA for ejection was chosen based on the 
linear kinetics of DA uptake at this concentration, i.e., DA concentrations that do 
not saturate DAT in striatum (Zahniser et al., 1999). 
 
The electrode/micropipette assembly was lowered into the dorsal striatum 
(1.5 mm anterior to bregma, 2.3 mm lateral from midline, and 4.0 - 5.5 mm below 
the surface of the cortex) or MPFC (cingulate cortex; 2.9 mm anterior to bregma, 
1.0 mm lateral from midline, and 2.5 – 5.0 mm below the surface of the cortex), 
according to the rat brain atlas of Paxinos and Watson (1986).  Exogenous DA 
was pressure ejected (30 - 50 psi, 0.05 ms – 2.5 s) at 5-min intervals using a 
Picosprizter II (General Valve Corporation, Fairfield, NJ), until reproducible 
baseline signals (variation in signal amplitude < ± 10%) were obtained.  Using a 
stereomicroscope fitted with a reticule in one eyepiece, ejection volume (250 
nl/mm) was monitored by measurement of the fluid displaced from the 
micropipette.   
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In the first series of experiments, dose-response curves for nicotine 
modulation of DAT function in striatum and MPFC were generated, with nicotine 
dose and brain region as between-groups factors.  Rats were randomly assigned 
to 5 treatment groups to assess the effect of nicotine (0.1 - 0.8 mg/kg, s.c.) or 
vehicle (saline) on DAT function in striatum.  Rats were assigned to 6 treatment 
groups to assess the effect of nicotine (0.1 - 0.8 mg/kg, s.c.) or vehicle (saline) 
on DAT function in MPFC.  In an attempt to generate the full dose-response 
relationship in MPFC, the effect of an additional nicotine dose (0.3 mg/kg) was 
determined based on the dose-response curve obtained. 
 
For each experiment, nicotine was administered once reproducible baseline 
signals were obtained.  Pressure ejection of DA continued at 5-min intervals for 
60 min following nicotine or vehicle injection.  In the majority of MPFC 
experiments, rats were pretreated with desipramine (25 mg/kg, s.c.) to assure 
that DAT function was measured and that the norepinephrine transporter (NET) 
did not play a prominent role.  Previous in vivo voltammetry studies have shown 
that the MPFC is heterogeneous with respect to transporter regulation of 
extracellular DA concentrations (Cass and Gerhardt, 1995).   Results from the 
latter study reveal that at deep recording depths (2.5 – 5.0 mm below the cortical 
surface), DAT primarily clears DA from the extracellular compartment.  At more 
superficial recording depths (0.5 - 2.25 mm the cortical surface), NET plays a 
greater role.  As such, local application of desipramine into MPFC at superficial 
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depths resulted in inhibition of DA clearance.  At deep recording depths, 
desipramine had no effect on DA clearance.  In contrast, local application of GBR 
12909, a selective DAT inhibitor, produced the reverse effect, i.e., inhibited DA 
clearance at deep recording depths and had no effect at superficial depths in 
MPFC.  In the current study, recording was deeper in the MPFC (2.5 – 5.0 mm 
below the cortical surface), in an attempt to also ensure that the effect of nicotine 
on DAT function was evaluated.  Comparisons of results in the absence and 
presence of desipramine revealed no significant differences in the effect of 
nicotine on DA clearance. 
 
To determine if nicotinic receptors mediated the response to nicotine on DA 
clearance in striatum and MPFC, the effect of mecamylamine, a noncompetitive 
nicotinic receptor antagonist (Varanda et al., 1985; Loiacono et al., 1993; Peng et 
al., 1994), was determined.  Rats were randomly assigned to 8 treatment groups 
(4 treatment groups/brain region).  Each group was injected s.c. with either 
mecamylamine or saline, followed 40 min later by a second injection s.c. of 
nicotine or saline; such that herein, treatment groups are designated as 
first/second injection (i.e., mecamylamine/saline, mecamylamine/nicotine, 
saline/nicotine and saline/saline groups).  Once reproducible baseline signals 
were obtained, mecamylamine (1.5 mg/kg) or vehicle (saline) was injected.  The 
dose of mecamylamine was chosen primarily based on previous behavioral 
studies from our laboratory and others in which a similar dose of mecamylamine 
(1.2 mg/kg) inhibited both the acute effects of nicotine on locomotor activity and 
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the sensitization induced by repeated administration of nicotine (Miller et al., 
2001).  A lower dose of mecamylamine (1.0 mg/kg) was previously shown to 
inhibit nicotine-induced locomotor stimulation (Clarke and Kumar, 1983).  The 
dose of mecamylamine chosen was also within the range of that inhibiting 
nicotine self-administration in rats (Rauhut et al., 2002; Rezvani et al., 2002).  
Mecamylamine (1.0 mg/kg) also was shown to inhibit the effect of nicotine (0.4 
mg/kg) to enhance DA clearance in nucleus accumbens using in vivo 
voltammetry (Hart and Ksir, 1996).  Previous studies have shown that injection of 
mecamylamine 20 min prior to nicotine injection completely inhibited the nicotine-
induced increase in locomotor activity for one hour following nicotine injection 
(Miller et al., 2001).  In the current studies, mecamylamine was injected 40 min 
prior to nicotine to ensure that mecamylamine had sufficient time to get to the 
brain and to its site of action.  Based on results of the current nicotine dose-
response curves in the first series of experiments, nicotine doses (0.8 and 0.4 
mg/kg) that produced a maximal effect in striatum and MPFC, respectively, were 
chosen.  DA was pressure ejected every 5 min during the 40 min period following 
the first s.c. injection and for 60 min following the second s.c. injection.  For all 
experiments, drug dose represents the salt weight, and the injection volume was 
1 ml/kg body weight.   
 
High-speed chronoamperometric electrochemical measurements were made 
continuously (5 times/s, 5 Hz and averaged to 1 Hz), using an electrochemical 
recording system (IVEC 10; Medical Systems Corporation, Greenvale, NY).  The 
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oxidation potential was a square wave of +0.55 volts applied for 100 ms (versus 
the Ag/AgCl reference electrode), and the resting potential was 0.0 volts for 100 
ms. When the voltage was applied, DA was oxidized to para-ortho-quinone DA 
resulting in the release of 2 electrons (Figure 6).  The electrons coming from the 
oxidized DA were measured by the electrode and converted to a concentration 
measure using the IVEC 10.  Oxidation currents were digitally integrated during 
the last 80 ms of each 100-ms pulse.   
 
IId.  Data and Statistical Analysis.   Data are represented as mean 
values + S.E.M., and n represents the number of animals in a treatment group.  
Three parameters were determined from the DA oxidation currents; maximal 
signal amplitude, which is defined by the maximal change in extracellular DA 
concentration; T80, the time for the signal to decay by 80% minus the rise time of 
the signal; and DA clearance rate, the slope of the initial pseudolinear portion of 
the decaying signal (between the T20 and T60 time points; Figure 7), integrating 
signal amplitude and time course of decay.  During the conduct of this 
dissertation project, attention was brought to the measure of the clearance rate 
parameter in that the presentation of the data was backwards from the result of 
the experiments.  Therefore, to alleviate confusion the classical pharmacokinetic 
measure was utilized (discussed in Chapter Three). 
 
For the first series of experiments generating nicotine dose-response 
curves in striatum and MPFC, time courses for the nicotine dose effect were 
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analyzed by two-way mixed-factor ANOVA, with dose as a between-groups 
factor and time as within-subjects factor.  A separate ANOVA was performed to 
analyze the time course for each of the three parameters assessed, maximal 
signal amplitude, T80 and clearance rate for each brain region.  To determine the 
dose-related effect of nicotine, one-way ANOVAs were conducted on the signal 
amplitude data from striatum at each 5-min time point during the 30-60 min 
period following nicotine injection.  One-way ANOVAs were also conducted on 
the dose response for signal amplitude and clearance rate data from MPFC at 
each time point during the 30-60 min period following nicotine injection.   The 
time period chosen for the latter analyses was based on previous results in rat 
nucleus accumbens following a single dose (0.4 mg/kg, s.c.) of nicotine (Hart and 
Ksir, 1996).  Dunnett’s post hoc analysis was performed to determine differences 
from saline control.  Additionally, specific within-subject contrasts determined the 
time point at which nicotine significantly decreased signal amplitude compared to 
baseline (prior to drug injection).  Furthermore, for both striatum and MPFC, 
signal amplitude data were summed across the 60-min recording period to 
assess nicotine dose-response relationships, and these data were analyzed by 
one-way ANOVA and Tukey test to determine the nicotine dose that significantly 
decreased signal amplitude.   
 
Analysis of mecamylamine-induced inhibition of the effect of nicotine on 
each of the three parameters (maximal signal amplitude, T80 and clearance rate) 
for each brain region was accomplished using separate three-way mixed-factor 
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ANOVAs, with mecamylamine and nicotine as between-group factors and time 
as a within-subjects factor.   Significant interactions were found for the data 
expressed as signal amplitude and clearance rate, such that one-way ANOVAs 
were utilized to assess the effect of nicotine and mecamylamine at individual time 
points.  Additionally, specific within-subjects contrasts were performed for the 
group administered saline followed by nicotine to determine the time point at 
which nicotine significantly decreased signal amplitude compared to baseline.    
 
ANOVA, specific contrasts and post hoc analyses were performed using 
SPSS (standard version 11.0, Chicago, IL).  p < 0.05 was considered significant.  
Based on the apriori directional hypothesis being tested, one-tailed tests were 
considered statistically significant; however, two-tailed tests were reported herein 
unless otherwise indicated.  Nonlinear curve fitting of the cumulative nicotine 
dose-response data was performed by Prism through a nonweighted iterative 
process (Prism v3.0, GraphPad software, Inc., San Diego, CA).    
 
III.  Results 
IIIa.  Effect of Nicotine on Exogenous DA Clearance in Striatum.   The 
effect of systemic administration of nicotine (0.1 – 0.8 mg/kg) on exogenous DA 
clearance in the medial dorsal striatum of urethane-anesthetized rats was 
determined.   Pressure ejection of 200 μM DA every 5 min resulted in stable 
baseline signals, with a maximal signal amplitude of 4.21 μM (± 0.22 μM; mean ± 
S.E.M.; range, 1.51 – 9.90 μM), T80 value of 32.6 s (± 3.1 s) and clearance rate of 
  
51 
0.307 μM/s (± 0.056 μM/s; n = 32 independent experiments).  Maximal signal 
amplitude during measurement of basal DA clearance varied with the placement 
of the electrode/micropipette assembly in the striatum.  While there was some 
between group variability in maximal signal amplitude, the within animal baseline 
signals were stable.  Figure 7 illustrates the reproducible pattern of a series of 
baseline signals for a representative rat obtained prior to systemic injection of 
nicotine (0.8 mg/kg) or saline (Figure 7, top panel).  Maximal signal amplitude 
under basal conditions for the represented rat was 3.64 μM, which was near the 
median response and within one SD of the mean response of the group.  Once 
baseline signals had stabilized, rats were injected with either nicotine or saline 
(control), and pressure ejection of DA continued every 5 min for 60 min.  The 
effect of nicotine on maximal signal amplitude, T80 and clearance rate was 
determined at 5 min intervals and compared to that after saline injection.  An 
overlay of representative signals, obtained in striatum at the 45-min time point 
after injection when the maximal effect of nicotine (0.8 mg/kg) was observed, 
reveals a large decrease (45%) in maximal signal amplitude (Figure 7, bottom 
panel).  Rise time, duration and decay of the DA signal were not different 
between nicotine- and saline-treated rats.  
 
Analysis of the data from the control group (saline injected) reveals that 
DA signal amplitude gradually decreased by ~15% of baseline during the 55-min 
period after saline injection; however, a decrease (~23%) in signal amplitude was 
significant only at the 60-min time point (Figure 8, top panel).  Following repeated 
  
52 
DA pressure ejection in the saline control rats, DA signal amplitude decreases 
and DA clearance increases slightly across the 60-min recording session.  It is 
possible that the decrease in signal amplitude is due to changes in the properties 
of the recording electrode.  During the experiment the electrodes become less 
sensitive to DA (30% decrease in sensitivity).  Therefore, the decrease in signal 
amplitude may be due to at least in part a decrease in sensitivity of the electrode.  
While the electrodes are less sensitive, the electrodes retain selectivity for DA.  It 
is also possible that following repeated DA pressure ejection the extracellular 
space around the ejection site is altered.  Thus, changes in extracellular space 
could modulate DA clearance and play a role in the slight decrease decrease in 
signal amplitude observed in the saline control group.    T80 did not change 
across the time course of the experiment in the saline-injected group (Figure 8, 
middle panel).  Similar to signal amplitude, DA clearance rate also gradually 
decreased by ~15% of baseline across the time course of the session (Figure 8, 
bottom panel).  The bottom panel illustrates that at the 60-min time point, DA 
clearance rate decreased by 40%; however, there were no significant main 
effects or interactions, such that posthoc analyses were not performed.  Thus, 
repeated DA application at 5-min intervals following saline injection resulted in a 
small increase in DAT function across the 60-min session. 
 
The dose response for nicotine-induced modulation of DAT function in 
striatum was determined and the results are shown in Figure 8.  The parameters 
of DAT function (maximal signal amplitude, T80 and clearance rate) were 
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analyzed using separate two-way ANOVAs.  With respect to signal amplitude, a 
significant interaction of dose and time was found (F52,351 = 1.58, p < 0.05).   To 
further analyze the interaction, separate one-way ANOVAs of signal amplitude 
were conducted on the data from each 5-min time point during the 30-60 min 
after injection (Figure 8, top panel).   Dose-related decreases in signal amplitude 
were observed at various time points.  Significant main effects of nicotine dose 
were found at 40-45 min (p < 0.05), and at the 35 min and 50-55 min time points 
(p < 0.05, one-tailed) after injection.  Dunnett’s post hoc analysis revealed that 
DA signal amplitude was decreased 35-55 min in the 0.8 mg/kg group compared 
to the control group.  Signal amplitude decreased by a maximum of 48% of 
control at 45 min after the 0.8 mg/kg dose of nicotine (between-groups 
comparison); however, when signal amplitude at this time point was compared to 
the baseline response (within-subject comparison), a 60% decrease in signal 
amplitude was found.  To determine the onset of the effect of nicotine, specific 
within-subjects contrasts were performed comparing DA signal amplitude at each 
time point following nicotine injection compared to signal amplitude at baseline.  
A significant decrease in signal amplitude occurred 15 min following nicotine 
injection (0.8 mg/kg, p < 0.01).  In contrast to the effect of nicotine on signal 
amplitude, no significant main effects or interactions were found for T80 or 
clearance rate, when the data were analyzed by two-way ANOVA (Fig 8, middle 
and bottom panels, respectively).  With respect to clearance rate, the highest 
dose (0.8 mg/kg) of nicotine tended to increase clearance rate, but did not reach 
significance.   Thus, compared to T80 and clearance rate, DA signal amplitude is 
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the more sensitive parameter for detection of the effect of nicotine on DAT 
function.  
 
To further evaluate the nicotine dose-response relationship, DA signal 
amplitude data for each dose were cumulated across the 60-min sampling period 
to generate a dose-response curve (Figure 9).  The nicotine dose-response 
curve was monophasic, and nonlinear regression revealed a significant fit to the 
data (r2 = 0.99).  Thus, as the nicotine dose increased, DA signal amplitude 
decreased, indicating that in a dose-related fashion nicotine enhances DAT 
function in striatum. 
 
IIIb.  Effect of Nicotine on Exogenous DA Clearance in MPFC.  To 
assess the effect of nicotine on DAT function in the mesocorticolimbic system, a 
range of nicotine doses (0.1 – 0.8 mg/kg) was administered s.c. to separate 
groups of rats, and exogenous DA clearance in MPFC was determined.  
Pressure ejection of DA (200 μM) resulted in stable baseline signals with a 
maximal signal amplitude of 4.54 μM (± 0.18 μM; mean ± S.E.M), T80 value of 
76.8 s (± 4.62 s), and clearance rate of 0.085 μM/s (± 0.011 μM/s; n = 33 
independent experiments).  Once baseline signals had stabilized, groups of rats 
were injected with either a dose of nicotine (0.1 – 0.8 mg/kg, s.c.) or saline and 
DA pressure ejection continued at 5-min intervals for 60 min.  The effect of 
nicotine on maximal signal amplitude, T80 and clearance rate was determined at 
5-min intervals and compared to the saline-injected control group (Figure 10).  
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Analysis of the data from the saline-injected control group revealed that 
DA signal amplitude gradually decreased by ~13% during the first 55 min of the 
session (Figure 10, top panel).  At 60 min after the injection of saline, signal 
amplitude was significantly decreased by 15% (p < 0.001).  T80 was not different 
from baseline across the duration of the session (Figure 10, middle panel).  DA 
clearance rate tended to decrease (~15% of baseline) across the session time 
course, but did not reach significance (Figure 10, bottom panel).   Thus, under 
control conditions, repeated DA application at 5-min intervals resulted in a small 
increase in DAT function across the 60-min session, similar to that observed in 
striatum. 
 
When the effect of nicotine on both signal amplitude and clearance rate 
were analyzed by two-way ANOVA, significant interactions of dose and time 
were found (F65,351 = 1.95, p < 0.001 and F65,351 = 1.74, p < 0.01, respectively).  
No significant main effects or interactions were observed for T80.  Signal 
amplitude data were analyzed further by one-way ANOVAs at individual 5-min 
time points, revealing dose-related decreases in signal amplitude at 15-30 min 
and 50-60 min (p < 0.05;  at 35 min, p < 0.05, one-tailed, Figure 10, top panel).  
Dunnett’s post hoc analysis revealed that compared to the control group, DA 
signal amplitude was decreased in the 0.4 mg/kg group at 15-30 min (p < 0.05), 
and at the 35 min and 50-55 min time points (p < 0.05, one-tailed).  Compared 
with the control group, a maximal decrease of 46% in signal amplitude was 
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observed 30 min after injection of nicotine (0.4 mg/kg); and when the data at this 
time point were compared to the within-subject baseline, a 53% decrease in 
signal amplitude was observed.  To assess the onset of nicotine effect, specific 
within-subjects contrasts were performed comparing signal amplitude at each 
time point after injection to that at baseline.  A significant (p < 0.001) decrease in 
signal amplitude was observed 10 min following nicotine (0.4 mg/kg) injection.   
 
With respect to clearance rate, one-way ANOVAs were conducted to 
assess the nicotine dose-response at each 5-min time point after injection 
(Figure 10, bottom panel).  Dose-related decreases in clearance rate were 
observed at 15-25 min and 60 min (p < 0.05), and at the 30 min and 50-55 min 
time points (p < 0.05, one-tailed) post injection.  Dunnett’s post hoc analysis 
revealed that DA clearance rate was decreased in the 0.4 mg/kg group 
compared to the control group at 15-25 min (p < 0.05) and at 30 min (p < 0.05, 
one-tailed) after injection.  Compared to the control, clearance rate after 0.4 
mg/kg decreased by a maximum of 33% at the 45-min time point; whereas a 
maximum decrease of 44% was observed when compared to the within-subject 
baseline response.  The onset of the nicotine effect on clearance rate occurred at 
10 min following nicotine injection (0.4 mg/kg, p < 0.01).   
 
DA signal amplitude was also expressed as a cumulative change across 
the 60-min sampling period to evaluate the nicotine dose-response relationship 
(Figure 11).  Surprisingly, a U-shaped dose-response relationship was apparent.  
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Only the 0.4 mg/kg dose of nicotine decreased DA signal amplitude in MPFC.  
Similarly, a U-shaped dose-response relationship was observed for clearance 
rate (data not shown).  Thus, nicotine also modulates DAT function in MPFC; 
however, the dose-response pattern was different from that observed in striatum, 
and the time of onset and of maximal response occurred more rapidly after 
systemic nicotine injection in MPFC than in striatum.  
 
IIIc.  Effect of Mecamylamine on Nicotine-induced Modulation of DAT 
Function in Striatum.  To ascertain if the effect of nicotine on DAT function is 
mediated by nicotinic receptors, the ability of mecamylamine to inhibit the 
nicotine-induced increase in DA signal amplitude was determined.  Pressure 
ejection of DA (200 μM) resulted in a maximal signal amplitude of 6.75 μM (± 
0.43 μM; mean ± S.E.M.), T80 value of 23.8 s (± 4.60 s), and clearance rate of 
0.902 μM/s (± 0.119 μM/s; n = 26 independent experiments).  Once baseline 
signals stabilized, groups of rats were injected with mecamylamine (1.5 mg/kg, 
s.c.) or saline, and 40 min later with nicotine (0.8 mg/kg, s.c.) or saline.  The dose 
of nicotine was chosen based on the above dose-response analysis.  DA 
pressure ejection continued every 5 min after mecamylamine or saline and every 
5 min for 60 min after nicotine or saline.  Data for the three parameters of DA 
clearance are illustrated in Figure 12.  
 
Since signal amplitude was the only parameter which detected the dose 
relationship for nicotine to enhance DAT function in striatum, a three-way 
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ANOVA on signal amplitude data was performed to determine if mecamylamine 
inhibited the effect of nicotine.  A significant three-way interaction of 
mecamylamine x nicotine x time was found (F13,286 = 1.82, p < 0.05).   As 
previously observed, DA signal amplitude tended to gradually decrease across 
the 60-min session when compared to baseline in the Saline-Saline control 
group; however, only at the 60-min time point did the decrease (25%) in signal 
amplitude reach significance.  In the Saline-Nicotine group, the onset of the effect 
of nicotine to decrease signal amplitude (30%) occurred at 25 min after nicotine 
injection (within-subject comparisons, p < 0.01).  At the 55-min time point, 
nicotine maximally decreased signal amplitude by 56% compared to baseline.  At 
the latter time point, comparison of the Saline-Nicotine and Saline-Saline groups 
revealed that nicotine decreased signal amplitude by a maximum of 36%.  With 
respect to the Mecamylamine-Saline group, no within-subject differences were 
observed across the time course of the session compared to baseline, indicating 
that mecamylamine alone had no effect on DAT function.  To determine if 
mecamylamine inhibited the effect of nicotine, one-way ANOVAs compared the 
treatment groups at each time point beginning at the onset of nicotine’s effect 
(i.e., 25-60 min).   At the 40, 45, 55 and 60 min time points, signal amplitude in 
the Mecamylamine-Nicotine group was significantly greater than that in the 
Saline-Nicotine group (p < 0.05, one-tailed) and not different from that in the 
Saline-Saline group, indicating that mecamylamine completely inhibited the effect 
of nicotine on DAT function in striatum.   
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IIId.  Effect of Mecamylamine on Nicotine-induced Modulation of DAT 
Function in MPFC.  To ascertain if nicotinic receptors also mediate nicotine-
induced modulation of DAT function in MPFC, the ability of mecamylamine to 
inhibit the nicotine-induced decrease in signal amplitude in urethane-
anesthetized rats was determined.  Stable baseline signals, obtained in response 
to pressure ejection of 200 μM DA, exhibited a maximal signal amplitude of 4.14 
μM (± 0.27 μM; mean ± S.E.M.), T80 value of 80.5 s (± 6.02 s), and clearance rate 
of 0.066 μM/s (± 0.008 μM/s; n = 24 independent experiments).  Once baseline 
signals stabilized, experiments were performed as described above, except that 
electrochemical measurements were made in MPFC (Figure 13).  A three-way 
ANOVA was performed to determine if mecamylamine inhibited the nicotine-
induced decrease in DA signal amplitude in MPFC.  A significant interaction of 
mecamylamine x nicotine x time (F13,260 = 2.08; p < 0.02) was found.  DA signal 
amplitude decreased to a maximum of 20% compared to baseline at 60 min 
following the second saline injection in the Saline-Saline group.  Within-subjects 
comparison in the Saline-Nicotine group revealed that the onset of the nicotine 
effect occurred 15 min after nicotine injection, at which time a significant (p < 
0.001) decrease in signal amplitude was observed compared to baseline 
response.  At the 35 min time point, nicotine produced a maximal decrease in 
signal amplitude (45%) compared to baseline; between-groups comparison of the 
response in the Saline-Nicotine and Saline-Saline groups revealed a maximum 
decrease of 25% at this time point.  Within-subjects comparisons in the 
Mecamylamine-Saline group revealed no differences across the session 
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compared to baseline, indicating that mecamylamine alone had no effect on DAT 
function in MPFC.  One-way ANOVA followed by Dunnett’s test compared data 
from the Mecamylamine-Nicotine and Saline-Nicotine groups at each time point 
from 15-60 min, when nicotine decreased signal amplitude compared to baseline.  
Signal amplitude was greater in the Mecamylamine-Nicotine group than that in 
the Saline-Nicotine group at 20-30, 40 and 50 min (p < 0.05) and 35, 45 and 60 
min (p < 0.05, one-tailed) of the session.  Importantly, the response in the 
Mecamylamine-Nicotine group was not different from that in the Saline-Saline 
group at these time points, indicating that mecamylamine completely inhibited the 
effect of nicotine on DAT function in MPFC.  Thus, these results suggest that 
nicotine modulates DAT function via a nicotinic receptor-mediated mechanism in 
MPFC. 
 
IV.  Discussion 
The results from the current in vivo voltammetry study demonstrate that 
nicotine in a dose-related manner decreases DA signal amplitude in both 
striatum and MPFC, indicating that nicotine enhances DA clearance in both brain 
regions.  However, across the same nicotine dose range, differential patterns in 
the nicotine dose-response curve were observed in striatum and MPFC.  That is, 
a monophasic dose-response curve was observed in striatum, whereas a U-
shaped curve was found in MPFC, both curves having a maximal 50% effect.  
Maximal effect occurred at a lower dose in MPFC than in striatum (0.4 and 0.8 
mg/kg, respectively).  In both brain regions, the onset of a significant effect on DA 
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clearance occurred 10-15 min after nicotine injection; however, DA clearance 
tended to increase by 5 min after nicotine injection.  Additionally, the time to 
maximal response was more rapid in MPFC compared to striatum (30 and 45 
min, respectively).  The time course of the response to nicotine in both brain 
regions is in good agreement with pharmacokinetic data showing a maximal 
nicotine concentration in rat brain at 5 min after peripheral nicotine injection and 
a brain t1/2 of 52 min (Ghosheh et al., 2001).   Of note, the nicotine-induced 
increase in DA clearance in striatum lasted for at least 2 hours following nicotine 
injection.  Thus, the effect of nicotine on DAT function is long-lasting.   
Nevertheless, the pattern of the nicotine dose-response curve in the present 
study was different between MPFC and striatum, with MPFC showing greater 
sensitivity to nicotine.   
 
The current results support and extend previous findings, showing that 
systemically administered nicotine increases DA clearance in several 
dopaminergic terminal regions, including MPFC and striatum (current study), and 
nucleus accumbens (Hart and Ksir, 1996).  The latter results are surprising since 
stimulation of nicotinic receptors results in depolarization of the plasma 
membrane (Calabresi et al., 1989) and since depolarization of the membrane 
generally decreases DA transport velocity (Sonders et al., 1997).  However, this 
was not the case with nicotine.  The current results demonstrate a dose-related 
nicotine-induced enhancement of DAT function in striatum and MPFC, and 
extend the findings of Hart and Ksir (1996) in nucleus accumbens.  
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Interestingly, following nicotine injection, nicotine-induced increases in DA 
release are not observed using this procedure.  It is possible that the electrodes 
used in the current study are not sensitive enough to be able to detect the 
released DA.  However, a more likely explanation is that the amount of DA 
released by nicotine at the recording site was not large enough to be detected.  
Thus, while nicotine has been shown in several studies to release DA, this 
mechanism does not appear to have an effect on the nicotine-induced increase 
in DA clearance.   
 
The present study also demonstrates that the nicotine-induced 
enhancement of DA clearance in both MPFC and striatum was inhibited by 
pretreatment of the rats with mecamylamine, a nonselective nicotinic receptor 
antagonist (Varanda et al., 1985).  These results suggest that nicotine stimulates 
nicotinic receptors to increase DAT function in these brain regions.  In the current 
study, mecamylamine had no effect on its own, but inhibited the effect of nicotine 
on DA clearance in both striatum and MPFC.  The current results are in 
agreement with the work of Hart and Ksir (1996), who also reported no effect of 
mecamylamine alone on DAT function in nucleus accumbens.  The observation 
that mecamylamine had no effect alone, suggests that nicotinic receptors, which 
modulate DAT function in these brain regions, are not tonically activated.   
 
The involvement of distinct nicotinic receptor subtypes in striatum and 
MPFC provides a likely explanation for the differential nicotine dose-response 
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pattern observed in the current study.   Recent studies have demonstrated the 
presence of multiple mRNAs for nicotinic receptor subunits (α2-α7 and β2-β4) 
and their respective proteins in DA cell bodies in both substantia nigra and 
ventral tegmental area; however, differences in the relative abundance of these 
subunits in substantia nigra and ventral tegmental area have also been reported 
(Klink et al., 2001; Azam et al., 2002; Zoli et al., 2002; Wooltorton et al., 2003).  
The nicotinic receptors expressed in the nigrostriatal and mesocorticolimbic DA 
systems depend on the specific combinations of subunits forming functional 
nicotinic receptors.  Pairwise expression of nicotinic receptor subunits in 
Xenopus oocytes initially revealed characteristic pharmacological profiles, i.e., 
relative sensitivity and responsiveness to a range of nicotinic ligands (Luetje and 
Patrick, 1991).   Inclusion of a third type of subunit (e.g., α5 with α3 and β2 
subunits) in similar expression systems further altered the physiological 
response, calcium permeability and desensitization characteristics of the 
expressed nicotinic receptor subtypes (Gerzanich et al., 1998).  Characterization 
of the physiological response of individual neurons in midbrain slices revealed 
four different patterns of nicotinic receptor-mediated currents, revealing the 
complexity of native nicotinic receptors which purportedly contained as many as 
four different subunits (Klink et al, 2001).   
 
Although the specific subunit composition of nicotinic receptor modulating 
DAT function in either striatum or MPFC is not known, the nicotinic receptor 
subtype modulating DAT function in MPFC may be more sensitive to nicotine 
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than the specific nicotinic receptor subtype modulating DAT function in striatum, 
since the nicotine dose producing an enhancement of DA clearance is lower in 
MPFC than in striatum.  The current results show that in both striatum and 
MPFC, 0.1 and 0.3 mg/kg produce no effect on DAT function; however, 0.4 
mg/kg enhances DAT function in MPFC, whereas 0.8 mg/kg enhances DAT 
function in striatum.  Thus, the descending portion of the dose-response in MPFC 
resembles the dose-response in striatum, but the curve from MPFC is shifted to 
the left of that from striatum.  Doses of nicotine above 0.8 mg/kg were not 
examined in the current study, since such doses elicit seizures that may have 
confounded the results.  Thus, the differential pattern of response observed in 
the present study in MPFC and striatum with respect to nicotinic receptor-
mediated modulation of DAT function is likely the result of stimulation of distinct 
nicotinic receptor subtypes. 
 
An alternative explanation for the differential nicotine dose-response 
relationships in striatum and MPFC is the lower dopaminergic terminal density in 
MPFC compared to striatum, and the decreased number of DAT per terminal in 
MPFC compared to striatum (Sesack et al., 1998).  It may be that a higher dose 
of nicotine is required to observe the modulation of DAT function in striatum 
simply due to the greater number of DAT protein in striatum compared to MPFC.    
 
Another potential explanation for the difference in regional dose-response 
is that the local neuronal circuitry is different between these two brain regions, 
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i.e., different afferents impinge on the dopaminergic terminals in striatum and 
MPFC potentially providing differential regulation of DAT function.   In this regard, 
the U-shaped function in MPFC may be the result of nicotine-induced stimulation 
of an additional neurotransmitter system in the MPFC.  The result of activation of 
the additional neurotransmitter may have opposed the nicotinic receptor-
mediated enhancement of DAT function.  For example, high concentrations of 
nicotine have been shown to activate alpha7 nicotinic receptors, resulting in 
glutamate release in frontal cortex (Kaiser and Wonnacott, 2000; Schilstrom et 
al., 2000; Marchi et al., 2002).  For example, stimulation of metabotropic 
glutamate receptors have been reported to decrease DAT function (Page et al., 
2001).  Thus, activation of alpha7 receptors indirectly through glutamate 
neurotransmission could result in inhibition of DAT function, counteracting 
activation of the high affinity heteromeric nicotinic receptors, which enhance DAT 
function.   
 
Alternatively, nicotinic receptors may indirectly modulate DAT function 
through activation of neural circuitry at the cell body level.  Local administration of 
nicotine into the substantia nigra and ventral tegmental area has been shown to 
evoke DA release in striatum and nucleus accumbens, respectively, via 
stimulation of nicotinic receptors in the cell body region (Blaha and Winn, 1993; 
Sziraki et al., 2002).  Additionally, the effect of peripheral administration of 
nicotine to increase DA release in the nucleus accumbens determined using 
microdialysis was inhibited by local administration of mecamylamine into the 
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ventral tegmental area (Sziraki et al., 2002).  Thus, it seems plausible that in the 
current study, peripherally administered nicotine may be acting at nicotinic 
receptors at the level of the cell body to modulate DAT function at the terminal.  
Furthermore, different nicotinic receptor subtypes expressed at the cell body may 
be responsible for the different dose-response patterns observed in MPFC and 
striatum with respect to DA clearance.   
   
In both striatum and MPFC, the mechanism by which nicotine modulates 
DAT function may be via nicotinic receptor-induced augmentation of DAT 
trafficking to the presynaptic terminal membrane consistent with an increase in 
DA clearance.  The relatively rapid nicotine-induced increase in DA clearance 
suggests that new synthesis of DAT protein is not responsible.  Rather, the time 
course of response is consistent with trafficking of intracellular stores of DAT 
protein to the terminal membrane.  Cocaine, another drug of abuse, has been 
shown to dynamically regulate DAT function by increasing DAT trafficking to the 
plasma membrane in cells expressing hDAT (Little et al., 2002).  In contrast, 
amphetamine diminished DAT localization at the plasma membrane in hDAT 
expressing cells (Saunders et al., 2000) and in rat striatal dopaminergic terminals 
(Fleckenstein et al., 1997).  Investigation of the effect of nicotine on DAT 
trafficking is warranted based on the enhanced DA clearance using in vivo 
voltammetry in the current study.  
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Due to the lower DAT density and decreased number of DAT per terminal 
in MPFC compared to striatum, metabolism and diffusion likely play a larger role 
in clearing DA from the extracellular space in MPFC under physiological 
conditions.   However, following pharmacological treatment with nicotine, 
enhanced DAT function in MPFC would be predicted to have a large impact on 
dopaminergic transmission.  Nicotine enhancement of DAT function would result 
in more efficient DA clearance from the extracellular space, and cortical function 
would be disinhibited.  Thus, the ability of nicotinic receptors to modulate DAT 
function, and thereby extracellular DA concentration, may have physiological 
importance with respect to nicotine enhancement of cognitive processes such as 
attention, learning and memory, as well as important clinical relevance with 
respect to schizophrenia and drug abuse. 
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Figure 6.  Schematic representation of the electrode micropipette 
assembly.  A micropipette filled with DA is attached to a nafion-coated electrode.  
Following DA pressure ejection, DA is oxidized to para-ortho-quinone DA 
releasing 2 electrons.  The electrons are measured by the electrode and the 
electrochemical signal is converted to a concentration measurement using the 
IVEC-10 system allowing for determination of the DA concentration at the 
electrode site. 
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Figure 7.  Representative DA signals in striatum of urethane-anesthetized 
rats prior to (top panel) and 45 min following nicotine or saline injection 
(bottom panel).   Reproducible electrochemical signals were obtained following 
pressure ejection of DA (200 μM) and represent the baseline response (top 
panel).  Representative DA signals 45 min following injection of nicotine (NIC; 0.8 
mg/kg, s.c.) or saline are represented by dashed and solid lines, respectively 
(bottom panel).   Data are expressed as μM DA as a function of time (sec) after 
DA pressure ejection.  DA concentrations were calculated based on calibration 
curves generated in vitro.    
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Figure 8.  Dose-response for systemically administered nicotine to alter DA 
signal amplitude (top panel), T80 (middle panel), and clearance rate (bottom 
panel) in striatum of urethane-anesthetized rats.  Nicotine in a dose-related 
manner decreased signal amplitude, but did not significantly alter T80 or 
clearance rate across 60-min recording sessions.  After stable baseline signals 
were obtained in response to pressure ejection of DA (200 μM) at 5-min intervals, 
either a dose of nicotine (NIC; 0.1 – 0.8 mg/kg) or saline was injected s.c. 
(indicated by the arrow), and pressure ejection of DA at 5-min intervals continued 
for 60 min.  Data are expressed as mean, S.E.M. as a percentage of the 
respective baseline values as a function of time (min). Mean baseline values for 
each parameter are provided in the Results section. (n = 5 - 8 rats/group)   
* difference from saline control at the corresponding time point (p < 0.05); + first 
time point at which nicotine decreased signal amplitude compared to the 
corresponding basal. 
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 Figure 9.  In a dose-related manner, nicotine decreased signal amplitude 
cumulated across the 60-min sampling period.  For each experiment, the 
change in signal amplitude was cumulated across the 60-min period of 
electrochemical recording in striatum.  Data are expressed as mean + S.E.M. as 
a percent of baseline. (n = 5 – 8 rats/group) 
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Figure 10. Dose-response for systemically administered nicotine to alter 
DA signal amplitude (top panel), T80 (middle panel) and clearance rate 
(bottom panel) in MPFC of urethane-anesthetized rats.  Nicotine in a dose-
related manner decreased signal amplitude (top panel) and DA clearance rate 
(bottom panel), but did not alter the T80 (middle panel) across the 60-min 
recording session.  After stable baseline signals were obtained in response to 
pressure ejection of DA (200 μM) at 5-min intervals, either a dose of nicotine 
(NIC; 0.1 – 0.8 mg/kg) or saline was injected s.c. (indicated by the arrow), and 
DA pressure ejection continued at 5-min intervals for 60 min.  Data are 
expressed as mean, S.E.M. as a percentage of within-subject baseline values as 
a function of time (min). Baseline values for each parameter are provided in the 
Results section.  (n = 5 - 7 rats/group)  * difference from saline control at the 
corresponding time point (p < 0.05); # difference from saline control at the 
corresponding time point (p < 0.05; one-tailed);  + first time point at which nicotine 
decreased signal amplitude compared to the corresponding basal.  
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Figure 11.  In a dose-related manner, nicotine decreased signal amplitude 
cumulated across the 60-min sampling period.  For each experiment, the 
change in signal amplitude was cumulated across the 60 min period of 
electrochemical recording in MPFC.  Data are expressed as mean + S.E.M. as a 
percent of baseline. (n = 5 – 7 rats/group)  
 
 
CON
-700
-500
-300
-100
100
300
0.1 0.2 0.3 0.4 0.6 0.8 1.0
mPFC
Nicotine (mg/kg)
C
um
ul
at
iv
e 
C
ha
ng
e 
in
Si
gn
al
 A
m
pl
itu
de
(%
 b
as
el
in
e)
 
 
 
 
 
 
 
 
  
77 
Figure 12.  Effect of mecamylamine to inhibit the nicotine-induced decrease 
in signal amplitude in striatum.  Signal amplitude is shown in the top panel; T80 
and clearance rate are shown in middle and bottom panels, respectively, for 
comparison.  No significant differences in were observed in T80 or clearance rate. 
After stable baseline signals were obtained in response to pressure ejection of 
DA (200 μM) at 5-min intervals, either mecamylamine (MEC; 1.5 mg/kg) or saline 
was injected s.c. and 40 min later nicotine (NIC; 0.8 mg/kg) or saline was injected 
s.c.(second injection indicated by the arrow).  DA continued to be pressure 
ejected at 5-min intervals for 60 min following the second injection.  Data are 
expressed as mean, S.E.M. as a percentage of the respective baseline values as 
a function of time (min). Baseline values for each parameter are indicated in the 
Results section.  Legend indicates treatment group designating first and second 
injections.  (n = 6 - 7 rats/group)  # difference between Mecamylamine/Nicotine 
group and Saline/Nicotine group at the corresponding time point (p < 0.05; one-
tailed);  + first time point at which nicotine decreased signal amplitude compared 
to the corresponding basal.
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Figure 13. Effect of mecamylamine to inhibit the nicotine-induced decrease 
in signal amplitude in MPFC.  Signal amplitude is shown in the top panel; T80 
and clearance rate are shown in middle and bottom panels, respectively, for 
comparison.  No significant differences in were observed in T80 or clearance rate. 
After stable baseline signals were obtained in response to pressure ejection of 
DA (200 μM) at 5-min intervals, either mecamylamine (MEC; 1.5 mg/kg) or saline 
was injected s.c. and 40 min later injected s.c. with nicotine (NIC; 0.4 mg/kg) or 
saline (second injection indicated by the arrow).  DA was pressure ejected at 5-
min intervals for 60 min following the second injection.  Data are expressed as 
mean, S.E.M. as a percentage of the respective baseline values as a function of 
time (min). Baseline values for each parameter are indicated in the Results 
section.  Legend indicates treatment group designating first and second 
injections.  (n = 5 - 7 rats/group)  * difference between Mecamylamine/Nicotine 
group and Saline/Nicotine group at the corresponding time point (p < 0.05); # 
difference between Mecamylamine/Nicotine group and Saline/Nicotine group at 
the corresponding time point (p < 0.05; one-tailed); + first time point at which 
nicotine decreased signal amplitude compared to the corresponding basal. 
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Chapter Three 
Nornicotine Decreases Dopamine Transporter Function In Vivo in Striatum 
via a Nicotinic Recpetor-Mediated Mechanism 
I.  Introduction 
Tobacco use is the number one preventable cause of death in the US 
(USDHS, 1998), which has prompted the development of cessation 
pharmacotherapies.  Nicotine is believed to be the alkaloid in tobacco that is 
primarily responsible for chronic tobacco use and dependence (Clarke, 1987; 
Pomerleau and Pomerleau, 1992).  Activation of nicotinic receptors by nicotine 
results in an increase in the extracellular DA concentrations in brain, which is 
generally accepted as mediating at least in part, reward produced by nicotine, 
which subsequently leads to tobacco dependence (Koob, 1992; Corrigall et al., 
1992; Stolerman and Jarvis, 1995).  The mesocorticolimbic and nigrostriatal DA 
systems, including the nucleus accumbens, medial prefrontal cortex and striatum 
and the associated circuitry, have been implicated in drug-induced reward.  The 
nucleus accumbens shell is believed to encode primary appetitive stimuli 
associated with unconditioned drug reward (Wise and Bozarth, 1987; Bardo, 
1998; Koob, 1999; Kelley and Berridge, 2002), including reward produced by 
nicotine (Fibiger and Phillips, 1987; Corrigall et al., 1992; Mansvelder and 
McGehee, 2002; Mathieu-Kia et al., 2002).  The medial prefrontal cortex encodes 
secondary conditioned stimuli associated with environmental cues paired with 
drug, integrating sensory information and leading to reward expectancy, 
recognized as important to the addiction process and to relapse to drug use 
  
82 
(Berridge and Robinson, 1998; Shima and Tanji, 1998; Kelley and Berridge, 
2002; DiChiara et al., 2004; Rose and Behm, 2004; Brody et al., 2004).  
Integration of the motivational information from medial prefrontal cortex occurs at 
least in part in striatum leading to the initiation and execution of movement in 
reward expectancy and detection of reward (Martin-Soelch et al., 2001).  In 
smokers, nicotine dose-dependently increases neuronal activity in these brain 
regions assessed using fMRI and PET (Stein et al., 1998; Barrett et al., 2004).  
 
Current tobacco use cessation pharmacotherapies (i.e., bupropion and 
nicotine) have demonstrated only limited efficacy, since relapse rates are 
reported to be high (Hurt et al., 2003; George and O’Malley, 2004; Wileyto et al., 
2004), indicating a need for the development of alternative, more efficacious 
smoking cessation therapies. Bupropion acts as an inhibitor of neurotransmitter 
transporters resulting in increased extracellular DA concentrations (Richelson 
and Pfenning; 1984; Nomikos et al., 1989; Ascher et al., 1995; Li et al., 2002; 
Damaj et al., 2004).  Recently, bupropion has been reported to also act as a 
nicotinic receptor antagonist within the same concentration range that it inhibits 
neurotransmitter transporter function (Fryer and Lukas, 1999; Slemmer et al., 
2000; Miller et al., 2002; Gumilar et al., 2003; Damaj et al., 2004).  The use of 
nicotine replacement as a cessation therapy is based on activation of nicotinic 
receptors resulting in DA release.  Nicotine-induced DA release is concentration-
dependent and observed in presynaptic terminal regions in both the mesolimbic 
(Imperato et al., 1986; Rowell et al., 1987; Clarke et al., 1988; Vezina et al., 1992; 
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Wonnacott, 1997) and nigrostriatal (Westfall et al., 1983; Teng et al., 1997; 
Wonnacott, 1997; Kaiser et al., 1998; Dwoskin et al., 1999; Vezina et al., 1992) 
DA systems in both in vivo and in vitro studies.  This effect of nicotine is inhibited 
by mecamylamine, a nonselective and noncompetitive nicotinic receptor 
antagonist (Mifsud et al., 1989; Nisell et al., 1994a; Sacaan et al., 1995; Teng et 
al., 1997).   
 
Extracellular DA concentrations are the net result of DA release from the 
presynaptic terminal and DA uptake back into the terminal by the DA transporter 
(DAT).  Systemic administration of nicotine has been shown to modulate DAT 
function in vivo in striatum, nucleus accumbens and medial prefrontal cortex, 
resulting in an increase in DA clearance (Ksir et al., 1995; Hart and Ksir, 1996; 
Middleton et al., 2004).  Nicotine enhancement of DAT function is mediated by 
nicotinic receptors, as indicated by mecamylamine inhibition of this effect 
(Middleton, et al., 2004).  Considering that DAT function is inhibited by membrane 
depolarization (Sonders et al., 1997; Huang et al., 1999), it is surprising that 
nicotine, which depolarizes neurons, enhances DAT function.  The nicotine-
induced increase in DA release and the concurrent enhancement of DAT function 
appear to produce a sharpened DA signal.  In contrast, when synaptosomes from 
drug-naïve rats are exposed to nicotine, DAT function is not altered (Zhu et al., 
2003), suggesting that nicotine acts at nicotinic receptors located at sites other 
than on DA terminals to modulate DAT function.   
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Attention has focused on the N-demethylated nicotine metabolite and 
minor tobacco alkaloid, nornicotine, as contributing to the neuropharmacological 
effects of nicotine exposure and tobacco use (Crooks and Dwoskin, 1997).  
Nornicotine inhibits [3H]nicotine binding to rat brain membranes with a 50-fold 
lower affinity (Ki = 47 nM) compared with nicotine (Ki = 1.0 nM) (Reavill et al., 
1988; Copeland et al., 1991; Zhang and Nordberg, 1993; Xu et al., 2001).  In 
contrast, nicotine and nornicotine exhibit similar affinities for the 
[3H]methyllycaconitine binding site (Ki = 770 nM  and 1340 nM, respectively) in 
brain (Xu et al., 2001).  These results indicate interaction of these alkaloids with 
both α4β2* and α7* nicotinic receptors.  Similar to nicotine, nornicotine evokes a 
concentration-dependent, Ca2+-dependent and mecamylamine-sensitive increase 
in DA release from rat striatal and nucleus accumbens slices (Dwoskin et al., 
1993; Teng et al., 1997; Green et al., 2001), indicating that nornicotine acts as an 
agonist at nicotinic receptor subtypes modulating DA release.  In the latter 
studies, whereas nicotine and nornicotine were equipotent in releasing DA from 
striatal slices, nicotine was 43-fold more potent than nornicotine (EC50 = 70 nM 
and 3.0 μM, respectively) in releasing DA from nucleus accumbens slices.   It is 
interesting to note that nornicotine has a longer half-life than nicotine in plasma 
and brain (Kyerematen et al., 1990; Crooks et al., 1995, 1997; Ghosheh et al., 
2001); and following chronic treatment with nicotine, nornicotine accumulates in 
brain reaching pharmacologically relevant concentrations (Ghosheh et al., 2001).   
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In order to more fully elucidate the pharmacological actions of nornicotine, 
the ability of nornicotine to modulate striatal DAT function was assessed using in 
vivo voltammetry and in vitro synaptosomal [3H]DA uptake.   The hypothesis is 
that nornicotine, similar to nicotine, will increase DA clearance in the striatum via 
a nicotinic receptor-mediated mechanism.  Thus, the current study provides 
preclinical data on the pharmacology of nornicotine and provides additional 
information to assess its potential utility as a new tobacco use cessation agent. 
 
II.  Methods 
IIa.  Chemicals.    
      [3H]DA (3,4-ethyl-2-[N-3H]-dihydroxyphenylethylamine; specific 
activity, 27.1 Ci/mmol) was purchased from PerkinElmer Life Science (Boston, 
MA).  S(-)-Nornicotine was prepared as previously described (Swango et al., 
1999), and was utilized as the perchlorate salt.  S(-)-Nicotine di–d-tartrate, 
mecamylamine hydrochloride, nomifensine maleate, catechol, pargyline HCl, D-
glucose, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) and 
bovine serum albumin (BSA) were purchased from Sigma/RBI (Natick, MA).  
Sodium chloride, potassium phosphate, potassium chloride, magnesium sulfate, 
calcium chloride, and disodium ethylenediamine tetraacetate used in the 
preparation of the uptake assay buffer were purchased from Fisher Scientific 
International Inc. (Pittsburgh, PA).   
    
IIb.  Subjects 
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Male Sprague Dawley rats (200–250 g) were obtained from Harlan 
Laboratories (Indianapolis, IN) and were housed two per cage with free access to 
food and water in the Division of Lab Animal Resources at the College of 
Pharmacy, University of Kentucky.   Experimental protocols involving the animals 
were in strict accord with the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care and Use Committee 
at the University of Kentucky.   
        
IIc.  DAT Function In Vivo.   
Electrochemical electrodes were prepared and experiments conducted 
using previously described methods (Middleton et al., 2004).  Electrodes 
contained a single carbon fiber (33 μm diameter) in a pulled glass capillary (4 
mm outer diameter, 0.80 mm wall diameter).  The exposed carbon fiber extended 
50-150 μm beyond the tip of the glass capillary.  Electrodes for some 
experiments were purchased from Quanteon (Lexington, KY).  To enhance 
selectivity for DA, the carbon fiber electrode was coated with Nafion polymer (5% 
solution, 6-8 coats).  Electrodes were calibrated in vitro to determine the 
sensitivity and selectivity for DA.  Calibration curves were generated using a 
range of DA concentrations (1.0 – 10 μM, at 22 °C in 0.1 M phosphate buffered 
saline solution, pH 4.0).  Electrodes were sensitive to DA and the mean 
selectivity ratio of DA/ascorbic acid was 606 ± 71 to 1 (n = 57).  Subsequently, 
each carbon fiber electrode was attached to a single barrel micropipette (tip 
diameter of 10-15 μm) with dental wax.  The tips of the electrode and 
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micropipette were positioned 250 - 300 μm apart.  Micropipettes were prepared 
from monofilament glass (1.0 mm O.D., 0.58 mm I.D.) using a vertical pipette 
puller (Model 720, David Kopf Instruments, Tujunga, CA).  Single barreled 
micropipettes were filled with DA (200 μM, in 154 mM NaCl and 100 μM ascorbic 
acid, pH 7.4) immediately before conducting the experiment.  The concentration 
of DA for ejection was chosen based on the linear kinetics of DA uptake at this 
concentration, i.e., DA concentrations that do not saturate DAT in striatum 
(Zahniser et al., 1999). 
 
Rats were anesthetized with urethane (1.25 - 1.5 g/kg, i.p.) and placed 
into a Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA).  Body 
temperature was maintained at 37 °C with a heating pad coupled to a rectal 
thermometer (Harvard Apparatus, Holliston, MA).  The scalp was reflected, and a 
section of the skull and dura overlying the frontal cortex was removed.  A small 
hole was drilled in the skull above the posterior cortex for placement of two 
Ag/AgCl reference electrodes, which were cemented into place with dental 
acrylic. The electrode/micropipette assembly was lowered into the dorsal striatum 
(1.5 mm anterior to bregma, 2.3 mm lateral from midline, and 4.0 - 5.5 mm below 
the surface of the cortex) according to the rat brain atlas of Paxinos and Watson 
(1986).  Exogenous DA was pressure ejected (30 - 50 psi, 0.05 ms – 2.5 s) at 5-
min intervals using a Picosprizter II (General Valve Corporation, Fairfield, NJ), 
until reproducible baseline signals (variation in signal amplitude < ± 10%) were 
obtained.  Using a stereomicroscope fitted with a reticule in one eyepiece, 
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ejection volume (250 nl/mm) was monitored by measurement of the fluid 
displaced from the micropipette.  High-speed chronoamperometric 
electrochemical measurements were made continuously (5 times/s, 5 Hz and 
averaged to 1 Hz), using an electrochemical recording system (IVEC 10; Medical 
Systems Corporation, Greenvale, NY).  The oxidation potential was a square 
wave of +0.55 volts applied for 100 ms (versus the Ag/AgCl reference electrode), 
and the resting potential was 0.0 volts for 100 ms. Oxidation currents were 
digitally integrated during the last 80 ms of each 100-ms pulse.   
 
Dose-response curves for nornicotine modulation of DAT function in 
striatum were generated, and each animal received only one dose of nornicotine 
(0, 0.35 – 12.0 mg/kg, s.c.).  Data for the nornicotine dose-response were 
collected as part of a larger study in which the dose-response for nicotine was 
also determined (Middleton et al., 2004).  As such, the saline condition was used 
as the control for both nicotine and nornicotine dose-response analyses.  
Nornicotine or vehicle (0.9% saline) was administered once reproducible 
baseline signals were obtained.  Pressure ejection of DA continued at 5-min 
intervals for 60 min following nornicotine or saline injection.  
 
To determine if nicotinic receptors mediate the response to nornicotine on 
DA clearance in striatum, the effect of mecamylamine was determined in 
separate experiments.  Once reproducible baseline signals were obtained, rats 
were injected s.c. with either mecamylamine (1.5 mg/kg) or saline, followed 40 
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min later by a second s.c. injection of nornicotine (8.0 mg/kg) or saline.  
Nornicotine dose was chosen based on the dose-response curves generated in 
the above experiments, i.e., maximal inhibition of DAT function was observed at 
8.0 mg/kg.  The mecamylamine dose was chosen based on its ability to inhibit 
the acute locomotor stimulant effects of nicotine (Miller et al., 2001).  DA was 
pressure ejected every 5 min during the 40 min period following the first s.c. 
injection and for 60 min following the second s.c. injection.  Doses of nornicotine 
represent the perchlorate salt weight, and the injection volume was 1 ml/kg body 
weight.   
 
IId.  [3H]DA Uptake Assay.   
 [3H]DA uptake assays were performed using rat striatal synaptosomes as 
previously described (Teng et al., 1997).  Striata from individual rats were 
homogenized in 20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM 
NaHCO3, pH 7.4) with 14 passes of a Teflon pestle homogenizer (clearance 
0.003 inches).  Homogenates were centrifuged (2000g, 10 min, 4°C), and 
resulting supernatants were centrifuged (20,000g, 15 min, 4°C).  Pellets were 
resuspended in 2.4 ml of ice-cold assay buffer (125 mM NaCl, 5 mM KCl, 1.5 mM 
MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO4, 10 mM -D-glucose, 25 mM HEPES, 
0.1 mM EDTA, 0.1 mM pargyline, and 0.1 mM ascorbic acid, saturated with 95% 
O2/5% CO2, pH 7.4).  Final protein concentration was 20 µg/ml.  Assays were 
performed in duplicate in a total volume of 500 µl.  Aliquot parts of synaptosomal 
suspension (50 µl) were added to tubes containing 350 µl of buffer and 50 µl of 
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one of nine concentrations of nornicotine or nicotine followed by 50 µl of [3H]DA 
(final concentration, 0.1 µM).  Accumulation proceeded for 10 min at 34°C, and 
was terminated by addition of 3 ml of ice-cold buffer containing catechol (1 mM), 
followed by rapid filtration through Whatman GF/B glass fiber filters presoaked 
with catechol (1 mM).  Filters were washed three times with ice-cold buffer, 
transferred to scintillation vials and radioactivity determined.  
 
 IIc.  Data Analysis   
 In vivo voltammetry data are represented as mean values + SEM, and n 
represents the number of animals in a treatment group.  Three parameters were 
determined from the DA oxidation currents; Amax, which is defined by the maximal 
change in extracellular DA concentration; T80, the time for the signal to decay by 
80% minus the rise time of the signal; and DA clearance rate (CLDA), which 
provides a measure of the efficiency of DAT to remove DA from the extracellular 
space and is defined as the amount of DA pressure ejected, divided by the area 
under the curve for the DA signal (AUCDA).  AUC DA was determined by fitting the 
decay segment of each DA signal trace following the maximal DA signal 
amplitude to the following equation: AUCDA = Σ (yi + yi+1 / 2)*(ti+1- ti); where y is 
the amplitude of the DA signal (micromolar concentration) at any time (t, 
seconds) following DA ejection, and i is initial amplitude of the DA signal trace at 
time zero.  AUCDA of the decay segments of DA signals in striatum were 
determined for the duration of the signal.  Thus, CLDA (L/sec) for each DA signal 
was derived from the amount of ejected DA (moles) divided by the AUCDA 
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(moles/L/sec) for each DA signal.  Figure 14 shows a representative baseline 
signal from striatum and illustrates the parameters utilized to assess DA 
clearance.  Amax is influenced by the clearance at the point in time at peak DA 
concentration. CLDA is a time-averaged estimate over the entire interval of the DA 
signal.  Thus, the observed changes in Amax and CLDA following nornicotine 
injection may not be equivalent.   
 
  Nornicotine dose-response curve and time course were analyzed by two-
way mixed-factor ANOVA, with dose as a between-groups factor and time as 
within-subjects factor.  A separate ANOVA was performed to analyze the time 
course for each of the three parameters, Amax, T80 and CLDA.  To determine the 
dose-related effect of nornicotine, one-way ANOVAs were conducted on the Amax 
and CLDA data at each 5-min time point during the 10-60 min period following 
nornicotine injection.  Dunnett’s post hoc analysis was performed to determine 
differences between treatment means and control mean.  Additionally, apriori 
specific within-subject contrasts determined the time point at which nornicotine 
increased Amax and decreased CLDA compared to baseline (i.e., prior to drug 
injection).    
 
Analysis of mecamylamine-induced inhibition of the effect of nornicotine 
on Amax, T80 and CLDA was accomplished using separate three-way mixed-factor 
ANOVAs, with mecamylamine and nornicotine as between-group factors and 
time as a within-subjects factor.   One-way ANOVAs were utilized to assess the 
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effect of nornicotine and mecamylamine at individual time points.  Additionally, 
apriori specific within-subjects contrasts were performed for each group to 
determine the time point at which Amax and CLDA increased compared to 
baseline.  ANOVA, specific contrasts and post hoc analyses were performed 
using SPSS (standard version 11.0, Chicago, IL); p < 0.05 two-tailed was 
considered significant, unless otherwise indicated.   
 
 For [3H]DA uptake assays, to generate IC50 values for each concentration-
response curve nonlinear regression with sigmoidal curve fit were used 
(GraphPad Prism, version 3.0; GraphPad Software, San Diego, CA).    
 
III.  Results 
IIIa.  Effect of nornicotine on DAT function. 
In the previous chapter data were calculated according to methods 
reported in the literature (Chapter One: Figure 8).  To compare the effect of 
nornicotine on CLDA to the effect of nicotine on CLDA, data from Figure 8 (bottom 
panel) were re-analyzed using the classical pharmacokinetic measure of DA 
clearance described in the Methods section.  Following systemic administration, 
nicotine increases CLDA in striatum (Figure 15).  Nicotine in a dose-related 
manner increased CLDA across 55-min recording sessions.  Two way repeated 
measures ANOVA revealed a significant dose x time interaction (F24,156 = 4.87, p 
< 0.001).  Dunnett’s post hoc analysis determined that the nicotine (0.8 mg/kg) 
group was significantly (p < 0.02) different from the saline control group.  After 
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stable baseline signals were obtained in response to pressure ejection of DA 
(200 μM) at 5-min intervals, either a dose of nicotine (0.6 or 0.8 mg/kg) or saline 
was injected s.c., and pressure ejection of DA at 5-min intervals continued for 60 
min.  Compared to the previous method of calculating DA clearance in Figure 8 
(Chapter One), the graphical presentation shows the curve projected upward 
reflecting an increase in DA clearance (increased CLDA).   
    
The effect of systemic administration of nornicotine (0.35 – 12.0 mg/kg) on 
exogenous DA clearance was determined in the medial dorsal striatum of 
urethane-anesthetized rats using in vivo voltammetry.  Pressure ejection of 200 
μM DA into the striatum at 5-min intervals resulted in stable baseline signals, with 
an Amax of 3.90 μM (± 0.24 μM; mean ± SEM), T80 value of 29.9 s (± 4.09 s) and 
CLDA of 3.54 x 10-8 L/sec (± 0.61 x 10-8 L/sec; n = 32 independent experiments).  
Once the baseline signal stabilized, rats were injected with either a dose of 
nornicotine or saline (control); pressure ejection of DA was continued at 5-min 
intervals for 60 min.  The effect of nornicotine on Amax, T80 and CLDA was 
determined and compared to that obtained after saline injection.  Rise time, 
duration and decay of the baseline DA signal were not different between 
nornicotine- and saline-treated rats.  
 
The dose response for nornicotine-induced modulation of DAT function in 
striatum was determined and the results are shown in Figure 16.  Amax, T80 and 
CLDA were analyzed using separate two-way ANOVAs.  With respect to Amax and 
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CLDA, significant interactions of dose and time were found (F52,351 = 3.58, p < 
0.001 and F52,364 = 1.41, p< 0.05; respectively).  No significant main effects or 
interactions were observed for T80.  To further analyze the interaction for Amax, 
separate one-way ANOVAs were conducted on the data at each 5-min time point 
beginning 10 min after injection of nornicotine or saline (Figure 16, top panel).   A 
nornicotine dose-related increase in Amax was observed; such that significant 
effects of the 8 mg/kg dose of nornicotine were found at 15-40 min and of the 12 
mg/kg dose at 10-60 min (ps < 0.05).   Within subject comparisons revealed that 
the Amax for the saline control group gradually decreased by ~15% of baseline 
during the 55-min period after injection; however, at the 60-min time point, the 
decrease (~23%) in Amax reached significance.  To determine the onset of the 
effect of nornicotine, specific within-subjects contrasts were performed 
comparing Amax at each time point following nornicotine injection to Amax at 
baseline.  A significant increase in Amax was observed 20 min following both the 
8.0 and 12.0 mg/kg doses of nornicotine (p < 0.05).  Amax was increased by a 
maximum of 43% of baseline after the highest dose of nornicotine at the 60 min 
time point.   
 
One-way ANOVAs were conducted also on the CLDA data to assess the 
dose-response at each 5-min time point after nornicotine or saline injection 
(Figure 16, bottom panel).  For the group administered saline, CLDA gradually 
increased by ~25% of baseline across the time course of the session, 
demonstrating that DA application at 5-min intervals across the 60-min session 
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resulted in a small increase in DAT function in the control condition.  Nornicotine 
dose-related decreases in CLDA were observed at 15, 25-45 and 55-60 min (ps < 
0.05).  Dunnett’s post hoc analysis revealed that CLDA was decreased from 25-45 
min in the 8 mg/kg group and at 15, 25-45 and 55-60 min in the 12 mg/kg group 
compared to the control group.  Onset of the effect of nornicotine after the 8.0 
and 12.0 mg/kg doses on CLDA occurred at 20 and 25 min respectively, following 
administration.  A maximum decrease of 30% was observed after 12 mg/kg, 
when compared to the within-subject baseline response.  Comparing the 
nornicotine dose-response curves for Amax and CLDA reveals that the percent 
increase in Amax was similar to the percent decrease in CLDA, suggesting similar 
kinetics over the time course of ~ 60 sec (Figure 16).   
 
To ascertain if the effect of nornicotine on DAT function was mediated by 
nicotinic receptors, the ability of mecamylamine to inhibit nornicotine-induced 
modulation of Amax, T80 and CLDA was determined.  Pressure ejection of DA (200 
μM) resulted in an Amax of 5.78 μM (± 0.58 μM; mean ± SEM), T80 value of 17.4 s 
(± 3.49s), and CLDA value of 4.82 x 10-8 L/sec (± 0.80 x 10-8 L/sec; n = 25 
independent experiments).  Once the baseline signals stabilized, groups of rats 
were injected with mecamylamine (1.5 mg/kg, s.c.) or saline, and 40 min later 
with nornicotine (8 mg/kg, s.c.) or saline.  DA pressure ejection continued at 5-
min intervals for 40 min after the first injection and at 5-min intervals for 60 min 
after the second injection.  Data for the three parameters of DA clearance for 
these experiments are illustrated in Figure 17.  
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Three-way ANOVAs on Amax, T80 and CLDA data were performed to 
determine if mecamylamine inhibited the effect of nornicotine on DAT function.  A 
significant three-way interaction of mecamylamine x nornicotine x time was found 
(F13,325 = 4.04, p < 0.001 and F13,325 = 2.47, p < 0.01) for Amax and CLDA, 
respectively.  No significant interactions or main effects were observed for T80.  In 
the control group injected only with saline, Amax tended to decrease across the 
60-min session when compared to its baseline; and significance was reached at 
45 min following the second saline injection.  For the group administered 
mecamylamine and saline, no differences were observed across the time course 
of the session when compared to within-subject baseline response, indicating 
that mecamylamine alone had no effect on Amax.  For the group administered 
saline and nornicotine, the onset of the nornicotine-induced increase in Amax 
occurred 25 min after the nornicotine injection (within-subject comparison, p < 
0.05).  At the 60-min time point, nornicotine maximally increased Amax by 32% 
compared to baseline.  To determine if mecamylamine inhibited the effect of 
nornicotine, one-way ANOVAs were performed to compare the treatment groups 
at each time point, beginning at the onset of the nornicotine effect (i.e., from 25-
60 min).   From 45-60 min, Amax for the group administered mecamylamine and 
nornicotine was significantly less than that for the group administered saline and 
nornicotine (p < 0.05), and not different from the group administered only saline, 
indicating that mecamylamine completely inhibited the effect of nornicotine.  
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Similar results were obtained when the CLDA parameter was analyzed 
(Figure 17, bottom panel).  As in the previous experiments described above, one-
way ANOVA comparing the groups at each time point revealed that CLDA for the 
group administered saline and nornicotine was lower at 15-25, 35, 45, and 55 
min than that for the control group administered only saline (p < 0.05, one tailed).  
Moreover, CLDA for the group administered saline and nornicotine was lower than 
the group administered mecamylamine and nornicotine across the same time 
period.  Importantly, the group administered mecamylamine and nornicotine was 
not different from the control group only administered saline, indicating that 
mecamylamine completely inhibited the effect of nornicotine.   
 
Comparing the percent change in Amax and CLDA for the group 
administered mecamylamine and saline and for the group administered saline 
and nornicotine revealed similar percentage changes.  However, comparison of 
the percentage change in Amax and CLDA for the saline control group and for the 
group administered mecamylamine and nornicotine revealed a decrease in Amax 
of 20% for each group, whereas CLDA increased 50% and 60%, respectively.  
These results appear to be due to greater variability in the CLDA estimates 
relative to the estimate for Amax.   
 
To determine if nicotine and nornicotine were acting at nicotinic receptors 
located on DA nerve terminals to inhibit DAT function, the [3H]DA uptake assay 
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was performed using striatal synaptosomes from drug-naïve rats.  [3H]DA uptake 
was not inhibited by either nicotine or nornicotine (IC50 > 100 μM; Table 1).  
 
IV.  DISCUSSION 
 
Results from the current in vivo voltammetry study show that systemic 
administration of nornicotine decreased DA clearance in striatum in a dose-
related manner, demonstrating that nornicotine inhibits striatal DAT function.  The 
nornicotine-induced decrease in DA clearance was inhibited completely by 
mecamylamine, a noncompetitive and nonselective nicotinic receptor antagonist, 
indicating that this effect of nornicotine on DAT function is mediated by nicotinic 
receptors.  In contrast, nornicotine did not inhibit [3H]DA uptake into striatal 
synaptosomes obtained from drug-naïve rats.  Taken together, these results 
suggest that nornicotine activates nicotinic receptors which are located at sites 
other than on DA nerve terminals in striatum to inhibit DAT function in vivo.   
In the current studies mecamylamine was chosen as the nicotinic receptor 
antagonist to show nicotinic receptor mediation of the effect of nornicotine.  The 
hallmark of an action at nicotinic receptors is blockade by mecamylamine.  This 
is the first approach that the majority of studies use to show nicotinic receptor 
involvement (Meyer et al., 1997; Papke et al., 2001; Middleton et al., 2004; 
Damaj et al., 2005; Levin et al., 2005; Sacco et al., 2005).  It will be interesting in 
future studies to examine the effects of subtype selective antagonists on the 
nornicotine-induced decrease in DA clearance.    
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Previous studies have shown that nicotine and nornicotine evoke DA 
release from rat striatal slices (Dwoskin et al., 1993; Teng et al., 1997; 
Puttfarcken et al., 2000; Wonnacott et al., 2000; Green et al., 2001).  
Furthermore, in a dose-related manner, nicotine enhances DAT function in 
striatum, as demonstrated by increased DA clearance using in vivo voltammetry 
(Middleton et al., 2004).  In contrast to nicotine, the current study shows that 
nornicotine decreases DA clearance in vivo using the same methodological 
preparation.  The observation that nornicotine exhibits antipodal effects 
compared to nicotine with respect to DAT function in vivo was unexpected and 
does not support the hypothesis.  Potential mechanisms underlying the diametric 
effects of nicotine and nornicotine on DAT function may be due to the 
involvement of different nicotinic receptor subtypes modulating DAT function 
and/or may be associated with differential neural circuitry (see Chapter Six for 
further discussion).   
The current study also shows that both nornicotine and nicotine have no 
effect on [3H]DA uptake into striatal synaptosomes, which is consistent with 
previous reports determining the effect of nicotine in vitro (Carr et al., 1989; Zhu 
et al., 2003).  Taken together with the results from the in vivo voltammetry 
studies, these findings suggest that the nicotinic receptors mediating DAT 
function in vivo are located on dopaminergic cell bodies in the substantia nigra or 
in brain regions other than striatum.  However, procedural differences between 
the in vivo and in vitro preparations, such as the use of the urethane anesthetic in 
vivo, may also contribute to the differential results obtained.  Evidence supporting 
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a critical role for nicotinic receptors at the level of the dopaminergic cell body is 
provided from studies in which local administration of nicotine into the substantia 
nigra or ventral tegmental area evokes DA release in striatum and nucleus 
accumbens, respectively (Blaha and Winn, 1993; Nisell et al., 1994b; Panagis et 
al., 1996; Sziraki et al., 2002).  Additionally, local administration of 
mecamylamine into the ventral tegmental area was shown to inhibit DA release 
in the nucleus accumbens following peripheral administration of nicotine (Sziraki 
et al., 2002).  Thus, as has been suggested for nicotine, nicotinic receptors at the 
level of the substantia nigra may be involved in modulating DAT function in 
striatum following peripheral nornicotine administration.  
 
DA cell bodies in substantia nigra have mRNAs that express multiple 
nicotinic receptor subunits (α2- α7 and β2- β4; Klink et al., 2001; Azam et al., 
2002; Zoli et al., 2002; Wooltorton et al., 2003).  The specific nicotinic receptor 
subtypes expressed by nigrostriatal neurons are defined by specific combinations 
of subunits expressed.  Pair-wise expression of nicotinic receptor subunits in 
Xenopus oocytes initially revealed characteristic pharmacological profiles, i.e., 
relative sensitivity and responsiveness to a range of nicotinic agonists and 
antagonists (Luetje and Patrick, 1991).   Furthermore, inclusion of a third type of 
subunit (e.g., α5 with α3 and β2) in cell expression systems resulted in an altered 
responsiveness (i.e., calcium permeability and desensitization characteristics) 
when compared with pair-wise subunit expression (Gerzanich et al., 1998).  
Moreover, patch-clamp results from neurons in midbrain slices revealed four 
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different patterns of nicotinic receptor-mediated currents, suggesting stimulation 
of structurally complex native nicotinic receptors potentially containing 
combinations of as many as four different subunits (Klink et al, 2001).   
Furthermore, nicotinic receptor subtypes expressed at the level of the substantia 
nigra may be different from those at the terminals in striatum (Klink et al., 2001; 
Azam et al., 2002; Zoli et al., 2002; Wooltorton et al., 2003), which also could 
explain the lack of nornicotine inhibition of DA uptake using striatal 
synaptosomes.  More than one nicotinic receptor subtype has been suggested to 
mediate nicotine-evoked DA release in striatum (Kulak et al., 1997; Kaiser et al., 
1998; Dwoskin et al., 2004).  The current evidence provides the first report that 
more than one nicotinic receptor subtype may mediate DAT function, since 
nicotine and nornicotine both mediate DAT function but in a qualitatively different 
manner.   
 
    Nicotine is an effective pharmacotherapy for the cessation of tobacco 
smoking when used alone or in combination with other drugs or clinical programs 
(Po, 1993; Rose et al., 1994; Balfour and Fagerstrom, 1996; Glover and Glover, 
2001; Karnath, 2002).  However, despite efficacy with nicotine replacement, the 
majority of smokers continue to relapse, suggesting that more efficacious 
therapeutic agents are needed.  Nornicotine may offer a beneficial alternative to 
nicotine as a tobacco use cessation agent.  The pharmacokinetic profile of 
nornicotine, with its longer half-life and slower clearance compared to nicotine 
(Kyerematen et al., 1990; Crooks and Dwoskin, 1997; Ghosheh et al., 1999), may 
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afford additional advantages over nicotine.  Furthermore, since nornicotine is 
significantly less potent than nicotine in increasing blood pressure and heart rate 
(Mattila, 1963; Risner et al., 1988; Stairs et al., submitted 2005), the safety index 
for nornicotine may be greater than that for nicotine, especially among smokers 
with advanced cardiovascular disease.  Moreover, the ability of nornicotine to 
decrease DAT function in vivo, as shown in the present study, may afford another 
advantage over nicotine as a tobacco use cessation agent.  In this respect, the 
antidepressant agent, bupropion, which inhibits both DAT and norepinephrine 
transporter function (Ascher et al., 1995), has been shown to be efficacious as a 
tobacco smoking cessation agent (Hurt et al., 1997; Jorenby et al., 1999; 
Shiffman et al., 2000).  Thus, nornicotine incorporates both inhibition of DAT 
function and promotion of DA release properties into one molecule, and these 
pharmacological effects have been associated with the clinical efficacy of the 
currently available tobacco cessation products, nicotine and bupropion.   
 
Behavioral studies using animal models also provide support for the use of 
nornicotine as a tobacco use cessation agent.  Nornicotine produces nicotine-like 
discriminative stimulus effects (Rosecrans and Meltzer, 1981; Goldberg, et al., 
1989; Bardo et al., 1997; Desai et al., 1999), as well as nicotine-like effects on 
schedule-controlled operant responding (Risner et al., 1985; 1988).  Recent 
results indicate that nornicotine functions as a positive reinforcer (Bardo et al., 
1999); however, under similar experimental conditions, nornicotine is associated 
with a lower rate of responding in comparison with nicotine (Corrigall and Coen, 
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1989; Donny et al., 1995; Bardo et al., 1999), suggesting that nornicotine has a 
lower reinforcing efficacy.  Moreover, nornicotine has been shown to decrease 
self-administration of nicotine in rats (Green et al., 2000).  Furthermore, across 
repeated nornicotine pretreatments, tolerance did not develop to nornicotine-
induced decrease in nicotine self-administration.  Thus, a simple structural 
change, i.e., removal of the N-methyl group from the pyrrolidine ring nitrogen of 
nicotine which affords nornicotine, causes a profound change in its effect on DAT 
function, which may be beneficial with respect to its pharmacological profile.  In 
summary, the current preclinical results suggest that nornicotine could be a 
promising candidate for development as a smoking cessation agent.  
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Figure 14.  Representative baseline DA signal in striatum of urethane-
anesthetized rats prior to nicotine or saline challenge.   Electrochemical 
signals were obtained following pressure ejection of DA (200 μM) and represent 
the baseline response.  Three parameters are obtained from each DA signal; 
Amax, T80 and CLDA.  Data are expressed as μM DA as a function of time (sec) 
after DA pressure ejection.  DA concentrations were calculated based on 
calibration curves generated in vitro.  
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Figure 15.  Following systemic administration, nicotine increases CLDA in 
striatum.  Nicotine in a dose-related manner increased CLDA across 55-min 
recording sessions.  After stable baseline signals were obtained in response to 
pressure ejection of DA (200 μM) at 5-min intervals, either a dose of nicotine (0.6 
or 0.8 mg/kg) or saline was injected s.c. (indicated by the arrow), and pressure 
ejection of DA at 5-min intervals continued for 60 min.  Data are expressed as 
mean, S.E.M. as a percentage of the respective baseline values as a function of 
time (min). (n = 4 - 7 rats/group)  *indicates significant difference from control.   
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Figure 16.  Dose-response for systemically administered nornicotine to 
alter DA signal amplitude (top panel), T80 (middle panel), and CLDA (bottom 
panel) in striatum of urethane-anesthetized rats.  Nornicotine in a dose-
related manner increased signal amplitude and decreased CLDA, but did not 
significantly alter T80 across 60-min recording sessions.  After stable baseline 
signals were obtained in response to pressure ejection of DA (200 μM) at 5-min 
intervals, either a dose of nornicotine (0.35 – 12.0 mg/kg) or saline was injected 
s.c. (indicated by the arrow), and pressure ejection of DA at 5-min intervals 
continued for 60 min.  Data are expressed as mean + SEM as a percentage of 
the respective baseline values as a function of time (min).  Mean baseline values 
for each parameter are provided in the Results section. *indicates significant 
difference between the norNIC (8.0 mg/kg) group and saline; # indicates 
significant difference between the norNIC (12.0 mg/kg) group and saline; norNIC, 
nornicotine; n = 6 - 7 rats/group. 
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Figure 17. Effect of mecamylamine to inhibit the nornicotine-induced 
increase in signal amplitude in striatum.  Signal amplitude is shown in the top 
panel; T80 and CLDA are shown in middle and bottom panels, respectively, for 
comparison.  After stable baseline signals were obtained in response to pressure 
ejection of DA (200 μM) at 5-min intervals, either mecamylamine (1.5 mg/kg) or 
saline was injected s.c., and 40 min later nornicotine (8.0 mg/kg) or saline was 
injected s.c.(second injection indicated by the arrow).  DA continued to be 
pressure ejected at 5-min intervals for 60 min following the second injection.  
Data are expressed as mean + SEM as a percentage of the respective baseline 
values as a function of time (min). Baseline values for each parameter are 
indicated in the Results section.  Legend indicates treatment group designated 
as first/second injection: saline/saline, saline/nornicotine, mecamylamine/saline 
and mecamylamine/nornicotine groups.  norNIC, nornicotine;  MEC, 
mecamylamine; *indicates significant difference between the saline,norNIC group 
and mec-norNIC group; n = 7 - 9 rats/group.   
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Table 1.  Nicotine and nornicotine do not inhibit [3H]DA uptake into striatal 
synaptosomes.   
 
 [
3H]DA Uptake (pmol/min/mg) 
mean ± S.E.M. 
Drug Control 1 nM 10 nM 100 nM 1 µM 10 µM    100 µM 
Nicotine 18.6±1.9 16.6±1.6 17.4±2.6 18.2±2.4 18.0±1.8 17.6±1.8 15.2±1.3
Nornicotine 10.9±1.6 10.2±1.7 10.9±1.8 10.6±1.4 10.8±1.4 10.4±1.0 10.7±1.1
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Chapter Four 
Tolerance Develops to the Nicotine-Induced Increase 
in Dopamine Transporter Function 
I.  Introduction 
 Nicotine is generally accepted to be the active alkaloid in tobacco 
responsible for the reinforcing effects of tobacco (Clarke, 1987; Pomerleau and 
Pomerleau, 1992).  The mesocorticolimbic DA system has been implicated in the 
rewarding properties of drugs of abuse leading to addiction (Tzschentke, 2001).  
Dependence liability for nicotine stems from its intrinsic reinforcing properties and 
the result of activation of DA pathways in brain (Fibiger and Phillips, 1987; 
Corrigall et al., 1992, 1994; Balfour and Benwell, 1993). The mesocorticolimbic 
and nigrostriatal DA systems, including the nucleus accumbens, MPFC and 
striatum and the associated circuitry, have been implicated in drug-induced 
reward.  The nucleus accumbens shell encodes primary appetitive stimuli 
associated with unconditioned drug reward (Kelley and Berridge, 2002), including 
that produced by nicotine (Corrigall et al., 1992; Mathieu-Kia et al., 2002).  The 
MPFC encodes secondary conditioned stimuli associated with environmental 
cues which have been paired with drug, and integration of the motivational 
information from MPFC occurs at least in part in striatum leading to the initiation 
and execution of movement in expectancy and detection of reward (Kelley and 
Berridge, 2002; Martin-Soelch et al., 2001).   
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Nicotine releases DA from its presynaptic terminals in a concentration-
dependent manner in both the mesolimbic (Clarke et al., 1988; Vezina et al., 
1992; Marshall et al., 1997; Puttfarcken et al., 2000; Grady et al., 2002; Bednar 
et al., 2004) and nigrostriatal (Giorguieff-Chesselet et al., 1979; Grady et al., 
1992, 1994; Harsing et al., 1992; Vezina et al., 1992; El-Bizri & Clarke, 1994; 
Marshall et al., 1997; Teng et al., 1997; Kaiser et al., 1998; Puttfarcken et al., 
2000; Wonnacott et al., 2000; Zhou et al., 2001; Grady et al., 2002; Mogg et al., 
2002; Rice and Cragg, 2004) DA systems.  Nicotine-evoked DA release is 
inhibited by mecamylamine, a nicotinic receptor antagonist (Teng et al., 1997).  
Nicotinic receptors are located on cell bodies and nerve terminals of 
dopaminergic pathways (Clarke and Pert, 1985; Varanda et al., 1985; Banerjee 
et al., 1990; Wonnacott, 1997).   
 
Although there are some studies (Grilli et al., 2005) that found that 10 
days of nicotine treatment did not change the releasing effect of nicotine in 
striatal or accumbal synaptosomes, i.e. nicotine released the same amount of 
dopamine after chronic treatment compared to acute nicotine, the majority of  
studies show an enhanced DA release following chronic nicotine.  In a number of 
studies, the effect of nicotine to release DA has been shown to be enhanced 
following repeated nicotine administration compared with its acute administration.  
Following 10 days of nicotine pretreatment, nicotine-evoked DA release from 
superfused striatal slices was greater than nicotine-evoked DA release from a 
control group of rats injected with saline for ten days (Yu and Wecker, 1994).  In 
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in vivo microdialysis studies, nicotine-evoked DA release in the prefrontal cortex 
and striatum was enhanced in rats pretreated with nicotine for 7 or 12 days, 
compared nicotine-evoked DA release from rats receiving acute nicotine (Nisell 
et al., 1996; Marshall et al., 1997).  Also in nucleus accumbens, extracellular DA 
levels in rats pretreated once daily for 5 days with nicotine were increased 
following nicotine challenge compared to the DA levels in rats acutely 
administered nicotine (Benwell et al., 1995).  A study examining the chronic use 
of tobacco in humans determined that DA levels were elevated in the striatum of 
smokers compared to nonsmokers (Court et al., 1998).  Although the effects of 
chronic nicotine on DA release have been studied, the effect of repeated nicotine 
on DA transporter (DAT) function and the role that DAT plays in enhancing 
extracellular DA concentrations in response to repeated nicotine have not been 
examined.   
 
Nicotine-induced alterations in DAT function may contribute to the 
observed nicotine-induced increase in extracellular DA concentrations described 
above.  DAT functions to regulate extracellular DA concentrations, and DAT is a 
target for psychostimulant drugs of abuse.  For example, amphetamine increases 
extracellular DA concentrations directly through an interaction with DAT, 
promoting reverse transport of DA (Liang and Rutledge, 1992; Sulzer et al., 
1995).  Cocaine inhibits DAT function, also resulting in increased extracellular DA 
concentrations (Kuhar et al., 1991).  Additionally, drugs indirectly alter DAT 
function through activation of specific receptors, e.g., raclopride inhibits DA D2 
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receptors which indirectly inhibit DAT function (Cass and Gerhardt, 1994) and 
NMDA stimulates ionotropic glutamate receptors to increase DAT function 
(Welch and Justice, 1996).  Acutely, nicotine also indirectly augments DAT 
function through activation of nicotinic receptors (Middleton et al., 2004).  In 
studies using high speed chronoamperometic recordings to assess DA clearance 
in vivo, acute systemic administration of nicotine dose-dependently increased DA 
clearance in nucleus accumbens, striatum and MPFC of anesthetized rats (Hart 
and Ksir, 1996; Middleton et al., 2004), and the effect of nicotine in MPFC and 
striatum was inhibited by mecamylamine, a noncompetitive, nonselective 
nicotinic receptor antagonist (Middleton et al., 2004).   
 
The goal of the current study was to test the hypothesis that repeated 
nicotine administration will further enhance the nicotine-induced increase in DA 
clearance in striatum and MPFC.  The results of these studies thereby begin to 
delineate the role that DAT plays in enhancing extracellular DA concentrations in 
response to repeated nicotine administration.  
 
II.  Methods 
IIa.  Materials.   S(-)-Nicotine ditartrate (nicotine), 3-hydroxytyramine 
hydrochloride (dopamine, DA), mecamylamine HCl (mecamylamine), 
desipramine hydrochloride and sodium phosphate dibasic were purchased from 
Sigma-Aldrich (Natick, MA).  Sodium phosphate monobasic, sodium chloride, 
ascorbic acid and urethane were purchased from Fisher Scientific (Pittsburgh, 
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PA).  Nafion perfluorinated ion-exchange resin was purchased from Aldrich 
Chemical Co. (Milwaukee, WI).  Dental wax was purchased from Patterson 
Dental Supply, Inc. (Louisville, KY).  Dental acrylic was purchased from CMA 
Microdialysis (Acton, MA).  Epoxylite and PX grade Graphpoxy were purchased 
from Epoxylite Corp. (Irvine, CA) and Dylon Industries, Inc. (Cleveland, OH), 
respectively.  Carbon fibers of 30 μm diameter were purchased from Textron, Inc. 
(Lowell, MA), and 28 gauge lacquer-coated copper wire was purchased from 
Radio Shack (Lexington, KY).  
 
IIb.  Animals.  Male Sprague Dawley rats (200 – 250 g) were obtained 
from Harlan Laboratories (Indianapolis, IN) and were housed two per cage with 
free access to food and water in the Division of Lab Animal Resources at the 
College of Pharmacy, University of Kentucky.  Experimental protocols involving 
the animals were in strict concordance with the NIH Guide for the Care and Use 
of Laboratory Animals and were approved by the Institutional Animal Care and 
Use Committee at the University of Kentucky. 
 
 IIc.  Treatment Protocol.  Groups of rats were pretreated (s.c.) with 
nicotine (0.4 or 0.8 mg/kg, 1 ml/kg, for MPFC and striatal experiments, 
respectively) or saline once daily for 5 days.  Twenty-four hours after the last 
nicotine or saline injection, in vivo voltammetry was performed.  During the 
voltammetry experiment, rats were injected with a challenge dose of either 
nicotine or saline.  For MPFC experiments, rats received a challenge injection of 
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either nicotine (0.4 mg/kg, salt weight) or saline.  For striatal experiments, rats 
received a challenge injection of either nicotine (0.8 mg/kg, salt weight) or saline.  
Thus, for each brain region, 4 groups of rats were used and are designated by 
pretreatment/challenge injections, i.e., saline/saline, saline/nicotine, 
nicotine/saline, nicotine/nicotine. 
 
IId.  In Vivo Electrochemical Measurements.  Clearance of exogenously 
applied DA using in vivo voltammetric measurements has been previously shown 
to reliably evaluate DAT function (Wightman et al., 1988; Cass et al., 1992).  
Rats were anesthetized with urethane (1.25 - 1.5 g/kg, i.p.) and placed into a 
Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA).  Previous studies 
from our laboratory have shown that a systemic injection of nicotine (0.4 and 0.8 
mg/kg salt weight for MPFC and striatum, respectively) increased DA clearance 
by ~50% (Middleton et al., 2004).  Thus, these doses of nicotine were chosen for 
the current study to examine the effect of repeated nicotine administration on DA 
clearance.  Body temperature was maintained at 37 °C with a heating pad 
coupled to a rectal thermometer (Harvard Apparatus, Holliston, MA).  The scalp 
was reflected, and a section of the skull and dura overlying the frontal cortex was 
removed.  A small hole was drilled in the skull above the posterior cortex for 
placement of two Ag/AgCl reference electrodes, which were cemented into place 
with dental acrylic. 
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Electrochemical electrodes were prepared and electrochemical 
experiments were conducted using previously described methods (Middleton, et 
al., 2004). Electrochemical recording electrodes contained a single carbon fiber 
(33 μm diameter) in a pulled glass capillary (4 mm outer diameter, 0.80 mm wall 
diameter) sealed with Epoxylite.  Graphite epoxy resin and a 28 gauge lacquer-
coated copper wire were inserted into the glass capillary to establish electrical 
contact with the carbon fiber.   The exposed carbon fiber extended 50-150 μm 
beyond the tip of the glass capillary.  Electrodes for some experiments were 
purchased from Quanteon (Lexington, KY).  To enhance selectivity for DA, the 
carbon fiber electrode was coated with Nafion polymer (5% solution, 6 - 8 coats) 
and cured by heating at 250 °C for 5 min.  Electrodes were calibrated in vitro and 
calibration curves were generated using a range of DA concentrations (1.0 – 10 
μM, at 22 °C in 0.1 M PBS solution, pH 4.0) to determine the sensitivity and 
selectivity for DA.  Electrodes were sensitive to DA and the mean selectivity ratio 
of DA/ascorbic acid was 3806 ± 549 to 1 (n = 69).  Each carbon fiber electrode 
was attached to a single barrel micropipette (tip diameter of 10-15 μm) with 
dental wax.  The electrode and micropipette were positioned 250 - 300 μm apart.  
Micropipettes were prepared from monofilament glass (1.0 mm O.D., 0.58 mm 
I.D.) using a vertical pipette puller (Model 720, David Kopf Instruments, Tujunga, 
CA).  Single barreled micropipettes were filled with DA (200 μM, in 154 mM NaCl 
and 100 μM ascorbic acid, pH 7.4) immediately prior to conducting the 
experiments.  The concentration of DA for ejection was chosen based on the 
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linear kinetics of DA uptake at this concentration, i.e., DA concentrations that do 
not saturate DAT in striatum (Zahniser et al., 1999). 
 
The electrode/micropipette assembly was lowered into the MPFC (2.9 mm 
anterior to bregma, 1.0 mm lateral from midline, and 2.5 – 5.0 mm below the 
surface of the cortex) or dorsal striatum (1.5 mm anterior to bregma, 2.3 mm 
lateral from midline, and 4.0 - 5.5 mm below the surface of the cortex) according 
to the rat brain atlas of Paxinos and Watson (1986).  Exogenous DA was 
pressure ejected at 5-min intervals using a Picosprizter II (General Valve 
Corporation, Fairfield, NJ).  Using a stereomicroscope fitted with a reticule in one 
eyepiece, ejection volume (250 nl/mm) was monitored by measurement of the 
fluid displaced from the micropipette.  The volume and amount of DA pressure 
ejected was constant within each experiment, but varied between experiments 
(12.5 – 200 nl, 2.5 – 40 pmol, 30 - 50 psi, 0.05 ms - 2.5 s).  Ejection volume for 
each experiment was chosen to provide reproducible baseline signals with a 
maximum peak height of ~4 μM (variation in signal amplitude < ± 10%).  High-
speed chronoamperometric electrochemical measurements were made 
continuously (5 times/s, 5 Hz and averaged to 1 Hz), using an electrochemical 
recording system (IVEC 10; Medical Systems Corporation, Greenvale, NY).  The 
oxidation potential was a square wave of +0.55 volts applied for 100 ms (versus 
the Ag/AgCl reference electrode), and the resting potential was 0.0 volts for 100 
ms. Oxidation currents were digitally integrated during the last 80 ms of each 
100-ms pulse.  Electrodes were stable throughout the time course of the 
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experiment, maintaining sensitivity and selectivity for DA.  In some cases, 
electrodes were used for multiple experiments. 
For each experiment, nicotine or saline challenge injection (s.c.) was 
administered once reproducible baseline signals were obtained.  Pressure 
ejection of DA continued at 5-min intervals for 60 min following nicotine or saline 
injection.  In experiments performed in MPFC, rats were pretreated with 
desipramine (25 mg/kg, s.c.) to block DA uptake via the norepinephrine 
transporter (Carboni et al., 1990).   
IIe.  Data and Statistical Analysis.  In vivo voltammetry data are 
represented as mean values + SEM, and n represents the number of animals in 
a treatment group.  Figure 18 shows a representative baseline signal obtained 
from MPFC and illustrates the parameters utilized to assess DA clearance. Three 
parameters were determined from the DA oxidation currents; Amax, which is 
defined by the maximal change in extracellular DA concentration; T80, the time for 
the signal to decay by 80% minus the rise time of the signal; and DA clearance 
rate (CLDA), which provides a measure of the efficiency of DAT to remove DA 
from the extracellular space and is defined as the amount of DA pressure 
ejected, divided by the area under the curve for the DA signal (AUCDA).  AUC DA 
was determined by fitting each DA signal trace following DA application to the 
following equation: AUCDA = ∑(yi + yi+1 / 2)*(ti+1- ti); where y is the amplitude of 
the DA signal (micromolar concentration) at any time (t, seconds) following DA 
ejection, and where i is an integral number from 1 to n that starts at the initial 
time point where the amplitude of the DA signal trace moves above the baseline 
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level.  AUCDA of the DA signals were determined for the duration of each DA 
signal trace.  Thus, CLDA (L/s) for each DA signal was derived from the amount of 
ejected DA (pmoles) divided by the AUCDA (s * pmoles/L) for each DA signal and 
is based on classical pharmacokinetic analysis (Ito et al., 1998; Shargel et al., 
2005).  The half-life or its reciprocal (i.e., the rate constant KT) which has been 
used to describe DA elimination is dependent upon both the volume into which 
the DA distributes as well as the clearance of DA.  The current study focused on 
CLDA, which is a physiological measurement of DA elimination independent of the 
amount or volume of DA that was pressure ejected and independent of the 
volume into which the DA distributes under linear conditions.  Thus, CLDA is a 
direct determination of the physiological process(es) responsible for the removal 
of DA from the pressure ejection site.   
Amax, expressed as amount (μM) at a point in time, is a single 
measurement that defines when the rate of DA dispersal from the ejection site to 
the detector electrode becomes exactly balanced by all rate processes (uptake 
and/or diffusion) that act to lower DA concentrations at a single instant in time.  
As such, Amax represents an instantaneous composite of DA dispersion, diffusion 
and uptake processes.  CLDA is a time-averaged estimate over the entire interval 
of the DA signal that more effectively defines the average efficiency of DA uptake 
into neurons.  Thus, drug-induced changes in Amax and CLDA, which measure 
different components of DA disposition, need not be equivalent.   
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Analysis of the effect of repeated nicotine administration on each of the 
three parameters (Amax, T80 and CLDA) for both brain regions was accomplished 
using separate three-way mixed-factor ANOVAs, with pretreatment and 
challenge as between-group factors and time as a within-subjects factor.   In both 
MPFC and striatum, significant interactions were found for the data expressed as 
Amax and CLDA such that one-way ANOVAs were utilized subsequently to assess 
the effect of repeated nicotine at individual time points.  Additionally, specific 
within-subjects contrasts were performed to determine the time point at which 
nicotine significantly altered Amax and CLDA compared to baseline.  ANOVA, 
specific contrasts and post hoc analyses were performed using SPSS (standard 
version 11.0, Chicago, IL).  p < 0.05 was considered significant, two-tailed.  
Graphs were generated using GraphPad Prism software (Prism v3.0, GraphPad 
software, Inc., San Diego, CA).    
 
III.  Results 
IIIa.  Effect of Repeated Nicotine Administration on Clearance of 
Exogenous DA in MPFC.  The effect of repeated nicotine (0.4 mg/kg) or saline 
administration (s.c.) on clearance of exogenous DA was determined in the MPFC 
using in vivo voltammetry.  Pressure ejection of 200 μM DA into the MPFC at 5 
min intervals resulted in stable baseline signals, with an Amax value of 4.44 μM (± 
0.20 μM; mean ± S.E.M), T80 value of 64.6 s (± 5.61 s), and CLDA of 4.40 x 10-8 
L/s (± 0.67 x 10-8 L/s; n = 33 independent experiments).  Once baseline signals 
stabilized, rats were injected with either a challenge dose of nicotine (0.4 mg/kg) 
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or saline; DA pressure ejection continued at 5-min intervals for 60 min.  The 
effect of the challenge dose of nicotine on Amax, T80 and CLDA was determined 
and compared to that obtained after saline injection (Figure 19).  Rise time, 
duration and decay of the baseline DA signal were not different between the rats 
repeatedly treated with nicotine compared to the saline control rats repeatedly 
injected with saline.   
 
The ability of a challenge dose of nicotine to alter DA clearance in MPFC 
in rats either repeatedly injected with nicotine or saline was determined and the 
data for each parameter (Amax, T80 and CLDA) analyzed using separate three-way 
ANOVAs.  No significant main effects or interactions were observed for T80.   With 
respect to Amax, the 3-way pretreatment x challenge x time interaction was not 
significant; however, the pretreatment x time interaction (F13, 377 = 5.35, p < 
0.001) and the challenge x time interaction (F13, 377 = 2.41, p < 0.01) were 
significant.  Analysis of the data from the group of rats receiving saline once daily 
for 5 days and then a saline challenge on the experiment day (saline control 
group) revealed that compared to baseline, Amax gradually decreased by ~18% 
during the 60-min period, reaching significance at 25 min and at 35-60 min 
following the saline challenge injection (Figure 19, top panel).  Thus, in the saline 
control group, DA application at 5-min intervals for 60 min resulted in a small, but 
significant, decrease in Amax.    
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Interestingly, this effect only occurred in the saline control group (rats 
injected with saline for 5 days and challenged with saline on the experiment day).  
In the groups repeatedly injected with nicotine (both when challenged with saline 
or nicotine on the experiment day) no significant decreases were observed in 
Amax.  It appears that repeated nicotine treatment produces tolerance to the 
increase in DAT function that was observed following saline injection.   
 
Between groups comparisons also revealed that Amax for the group of rats 
injected with saline for 5 days and challenged with nicotine on the experiment 
day (the nicotine control group) was significantly different (p < 0.01) from all of 
the other treatment groups (Figure 19, top panel).  Subsequent one-way 
ANOVAs conducted at each 5-min time point from 10-60 min following challenge 
injection revealed that Amax values for the nicotine control group were different (p 
< 0.05) from all other treatment groups during the period from 45-60 min.  
Compared to the baseline response (within-subject comparisons), the onset of 
the nicotine-induced decrease in Amax for the nicotine control group was 20 min 
following nicotine challenge, and a 41% decrease in Amax was observed at the 60 
min time point in this group.  In contrast, within-subject comparisons also 
revealed that Amax values did not differ from baseline across the 60 min session 
for the group injected with nicotine for 5 days followed by the nicotine challenge.  
Moreover, from 45-60 min, Amax was decreased in the nicotine control group 
compared to the group repeatedly injected with nicotine and then challenged with 
nicotine on the experimental day.  Furthermore, no differences were observed in 
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Amax values between the group repeatedly injected with nicotine and challenged 
with nicotine and the saline control group.  Taken together, these results indicate 
that repeated treatment with nicotine resulted in tolerance to the effect of nicotine 
to decrease Amax.  
 
Analysis of the effect of the nicotine challenge on CLDA revealed a 
significant pretreatment x time interaction (F13,377, p < 0.01) and challenge x time 
interaction (F13,377, p < 0.05).  With respect to the saline control group, there were 
no significant changes in CLDA during the 60 min recording period following 
saline injection compared to baseline, although there was a trend for CLDA to 
increase (Figure 19, bottom panel). With respect to the nicotine control group, 
compared to baseline, the onset of the nicotine-induced increase in CLDA 
occurred at 25 min after nicotine challenge (p < 0.05); and nicotine increased 
CLDA by 59% compared to the saline control group at the 55-min time point.  In 
contrast, within-subject comparisons revealed that CLDA did not differ from 
baseline across the 60 min session in the group repeatedly treated with nicotine 
and then challenged with nicotine on the experimental day.  Between groups 
comparisons also revealed that the nicotine control group was significantly 
different from the group repeatedly injected with nicotine and then challenged 
with nicotine (p < 0.01).  Separate one-way ANOVAs conducted at each time 
point from 10-60 min revealed that at 50 and 55 min, CLDA in the nicotine control 
group was significantly greater (81%) than that in the group repeatedly injected 
with nicotine followed by nicotine challenge.  Furthermore, no significant 
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differences were observed in CLDA values between the nicotine challenge group 
which was repeatedly injected with nicotine and the saline control group.  These 
results indicate that repeated treatment with nicotine resulted in tolerance to the 
effect of nicotine to increase CLDA in MPFC.   
 
IIIb.  Effect of Repeated Nicotine Administration on Clearance of 
Exogenous DA in Striatum.   The effect of repeated nicotine (0.8 mg/kg) or 
saline administration (s.c.) on clearance of exogenous DA was determined in the 
striatum.  Pressure ejection of 200 μM DA into striatum at 5 min intervals resulted 
in stable baseline signals, with an Amax value of 4.28 μM (± 0.14 μM; mean ± 
S.E.M.), T80 value of 18.8 s (± 2.51 s) and CLDA of 0.218 L/s (± 0.028 L/s; n = 33 
independent experiments).  Once baseline signals stabilized, rats were injected 
with either a challenge dose of nicotine (0.8 mg/kg) or saline; DA pressure 
ejection continued at 5-min intervals for 60 min.  The effect of the challenge dose 
of nicotine on Amax, T80 and CLDA was determined and compared to that obtained 
after saline injection (Figure 20).  Rise time, duration and decay of the baseline 
DA signal were not different between the rats repeatedly treated with nicotine 
and the saline control rats. 
 
The ability of a challenge dose of nicotine to alter DA clearance in striatum 
in rats either repeatedly injected with nicotine or saline was determined and the 
data for each parameter (Amax, T80 and CLDA) analyzed using separate three-way 
ANOVAs.  With respect to Amax, a significant interaction of pretreatment x 
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challenge x time was found (F13,403 = 2.22, p < 0.01).  Analysis of the data from 
the saline control group revealed that compared to baseline, Amax gradually 
decreased by ~10% during the 60-min period, however no significant effect was 
observed (Figure 20, top panel).  Thus, in the saline control group, DA 
application into striatum at 5-min intervals for 60 min did not alter Amax.  
 
To further analyze the interaction, subsequent between-groups one-way 
ANOVAs were conducted on the data from each 5-min time point from 10-60 min 
after injection (Figure 20, top panel).   These analyses revealed that the nicotine 
control group (rats repeatedly injected with saline and challenged with nicotine on 
the experiment day) was significantly different (p < 0.05) from all of the other 
treatment groups from 10-35 min.  Compared to the baseline response (within-
subject comparisons), the onset of the nicotine-induced decrease in Amax for the 
nicotine control group was 10 min after the nicotine challenge (p < 0.05), the 
duration of the decrease was from 10-35 min, and a maximal 36% decrease in 
Amax was observed at the 30 min point.  In contrast, within-subject comparisons 
also revealed that Amax values did not differ from baseline across the 60 min 
session for the group injected with nicotine for 5 days followed by the nicotine 
challenge.  Furthermore, no differences were observed in Amax values between 
the group repeatedly injected with nicotine then challenged with nicotine and the 
saline control group.  Taken together, these results indicate that repeated 
treatment with nicotine resulted in tolerance to the effect of nicotine to decrease 
Amax.  
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In contrast to the effect of nicotine on Amax, no significant main effects or 
interactions were observed for T80 and CLDA, when the data were analyzed by 
three-way ANOVA (Fig 20, middle and bottom panels, respectively). CLDA in the 
nicotine control group tended to increase, but this effect did not reach 
significance.  Thus, compared to T80 and CLDA, Amax appears to be the more 
sensitive parameter for detection of the effect of repeated nicotine on clearance 
of exogenous DA in striatum.   
 
IV.  Discussion 
The results from the current in vivo voltammetry study demonstrate that 
tolerance develops to the nicotine-induced increase in clearance of exogenous 
DA in MPFC and striatum.  Following repeated injection with saline, challenge 
with nicotine resulted in an increase in DA clearance in MPFC and striatum 
consistent with previous findings (Middleton et al., 2004).  The current study 
shows that in both MPFC and striatum, DA clearance was decreased in the 
group repeatedly administered nicotine and then challenged with nicotine on the 
experimental day compared to the nicotine control group, which was repeatedly 
administered saline and challenged with nicotine.  Furthermore, DA clearance in 
the group repeatedly administered nicotine and then challenged with nicotine 
was not different from the saline control group, which was repeatedly 
administered saline and then challenged with saline.  The data obtained from the 
CLDA parameter is more variable than the Amax parameter.  This is likely due to 
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the fact that CLDA takes into account multiple measurements over time, whereas, 
Amax only measure a single point.  Thus, tolerance develops to the nicotine-
induced increase in exogenous DA clearance in both MPFC and striatum.  The 
current results extend previous findings showing that nicotine acutely increases 
DA clearance in the MPFC, striatum, and nucleus accumbens and that this effect 
is mediated by nicotinic receptors (Hart and Ksir, 1996; Middleton et al., 2004). 
 
Previously, exogenous DA clearance has been defined as Amax/T80 with 
units of concentration/time (Zahniser et al., 1999).  In more recent assessments 
of DAT function by this group (Sabeti et al., 2002), another parameter has been 
elaborated called DA clearance efficiency.  DA clearance efficiency has been 
defined as a rate constant k, with units of s−1 and is determined by fitting the DA 
signal to a first-order exponential decay function, i.e., A(t)=Amax*e-k(t-t0)  (where A 
is the signal amplitude (µM) at any time t (s) following peak signal amplitude 
(Amax), and k is the first-order rate constant of decay of the DA signal).  However, 
the classical physiological measure of clearance is not represented by either 
Amax/T80 (DA clearance) or k (DA clearance efficiency).  In the current study, the 
classical pharmacokinetic approach has been utilized to assess exogenous DA 
clearance (Ito et al., 1998; Shargel et al., 2005).  The parameter determined in 
the current study, CLDA, was calculated as the amount of DA pressure ejected 
divided by the AUC for each DA signal, with units of volume/time.  CLDA can be 
directly equated to the physiological process of DA elimination from the ejection 
site and provides a direct measure of DA transport via DAT.  Importantly, CLDA is 
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independent of dose or volume of DA pressure ejected and is independent of the 
volume into which DA distributes under linear conditions.  Thus, this analysis 
directly measures the efficiency of DA removal after its exogenous application, 
i.e., the transport process via DAT. 
 
Nicotinic receptor activation acutely results in exocytotic DA release and 
an increase in the clearance of DA from the extracellular space.  The increase in 
DA clearance may result in a sharpening of the DA signal.  In both in vitro 
superfusion assays and in vivo microdialysis studies, nicotine-evoked DA release 
striatum and prefrontal cortex was reported to be greater following repeated 
systemic administration of nicotine than that in rats repeatedly injected with 
saline (Yu and Wecker, 1994; Nisell et al., 1996; Marshall et al., 1997).  
However, the role that DAT may play in the increase in extracellular DA levels 
following repeated nicotine was not considered in the previous studies.  Previous 
research shows that nicotine acutely increases DA clearance, in MPFC, striatum, 
and nucleus accumbens (Hart and Ksir, 1996; Middleton et al., 2004), which 
would result in decreased extracellular DA concentrations.  The current study 
shows that tolerance develops to the increase in DAT function (DA clearance) in 
MPFC and striatum following repeated nicotine administration.  Thus, diminished 
DAT function as a result of repeated nicotine administration would be expected to 
result in greater extracellular DA concentrations consistent with the results of 
previous in vitro superfusion and in vivo microdialysis studies (Yu and Wecker, 
1994; Marshall et al., 1997).   The greater concentrations of DA in the 
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extracellular space may contribute to the salience of the environmental cues 
associated with chronic tobacco use, resulting in an enhancement of conditioned 
reward, making smoking cessation difficult.   
 
Nicotinic receptor activation may modulate DAT function by alterations in 
DA reuptake into the presynaptic terminal and/or by altering DA efflux through 
the transporter under certain conditions.  Nicotine has been reported to enhance 
amphetamine-evoked [3H]DA release from MPFC slices incubated in assay 
buffer in the absence of calcium (Drew et al., 2000).  The absence of calcium in 
the assay buffer in the latter study precludes nicotine-evoked exocytotic DA 
release and suggest that nicotine-induced augmentation of the response to 
amphetamine involves DAT.  The observed nicotine enhancement of the effect of 
amphetamine was inhibited by nicotinic receptor antagonists, mecamylamine and 
dihydro-β-erythroidine, but not by α-bungarotoxin, indicating the involvement of 
heteromeric nicotinic receptors.  Interestingly, nicotine did not enhance 
amphetamine-evoked [3H]DA release in striatum or nucleus accumbens (Drew et 
al., 2000).  Furthermore, the nicotine-induced enhancement of amphetamine-
evoked [3H]DA release from MPFC was maintained after 10 days of nicotine 
administration (Drew and Werling, 2003).  Thus, these findings suggest that 
nicotinic receptors also modulate DAT function to enhance amphetamine-
stimulated reverse transport of DA by DAT, although in contrast to the current 
study, tolerance did not develop to the nicotinic receptor enhancement of reverse 
transport of DA by DAT.   
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One mechanism by which nicotine may modulate DAT function is via 
nicotinic receptor-induced augmentation of DAT trafficking to the presynaptic 
terminal membrane.  The relatively rapid nicotine-induced increase in DA 
clearance suggests that new synthesis of DAT protein is not responsible.  
Rather, the time course of response is consistent with trafficking of intracellular 
stores of DAT protein to the terminal membrane.  One potential explanation could 
involve the activation of second messenger signaling cascades.  A study in 
hippocampal neurons revealed that nicotinic receptor activation resulted in an 
increase in intracellular calcium, activating mitogen-activated protein (MAP) 
kinase and calcium/calmodulin-dependent protein kinase pathways to activate 
the cyclic AMP response element binding protein producing transcriptional 
effects (Hu et al., 2002).  Inhibition of the MAP kinase pathway results in 
trafficking of DAT from the plasma membrane to intracellular pools measured by 
biotinylation assays conducted in human embryonic kidney 293 cells (Morón et 
al., 2003).  Taken together, these data suggest a potential role of the MAP kinase 
pathway to increase DAT localization on the plasma membrane, which could 
increase DA clearance following acute administration of nicotine.  Repeated 
nicotine may result in an inhibition of the MAP kinase pathway resulting in 
trafficking of DAT from the plasma membrane, resulting in tolerance to the 
nicotine-induced increase in DA clearance.  
 
  
132 
Tolerance to chronic nicotine administration has been shown in various 
animal models, i.e., locomotor activity, striatal dopamine metabolism and of 
nicotine-induced antinociception (Stolerman et al., 1973; Marks et al., 1983; 
Marks et al., 1991; McCallum et al., 2000; Pietila and Ahtee, 2000).  Another 
potential explanation for the observed tolerance to the nicotine-induced 
enhancement of DA clearance is nicotinic receptor desensitization.  Chronic 
nicotine application resulted in an upregulation of α4β2 receptors in Xenopus 
oocytes (Fenster et al., 1999).  Furthermore, the EC50 for nicotine to produce 
desensitization was the same as that required for upregulation, suggesting that 
upregulation occurs as a result of desensitization.  Using various doses of 
nicotine and different dosing regimens, Rowell and Li (1997) showed that 
nicotinic receptor desensitization was dependent on dose and regimen of 
administration.  Concentrations of nicotine that are achieved by smokers 
desensitize nicotinic receptors located on the mesolimbic DA neurons 
(Pidoplichko et al., 1997).   Tolerance following chronic nicotine has been shown 
in the absence of upregulation of nicotinic receptors (Pauly et al., 1992; 
McCallum et al., 2000).  However, it is also possible that the observed tolerance 
is due to nicotinic receptor upregulation.  Mice chronically treated with nicotine 
have shown and increase in nicotine binding sites in brain (Marks et al., 1983; 
Schwartz and Kellar 1983; Collins et al., 1988; Kassiou et al., 2001; Nuutinen et 
al., 2005).  Recently, in β2 knockout mice, following chronic nicotine treatment, 
upregulation of nicotine binding sites is no longer observed (McCallum et al., 
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2005).  Therefore, nicotine may have differential effects on DAT function 
following repeated administration compared to acute nicotine administration.   
 
More than one nicotinic receptor subtype is thought to be located on DA 
neurons.  Neurotoxins (α-Conotoxin MII) as well as small molecules have been 
shown to inhibit only 50% of nicotine evoked [3H]DA release, suggesting the 
involvement of more than one nicotinic receptor subtype in the DA releasing 
properties of nicotine (Kulak et al., 1997; Kaiser et al., 1998; Wilkins et al., 2002; 
Grinevich et al., 2003; Wei et al., 2005).  Furthermore, nicotinic receptor subtpes 
also desensensitize at different rates, i.e., α7 desensitizes more rapidly than 
α4β2 (Fenster et al., 1997).  It is possible that the subtypes mediating DA release 
and those modulating DAT function desensitize differently.  Therefore, following 
repeated nicotine treatment the nicotinic receptors modulating exocytotic DA 
release may not desensitize leading to an increase in DA release, while the 
nicotinic receptors modulating DAT may desensitize resulting in tolerance to the 
nicotine-induced increase in DA clearance.  Together these mechanisms would 
result in an increase in the extracellular DA concentration.  Thus, chronic nicotine 
is enhancing DA release and concomitantly decreasing DA clearance (current 
study), which may be an important mechanism involved the maintenance of 
smoking behavior. 
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Finally, tolerance to the nicotine-induced increase in DA clearance may be 
due to an increase in nornicotine production.  Nornicotine decreases DAT 
function (Chapter Three).  Following systemic nicotine injection, nicotine reaches 
maximal brain concentration within 5 min and has a brain t1/2 of 52 min.  
However, nicotine metabolism results in production of nornicotine (Ghosheh et 
al., 1999).  Following nicotine injection nornicotine reaches maximal brain 
concentrations 60 min following nicotine injection and has a brain t1/2 of 166 min 
(Ghosheh et al., 1999).   Furthermore, following repeated nicotine treatment, 
nornicotine accumulates in brain (Ghosheh et al., 2001).  Therefore, it is possible 
the nicotine is no longer able to increase DAT function following repeated 
nicotine treatment because nornicotine is inhibiting DAT function. 
 
In summary, the current study shows that tolerance develops to nicotine-
induced enhancement of DAT function following repeated nicotine administration.  
Tolerance to the nicotine-induced increase in DA clearance may be important to 
our understanding of the rewarding properties of tobacco use.  Further studies 
are warranted to examine the pathways involved in the modulation of DAT 
function following both acute and repeated nicotine administration. 
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Figure 18.  Representative baseline DA signal in MPFC of urethane-
anesthetized rats prior to nicotine or saline challenge.   Electrochemical 
signals were obtained following pressure ejection of DA (200 μM) and represent 
the baseline response.  Three parameters are obtained from each DA signal; 
Amax, T80 and CLDA.  Data are expressed as μM DA as a function of time (s) after 
DA pressure ejection.  DA concentrations were calculated based on calibration 
curves generated in vitro.  
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Figure 19.  Tolerance develops to the nicotine-induced decrease in Amax and 
increase in CLDA in MPFC.  Amax, T80 and CLDA are illustrated in the top, middle 
and bottom panels, respectively.  Rats were injected (s.c.) with nicotine (0.4 
mg/kg) or saline once daily for 5 days; 24 hr after the last injection, rats were 
anesthetized and exogenous DA clearance determined using in vivo 
voltammetry.  After stable baseline signals were obtained in response to 
pressure ejection of 200 μM DA at 5-min intervals, rats were challenged with 
nicotine (0.4 mg/kg) or saline and exogenous DA applied at 5-min intervals for 60 
min.  Arrow indicates the time point that rats received the challenge injection.  
Data are expressed as mean and S.E.M. as a percentage of the respective 
baseline values as a function of time (min).  Baseline values for each parameter 
are provided in the Results section.  Legend indicates treatment groups, i.e., 
repeated injection - challenge injection.  SAL-SAL indicates the saline control 
group; SAL-NIC indicates the nicotine control group; NIC-SAL indicates the 
group repeatedly administered nicotine followed by saline challenge; NIC-NIC 
indicates the group repeatedly administered nicotine followed by nicotine 
challenge (n = 8 – 10 rats/group). # difference compared to baseline for the SAL-
SAL group; * difference between SAL-NIC group and all other groups.  
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Figure 20.  Tolerance develops to the nicotine-induced decrease in Amax 
and increase in CLDA in striatum.  Amax, T80 and CLDA are illustrated in the top, 
middle and bottom panels, respectively.  Experiments were conducted as 
described in Figure 19, except that the nicotine dose was 0.8 mg/kg and 
exogenous DA clearance was determined in striatum.  Baseline values for each 
parameter are indicated in the Results section.  Legend is as described in Figure 
19. (n = 8 – 10 rats/group).  Arrow indicates the time point that rats received the 
challenge injection.  * difference between SAL-NIC group and all other groups.  
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Chapter Five 
Nicotine Increases Dopamine Transporter Function  
via a Trafficking-Independent Mechanism 
I.  Introduction 
Nicotine is generally accepted to be the alkaloid in tobacco primarily 
responsible for nicotine dependence (Clarke, 1987; Pomerleau and Pomerleau, 
1992).  Activation of nicotinic receptors by nicotine results in an increase in the 
extracellular concentration of DA, which is thought to mediate the rewarding 
effects of nicotine and maintain tobacco use in dependent individuals (Corrigall et 
al., 1992; Koob,1992; Stolerman and Jarvis, 1995).  Acute nicotine increases DA 
release from its presynaptic terminals in the striatum in a concentration-
dependent manner (Andersson et al., 1981; Dwoskin et al., 1999; Kaiser et al., 
1998; Ksir et al., 1995; Pontieri et al., 1996; Rowell et al., 1987; Vezina et al., 
1992; Westfall et al., 1983).  Synaptic DA concentrations are regulated by the 
DAT, which transports extracellular DA into the presynaptic terminal.  DAT is a 
major target for psychostimulants, e.g., cocaine and amphetamine (Horn, 1990).  
DAT has been shown to be regulated by constitutive internalization and recycling 
(i.e., trafficking), involving transporter phosphorylation and protein-protein 
interactions (Kahlig and Galli, 2003; Loder and Melikian, 2003; Melikian, 2004; 
Torres et al., 2003; Zahniser and Doolen, 2001).   
 
Psychostimulants and second messengers alter DAT function and 
trafficking (Garcia et al., 2005; Gnegy et al., 2004; Kahlig et al., 2004; Holton et 
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al., 2005; Sorkina et al., 2005).  For example, cocaine and amphetamine act at 
DAT to decrease DA clearance in in vivo voltammetry studies (Cass et al., 1993; 
Zahniser et al., 1999).  In contrast, nicotine has been shown to increase the 
clearance of exogenously applied DA in rat striatum, nucleus accumbens and 
medial prefrontal cortex in in vivo voltammetry studies (Hart and Ksir, 1996; 
Middleton et al., 2004).  DAT surface expression in cell expression systems is 
also acutely sensitive to amphetamine and cocaine, which decreases and 
increases DAT surface levels, respectively (Daws et al., 2002; Little et al., 2002; 
Saunders et al., 2000; Zahniser and Sorkin, 2004).  Although through different 
mechanisms, nicotine and amphetamine both evoke [3H]DA release from 
superfused rat striatal slices (Corrigall et al., 1992; Koob, 1992; Stolerman and 
Jarvis, 1995).  Previous results shows that nicotine does not alter [3H]DA uptake 
into striatal synaptosomes upon in vitro exposure to nicotine (Carr et al., 1989; 
Zhu et al., 2003).  However, the effect of nicotine on [3H]DA uptake into striatal 
synaptosomes and on DAT trafficking has not been determined following 
systemic nicotine administration. 
 
Thus, the present study determined if nicotine administration altered 
[3H]DA uptake into rat striatal synaptosomes and the cellular localization of DAT 
in striatum using cell surface biotinylation and subfractionation approaches. The 
ability of nicotine to modulate DAT function, and thereby extracellular DA 
concentration, may have physiological importance with regards to nicotine 
enhancement of cognitive processes such as attention, learning and memory, as 
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well as important clinical relevance with respect to schizophrenia and drug 
abuse.  Therefore, understanding nicotine-induced regulation of DAT function 
may provide further insights into the mechanisms of nicotine action.   
 
The current series of experiments will test the hypotheses that 1) systemic 
pretreatment with nicotine will increase DAT function in striatal synaptosomes in 
vitro, similar to the increase in DA clearance observed in striatum in vivo, 2) the 
effect of nicotine to increase the Vmax of [3H]DA uptake in striatum is mediated 
by nicotinic receptors located on DA nerve terminals in striatum, 3) systemic 
administration of nicotine will increase the number of DAT sites in striatum as 
measured by radioligand binding, and 4) systemic administration of nicotine will 
increase the trafficking of DAT to the neuronal cell surface in striatum. 
 
II.  Methods 
 IIa.  Materials. Antibodies recognizing rat DAT (sc-1433; goat polyclonal 
antibody), calnexin (sc-11397; rabbit polyclonal antibody); β-actin (sc-7210; 
rabbit polyclonal antibody) and protein phosphatase 2A (PP2A; sc-6110; goat 
polyclonal antibody) were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).  Rabbit anti-goat antibody was purchased from Dako Cytomation (#Z 
0454; Carpinteria, CA).  Horseradish peroxidase (HRP) conjugated goat anti-
rabbit antibody was purchased from Bio-Rad (Hercules, CA).  GBR 12909, 
nicotine ditartrate and nomifensine maleate were purchased from Sigma 
Chemical Co. (St. Louis, MO).  Sulfosuccinimidobiotin (sulfo-NHS-biotin) and 
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immunoPure immobilized monomeric avidin gel were purchased from Pierce 
Biotechnology, Inc. (Rockford, IL).  [3H]Dopamine (3,4-ethyl-2 [N-3H] 
dihydroxyphenylethylamine; specific activity 31 Ci/mmol) and [3H]GBR 12935 
([Propylene-2,3-3H] (1-[2-diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine); 
specific activity 43.5 Ci/mmol) were purchased from New England Nuclear 
(Boston, MA).  D-Glucose was purchased from Aldrich Chemical Co, Inc. 
(Milwaukee, WI).  All other chemicals were purchased from Fisher Scientific 
(Pittsburgh, PA).  
 
IIb.  Animals.  Male Sprague-Dawley rats were obtained from Harlan 
Laboratories (Indianapolis, IN) and were housed with free access to food and 
water in a colony room in the Division of Laboratory Animal Resources in the 
College of Pharmacy at the University of Kentucky.  Animal handling procedures 
were approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of Kentucky and were performed in accordance with the 1996 
version of the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
 
IIc.  Synaptosomal [3H]DA uptake.  [3H]DA uptake assays were 
conducted using a previously published method (Zhu et al. 2003).  Separate 
groups of rats were injected with nicotine (0.8 mg/kg, s.c.) or saline.  Nicotine 
dose was chosen based on previous studies from our laboratory showing that 
nicotine (0.32 mg/kg, s.c.) increased DA clearance (~60%) in striatum in vivo 
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(Middleton et al., 2004).  In the current study, rats were killed 5, 10, 40 or 60 min 
post-injection.  Striata were homogenized in 20 ml of ice-cold 0.32 M sucrose 
solution containing 5 mM sodium bicarbonate (pH 7.4) with 16 passes of a Teflon 
pestle homogenizer (clearance, 0.015 in).  Homogenates were centrifuged (2,000 
g, 4 °C, 10 min), and resulting supernatants were centrifuged (20,000 g, 4 °C, 15 
min).  Resulting pellets were resuspended in 2.4 ml of ice-cold assay buffer (125 
mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO4, 10 mM 
glucose, 25 mM N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] 
(HEPES), 0.1 mM EDTA, 0.1 mM pargyline and 0.1 mM L-ascorbic acid, 
saturated with 95% O2/5% CO2, pH 7.4).  Striatal synaptosomes (20 µg protein in 
50 µl) were incubated in an oxygenated environment for 5 min at 34 °C.  
Subsequently, one of ten [3H]DA concentrations (1 nM - 5 µM) were added to 
each tube.  Total assay volume was 500 µl.  Nonspecific [3H]DA uptake was 
determined in the presence of 10 µM nomifensine.  Incubation continued for 10 
min at 34 °C and was terminated by the addition of 3 ml of ice-cold assay buffer 
containing pyrocatechol (1 mM), followed by immediate filtration through 
Whatman GF/B glass fiber filters (presoaked with 1 mM pyrocatechol for 3 h).  
Filters were washed 3 times with 3 ml ice-cold buffer containing 1 mM 
pyrocatechol using a Brandel cell harvester (Model MP-43RS; Biochemical 
Research and Development Laboratories Inc., Gaithersburg, MD).  Radioactivity 
was determined by liquid scintillation spectrometry (Model B1600TR, Perkin-
Elmer Life Sciences, Downers Grove, IL).  Protein concentrations were 
determined with bovine serum albumin as the standard (Bradford, 1976).  Vmax 
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and Kt were determined using GraphPad Prism software (GraphPad Prism, 
version 3.0; GraphPad Software, San Diego, CA). 
  
 IId.  [3H]GBR 12935 Binding.  To determine if nicotine pretreatment 
alters the total number of DAT sites, [3H]GBR 12935 binding assays were 
performed using striata obtained from groups of rats injected with nicotine (0.8 
mg/kg, s.c.) or saline and killed 5, 10 or 40 min post-injection.  Striata was 
obtained and stored at -70 °C until assay.  Striata were homogenized with a 
polytron homogenizer (setting 40; Tekmar, Cincinnati, OH), in 10 volumes of ice-
cold assay buffer (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, and 1.2 mM 
MgSO4, pH 7.5).  Homogenates were incubated at 37 °C for 5 min, placed on ice, 
and centrifuged (25,000 g, 20 min, 4 °C).  Pellets were resuspended in 10 
volumes of ice-cold Milli-Q water, incubated at 37 °C for 5 min, and centrifuged 
(25,000 g, 20 min, 4 °C).  Pellets were resuspended in 10 volumes of ice-cold 
10% assay buffer and incubation and centrifugation steps repeated twice.  Final 
pellets were stored in 10% assay buffer at -70 °C until assay, where upon pellets 
were resuspended in 20 ml assay buffer.  Samples (250 μl), consisting of 100 – 
140 μg of membrane protein and a range of [3H]GBR 12935 concentrations (0.1– 
35 nM) in assay buffer containing 50 mM Tris, were incubated for 90 min at 4 °C.  
Nonspecific binding was determined in the presence of 10 μM GBR 12909.  
Reactions were terminated by dilution of the samples with 3 ml of ice-cold 20 mM 
Krebs-HEPES buffer followed by immediate filtration through Whatman GF/B 
glass fiber filters presoaked for 2 hrs in 0.5% polyethylenimine using the Brandel 
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harvester.  Filters were rinsed 3 times with 3 ml of ice-cold 20 mM buffer, 
transferred to vials, and scintillation cocktail (4 ml) added.  Radioactivity was 
determined using a Tri-Carb 2100 TR liquid scintillation analyzer (PerkinElmer 
Life Sciences).  Protein concentrations were determined as previously described.  
Kinetic parameters (Bmax and Kd) of [3H]GBR 12935 binding were determined 
using GraphPad Prism software, version 3.0. 
 
IIe.  Biotinylation and Immunoblotting Assay.  For the determination of 
total, surface and intracellular levels of DAT protein in striatal synaptosomes, 
surface biotinylation and immunoblot analysis were performed as described 
previously (Apparsundaram et al., 1998; Melikian et al., 1996; Ramamoorthy et 
al., 1998; Zhu et al., 2005).  Striatal synaptosomes were obtained as described 
above for [3H]DA uptake assays.  Impermeant biotinylation reagent sulfo-NHS-
biotin was used for the isolation of plasma membrane proteins.  DAT protein was 
identified using polyclonal DAT antibody (Taubenblatt et al., 1999; Salvatore et 
al., 2003; Vaughan et al., 1997).  
 
Specifically, samples of striatal synaptosomes (500 µg total protein) were 
incubated for 1 h at 4 °C with continual shaking in 500 µl of 1.5 mg/ml sulfo-NHS-
biotin in phosphate buffered saline/Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5 
mM KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2, 0.1 mM CaCl2, pH 7.3).  After 
incubation, samples were centrifuged (8,000 g, 4 °C, 4 min).  To remove the free 
biotinylation reagent, the resulting pellet was resuspended in 1 ml of ice-cold 100 
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mM glycine in PBS/Ca/Mg buffer and centrifuged (8,000 g, 4 °C, 4 min).  The 
resuspension and centrifugation steps were repeated.  Final pellets were 
resuspended in 1 ml of ice-cold 100 mM glycine in PBS/Ca/Mg buffer and 
incubated with continual shaking for 30 min at 4 °C.  Samples were centrifuged 
(8,000 g, 4 °C, 4 min) and the resulting pellets were resuspended in 1 ml ice-cold 
PBS/Ca/Mg buffer and centrifuged again.  Resuspension and centrifugation 
steps were repeated twice to remove excess glycine.  Final pellets were lysed by 
sonication for 2-4 s in 300 µl Triton X-100 buffer (10 mM Tris, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1.0% Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM 
pepstatin, 250 µM phenylmethysulfonyl fluoride) followed by incubation and 
continual shaking for 20 min at 4 °C.  Lysates (300 µl) were centrifuged (21,000 
g, 4 °C, 20 min).  Pellets were discarded and 100 µl of each supernatant was 
stored at -20 °C for determination of total immunoreactive DAT.   Remaining 
supernatant was incubated with continuous shaking in the presence of 
monomeric avidin beads in Triton-X100 buffer (100 µl/tube) for 1 h at 22-24 °C.  
Samples were centrifuged (17,000 g, 4 min, 4 °C), and supernatants containing 
non-biotinylated proteins (intracellular) were stored at -20 °C.  Resulting pellets 
containing biotinylated proteins (cell-surface) were resuspended in 1 ml of 1.0% 
Triton X-100 buffer and centrifuged (17,000 g, 4 min, 4 °C), and the pellets were 
resuspended and centrifuged two times.  Final pellets consisted of biotinylated 
proteins adsorbed to monomeric avidin beads.  Biotinylated proteins were eluted 
by incubating with 50 µl Laemmli buffer (62.5 mM Tris-HCl, 20% glycerol, 2% 
sodium dodecyl sulfate (SDS), 0.05% β-mercaptoethanol and 0.05% 
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bromophenol blue, pH 6.8) for 20 min at 22-24 °C.  Total, intracellular and cell 
surface fractions were stored at -20 °C.    
 
Samples (total, intracellular and cell surface fractions) were thawed and 
subjected to gel electrophoresis and Western blotting as previously described 
(Melikian et al. 1994; Salvatore et al. 2003; Zhu et al., 2005).  Briefly, proteins 
were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
for 90 min at 150 V and transferred to Immobilon-P transfer membranes (Cat # 
IPVH00010, 0.45 µm pore size; MILLIPORE Co., Bedford, MA) in transfer buffer 
(50 mM Tris, 250 mM glycine, 3.5 mM SDS) using a Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd., Hercules, CA) for 110 
min at 72 V.  Transfer membranes were incubated with blocking buffer (5% milk 
powder in PBS containing 0.5% Tween 20) for 1 h at 22-24 °C, followed by 
incubation with goat polyclonal DAT antibody (1 µg/ml in blocking buffer) 
overnight at 4 ºC.  Transfer membranes were washed 5 times with wash buffer 
(PBS containing 0.5% Tween 20) at 22-24 °C, and then incubated with rabbit 
anti-goat antibody (1:2500 dilution in blocking buffer) for 1 h at 22-24 °C.  
Transfer membranes were then washed and incubated with peroxidase-
conjugated goat anti-rabbit antibody (diluted 1:5000) for 1 h at 22-24 °C.  Protein 
bands were detected using enhanced chemiluminescence and developed on 
Hyperfilm (ECL-plus; Amersham Biosciences UK Ltd., Little Chalfont 
Buckinghamshire, UK).  After detection and quantification of DAT protein, each 
blot was stripped using Tris buffer (62.5 mM Tris-HCl with 2% SDS and 100 mM 
β-mercaptoethanol, pH 6.8) and reprobed for detection of PP2A and calnexin.   
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PP2A, an intracellular protein (Janssens and Goris, 2001), served as a control 
protein to monitor the efficiency of biotinylation of cell surface proteins and was 
detected using goat polyclonal PP2A antibody (1:500).   Calnexin, an 
endoplasmic reticular protein (Hochstenbach et al., 1992; Krijnse-Locker et al., 
1995; Rajagopalan et al., 1994), was detected using rabbit polyclonal calnexin 
antibody (1:5000) to monitor biotinylation of intracellular proteins.  β-Actin was 
quantified to normalize for protein loading across samples.  
 
Immunoreactive bands were quantified by densitometric scanning using 
Scion image software (Scion Corp., Frederick, MD).  Band density 
measurements were used to calculate levels of DAT in total, non-biotinylated and 
biotinylated fractions.  Specifically, total DAT levels were calculated based on the 
density of DAT-immunoreactive bands in an aliquot of synaptosomal extract 
multiplied by the total volume of extract and divided by the total volume of 
synaptosomal extract subjected to SDS-PAGE.  DAT levels in the non-
biotinylated fractions were calculated as density of DAT-immunoreactive bands in 
an aliquot of supernatant post-avidin incubation multiplied by the total volume of 
the extract and divided by the volume of supernatant subjected to SDS-PAGE.  
In preliminary studies, quantification of PP2A revealed a maximum 10% 
contamination of intracellular proteins in the plasma membrane biotinylated 
fraction.  Immunoreactive bands were quantified and were within the linear range 
of detection. 
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IIf.  Subcellular Fractionation. To verify the results using the biotinylation 
approach, a subcellular fractionation strategy was adapted from previously 
described methods using presynaptic vesicular proteins (Clift-O'Grady et al., 
1990; Huttner et al., 1983).  Briefly, rat striata were homogenized in 0.32 M 
sucrose buffer containing 5 mM HEPES-NaOH (pH 7.3) using a Wheaton 
Instruments Potter Elvejhem homogenizer (10 strokes) and centrifuged (1000 g, 
10 min, 4ºC).  Supernatants were centrifuged (13,000 g, 17 min, 4ºC) to yield a 
crude synaptosomal pellet (P2).  Synaptosomes in this P2 fraction (1 mg) were 
lysed by homogenization (5 strokes) in ice-cold 5 mM HEPES-NaOH (pH 7.4) 
plus protease inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin, 250 
µM phenylmethysulfonyl fluoride).  Synaptic plasma membranes (LP1) and other 
large membranes were separated at 15,000 g for 20 min.  The vesicle enriched 
LP2 pellet was obtained following centrifugation of the resulting supernatant (LS1 
Fraction; 200,000 g, 30 min, 4ºC).  Proteins were extracted from each fraction 
with 1% SDS, 5 mM HEPES-KOH (pH 7.3), 1 mM EDTA, 1 mM EGTA and 
protease inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin, 250 µM 
phenylmethysulfonyl fluoride).  Protein concentrations were determined using the 
bicinchoninic acid method (Pierce, Rockford, IL).  Each fraction (50 µg) was 
subjected to immunoblot analysis with antibodies against DAT, PP2A, calnexin 
and β-actin.  DAT-immunoreactive bands were detected using goat polyclonal 
anti-DAT antibody (1 µg/ml) in blocking buffer (5% milk in PBS containing 0.05% 
Tween 20, pH 7.4) followed by rabbit polyclonal anti-goat antibody (1:2500 
dilution in blocking buffer) and goat alkaline phosphatase conjugated polyclonal 
  
151 
anti-rabbit antibody (1:10,000 dilution).  Protein bands present in the transfer 
membrane were measured using enhanced chemifluorescence (GE Healthcare, 
Piscataway, NJ) with a Typhoon Imaging System (GE Healthcare) and 
Imagequant TL software (GE Healthcare).  Immunoreactive bands were 
quantified and were within the linear range of detection.  β-Actin was quantified to 
normalize for protein loading across samples.  Relative proportion of DAT in the 
plasma membrane was expressed by calculating the ratio LP1/LP1+LP2.   
 
III.  Results 
IIIa.  Nicotine administration increases the Vmax for [3H]DA uptake in 
rat striatum.  Kinetic analysis of [3H]DA uptake was performed in synaptosomes 
obtained 5, 10, 40 or 60 min following administration of nicotine (0.8 mg/kg, s.c.) 
or saline.  Synaptosomal [3H]DA uptake was not different between the saline 
control groups across the time points and as such the data were pooled for 
statistical analysis and graphical presentation (Figure 21).  While the interaction 
between treatment and time was not significantly different, a main effect of 
nicotine treatment was observed (F1,48 = 4.16; p < 0.05).  Compared to the saline 
control group, nicotine  significantly increased (∼25%) the Vmax for [3H]DA uptake 
at 10 and 40 min post-injection (p<0.05).  The effect of nicotine on Vmax was not 
significant at either the 5 or 60 min time points.  There was no change in Kt at any 
time point (Table 2).   
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IIIb.  Nicotine administration does not alter [3H]GBR 12935 binding to 
rat striatal membranes.  No differences between nicotine (0.8 mg/kg) and saline 
groups were observed in either the Bmax or Kd for [3H]GBR 12935 binding at the 
5, 10 or 40 min time points (Table 3), suggesting that nicotine pretreatment does 
not alter the total amount of DAT protein in striatum. 
 
IIIc.  Nicotine administration does not alter the cellular localization of 
DAT in striatum.  To determine if nicotine pretreatment (0.8 mg/kg) altered cell 
surface localization of DAT, rats were administered nicotine or saline and killed 
10 or 40 min later.  Striatal synaptosomes were prepared and biotinylation and 
subfractionation assays were performed.  In all of the groups tested, DAT bands 
were observed at 80 kDa, as previously reported (Salvatore et al., 2003; Zhu et 
al., 2005).  In biotinylation assays, DAT-immunoreactive bands were detectable 
in all three fractions.  DAT band density was not different between nicotine and 
saline treated groups at the 10 and 40 min time points (Figure 22).  There were 
no between-group differences in the levels of control proteins, PP2A (60 kDa), 
calnexin (90 kDa) and β-actin (42 kDa).  Consistent with the results from the 
biotinylation assays, subfractionation experiments also revealed no difference in 
DAT levels in total and plasma membrane fractions (LP1).  No differences 
between the nicotine and saline control groups were observed in the ratio of 
LP1/LP1+LP2 at the 10 min and 40 min time points (Figure 23).  Also, there was 
no difference in the levels of control proteins, β-actin, PP2A and calnexin, 
between nicotine and saline control groups.    
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IV.  Discussion 
The current results demonstrate that 10 and 40 min following nicotine (0.8 
mg/kg) administration, a significant increase (25%) in the Vmax for [3H]DA uptake 
into striatal synaptosomes was observed.  These data are consistent with 
previous findings from our laboratory showing that systemic nicotine increases 
DA clearance in vivo in rat striatum (Middleton et al., 2004).  The increase in DA 
clearance observed in vivo is likely due to an increase in Vmax for DA.  The 
nicotine-induced increase in [3H]DA uptake into striatal synaptosomes was not 
accompanied by an increase in the total amount of DAT protein, as indicated by 
the lack of change in [3H]GBR 12935 binding and in total DAT protein assessed 
by immunoblotting methods in comparison with the saline control group.   
Furthermore, the biotinylation and subfractionation results revealed no changes 
in the cellular distribution of DAT in striatum following nicotine administration.  
Taken together, these results suggest that nicotine increases striatal DA uptake 
in vitro and DA clearance in vivo via a trafficking-independent mechanism.   
  
Previous research using in vivo voltammetry revealed that nicotine 
induced an increase in exogenous DA clearance in striatum in anesthetized rats 
(Middleton et al., 2004).   The nicotine-induced increase in DA clearance was 
dose dependent with the 0.8 mg/kg dose increasing clearance by ~60%.  
Nicotine significantly increased DA clearance 15 min following nicotine 
administration and the increase persisted for one hour post injection (Middleton 
et al., 2004).  Consistent with the latter study, results from the current study show 
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a 25% increase in Vmax for [3H]DA uptake into striatal synaptosomes.  However, 
the percent increase in the current study was lower than that observed in the in 
vivo voltammetry studies.  Furthermore, DAT function in the current in vitro study 
was increased at 10 and 40 min post-injection and was back to saline control 
levels by 60 min following nicotine injection, whereas the effect of nicotine was 
still apparent at 60 min in the in vivo voltammetry studies.  Differences in the 
magnitude and duration of nicotine effect on DAT function in the two assays may 
be due to the fact that DA clearance in the in vivo voltammetry assays is 
measured in localized areas of striatum, whereas the in vitro assay utilizes the 
entire striatum, potentially diluting localized changes.  In this regard, results from 
in vivo voltammetry studies show that the striatum is heterogeneous with respect 
to DA clearance, which may be related to variations in the density DAT (Ciliax et 
al., 1995).   Thus, the smaller magnitude of nicotine effect in the synaptosomal 
preparation may be due to an averaging of effect across this heterogeneous 
brain region.  Furthermore, differences between the assays, including use of 
anesthetic and repeated exposure to exogenous DA in the in vivo studies, may 
have contributed to the observed differences in the magnitude and duration of 
the effect of nicotine on DAT function. 
 
Although in vivo nicotine administration results in an increase in striatal 
DAT function as demonstrated using in vivo voltammetry and in vitro 
synaptosomal [3H]DA uptake, previous results show that when striatum is 
exposed to nicotine in vitro, nicotine produces no effect on  [3H]DA uptake (Carr 
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et al., 1989; Zhu et al., 2003).  These contrasting findings may be due to the 
effect of nicotine at the dopaminergic cell body or at circuitry which has been 
disrupted during the preparation of striatal slice or synaptosomes used in the in 
vitro studies.  
 
 Several studies have shown that DAT undergoes internalization and 
recycling, which may involve dynamin-clathrin mediated pathways and multiple 
protein-protein interactions, such as syntaxin-1A, PP2A, PICK1 and synuclein 
(Lee et al. 2004; Melikian, 2004; Torres et al., 2003; Zahniser and Doolen, 2001).   
Changes in DAT surface expression have been shown to be induced by 
psychostimulants or protein kinase C activation, and such changes correlate with 
alterations in [3H]DA uptake in striatum (Chi and Reith, 2003; Copeland et al. 
1996; Vaughan et al., 1997) and in cell systems expressing DAT (Kahlig et al., 
2004; Little et al., 2002; Pristupa et al. 1998).   The previous studies used 
biotinylation and subfractionation approaches to show drug-induced changes in 
DAT cellular localization.  One mechanism by which the nicotine-induced 
increase in DAT function may occur is via the trafficking of DAT to the cell 
surface.  To assess this potential mechanism, cell surface biotinylation and 
subfractionation approaches were employed to assess DAT cellular localization 
in striatum.  Recent studies have used the biotinylation approach for 
determination of DAT distribution in total, plasma membrane and intracellular 
fractions in rat striatal synaptosomes (Chi and Reith, 2003; Salvatore et al., 2003; 
Zhu et al., 2005).  In the current study, results were also verified using the 
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subfractionation approach for the determination of DAT localization.  However, 
the biotinylation assay revealed no differences in DAT cellular localization 
between the nicotine-treated and saline control groups; and, this finding was 
further confirmed using the subfractionation approach.  Thus, it appears that the 
nicotine-induced increase in DAT function in striatum may occur via a trafficking-
independent mechanism.   
 
Alterations in transporter function in the absence of changes in transporter 
trafficking have been reported previously (Apparsundaram et al., 2001; Zhu et al., 
2005).  Specifically, insulin increases norepinephrine transporter function without 
a change in transporter cellular localization (Apparsundaram et al., 2001).  The 
insulin-induced increase in NET function is likely due to activation of p38 MAP 
kinase and PI-3 kinase pathways (Apparsundaram et al., 2001).  Similarly, p38 
MAP kinase stimulation of the serotonin transporter was also recently shown to 
occur via a trafficking-independent mechanism (Zhu et al., 2005), suggesting that 
multiple pathways exist to regulate neurotransmitter transporter function.   
 
Nicotine has been shown to activate several different second messenger 
pathways.  For example, nicotine releases nitric oxide from rat hippocampal 
slices (Smith et al., 1998).  Nicotine-induced nitric oxide release is inhibited by α-
bungarotoxin, suggesting the involvement of Ca++ permeable α7 nicotinic 
receptors.  Also, nicotinic receptor activation induces extracellular signal-
regulated kinase phosphorylation in PC12 cells (Nakayama et al., 2001), as well 
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as alters calmodulin and mitogen-activated protein kinase function (Hu et al., 
2002).  Recently, the nitric oxide pathway has been implicated in increasing DAT 
function in striatum in studies using rotating disk electrode voltammetry (Volz and 
Schenk, 2004).  It is possible that such signaling mechanisms may be involved in 
the nicotine-induced increase in DAT function without altering cell surface 
localization of DAT.   
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Figure 21.  Nicotine administration increased the Vmax for [3H]DA uptake in 
striatal synaptosomes.  Rats were injected with nicotine (0.32 mg/kg, s.c.; open 
bars) or saline (control, CON; closed bar), and synaptosomes prepared 5, 10, 40 
or 60 min post-injection.  Specific [3H]DA uptake for the 5, 10, 40 and 60 min 
saline control groups was 32.8 ± 1.66,  29.7 ± 1.18, 27.8 ± 1.45, and 33.2 ± 1.72, 
respectively.  Nicotine increased the Vmax for [3H]DA uptake 10 and 40 min 
following nicotine injection.  Data are expressed as mean ± SEM percentage of 
the mean control group. *indicates significant difference from control, p < 0.05; n 
= 6/group.   
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Table 2.  Nicotine pretreatment does not alter the Kt in striatal 
synaptosomes measured by [3H]DA uptake.  
 
 Kt (μM) 
Time (min) Saline Nicotine (0.8 mg/kg) 
5 0.09 ± 0.03 0.12 ± 0.03 
10 0.09 ± 0.03 0.09 ± 0.03 
40 0.08 ± 0.03 0.11 ± 0.03 
60 0.10 ± 0.03 0.10 ± 0.02 
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Table 3.  Nicotine (0.8 mg/kg, s.c.) pretreatment does not alter [3H]GBR 
12935 binding to rat striatal membranes.   
  
Data are expressed as Mean ± S.E.M, n = 4-9/group. 
 Bmax (pmol/mg protein) Kd  (μM) 
Time (min) SALINE NICOTINE SALINE NICOTINE 
5 183 ± 22 192 ± 33 3.3 ± 0.4 4.6 ± 1.0 
10 290 ± 35 195 ± 32 5.3 ± 1.0 4.4 ± 0.5 
40 277 ± 69 229 ± 37 4.8 ± 1.0 5.0 ± 0.7 
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Figure 22.  Biotinylation assays revealed no change in the distribution of 
striatal DAT at 10 or 40 min following nicotine administration.  
Representative immunoblots (Top panel) for DAT, PP2A, calnexin and β-actin in 
total, biotinylated (BIOT) and nonbiotinylated (NB) fractions of striatal 
synaptosomes obtained 10 and 40 min following nicotine (0.32 mg/kg; s.c.) or 
saline injection. Group data for DAT in total, biotinylated (BIOT) and 
nonbiotinylated (NB) fractions of striatal synaptosomes obtained 10 and 40 min 
following nicotine  or saline injection are presented as mean ± S.E.M, n = 5/group 
(Bottom panel).  Immunoreactive bands were within the linear range of detection.  
Biotinylation assays used β-actin as a control for protein loading.  PP2A and 
calnexin were used to monitor biotinylation of proteins located in intracellular 
compartments and were found in the nonbiotinylated fractions.   
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Figure 23.  Subfractionation assays revealed no change in the distribution 
of striatal DAT at 10 and 40 min following nicotine administration.  
Representative immunoblots of DAT, PP2A, calnexin and β-actin in total, LP1 
(synaptic plasma membrane) and LP2 (vesicular) fractions of striatal 
synaptosomes from nicotine (0.32 mg/kg; s.c.) or saline injected rats 10 and 40 
min post-injection (Top panel).  Group data for DAT expressed as the 
LP1/LP1+LP2 ratio at 10 and 40 min following nicotine or saline injection (Bottom 
panel).  LP1/LP1+LP2 ratio represent fraction of DAT in the plasma membrane 
fraction as ratio of DAT in plasma membrane and vesicular fraction.   Data are 
presented as mean ± S.E.M, n = 5/group.  The levels of DAT-immunoreactivity (X 
105 arbitrary units) in total fractions were 18.0 ± 1.34 (saline, 10 min), 16.8 ± 2.37 
(NIC, 10 min), 13.8 ± 1.36 (saline, 40 min) and 15.2 ± 1.92 (NIC, 40 min). 
Immunoreactive bands that were quantified were within the linear range of 
detection.  β-actin was used as a protein loading control.   
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Chapter Six 
Discussion and Conclusions 
I.  Review 
Tobacco dependence is the most common drug of abuse and the leading 
preventable cause of death in the USA (Surgeon General’s Report, 1988; Jaffe, 
1990; USDHS, 2001).  Nicotine, the most abundant alkaloid in tobacco (Bush et 
al., 1993), has intrinsic rewarding properties, which are believed to be 
responsible for tobacco dependence (Koob, 1992; Corrigall et al., 1992; 
Stolerman and Jarvis, 1995; Di Chiara, 2000; Balfour, 2002; Mathieu-Kia et al., 
2002; Garrett et al., 2003).  Volunteers who habitually smoke and are tobacco 
deprived will self-administer nicotine (Henningfield and Goldberg, 1983; Harvey 
et al., 2004; Johnson et al., 2004).  Indicative of its reinforcing properties, nicotine 
is self-administered in animal models (Goldberg et al., 1981; Henningfield and 
Goldberg, 1983; Cox et al., 1984; Corrigall and Coen, 1989; Corrigall et al., 1992, 
1994; Sannerud et al., 1994; Donny et al., 1996, 2003; Rose and Corrigall, 1997; 
Shoaib et al., 1997; Valentine et al., 1997; Rasmusen and Swedberg, 1998; 
Caggiula et al., 2001, 2002; Suto et al., 2001; LeSage et al., 2002, 2003; Fu et 
al., 2003; Paterson et al., 2004).  While nicotine and acetylcholine both act at the 
nicotinic receptor, the brain responds differently to nicotine than acetylcholine.  
Acetylcholine undergoes rapid metabolism by acetylcholinesterase, whereas 
nicotine remains in the brain longer with a t1/2 of 52 min (Ghosheh et al., 1999).  
Thus, the effects of nicotine on synaptic events are prolonged relative to 
acetylcholine.  Therefore, the effect of nicotine on the DA system, and specifically 
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DAT which is responsible for regulating extracellular DA concentrations, is 
important in the overall function of the DA system.   
 
Previous research on the neurobiology of reward and drug addiction has 
focused on the mesocorticolimbic and nigrostriatal DA systems, emphasizing the 
role of the nucleus accumbens, MPFC and striatum.  Recently, focus has been 
placed on the involvement of the striatum and MPFC in reward and 
reinforcement.  The MPFC, which is innervated by dopaminergic projections from 
the ventral tegmental area, is believed to encode secondary conditioned stimuli 
associated with environmental cues paired with drug, leading to reward 
expectancy, which is recognized as important to the process of addiction and 
relapse to drug use (Berridge and Robinson, 1998; Shima and Tanji, 1998; 
Kelley, 1999; DiChiara, 2000; Kelley and Berridge, 2002; Peoples, 2002; Cohen 
et al., 2004; DiChiara et al., 2004; Rose and Behm, 2004; Brody et al., 2004a).  
Integration of the motivational information from the MPFC occurs at least in part 
in striatal neurons, which are innervated by dopaminergic projections from the 
substantia nigra, leading to the initiation and execution of movement in reward 
expectancy and detection of reward (Martin-Soelch et al., 2001). 
 
The experiments conducted in this dissertation project have shown that 
nicotine administration (s.c.) increases DA clearance in rat striatum and MPFC 
and this effect is inhibited by mecamylamine, suggesting nicotinic receptor 
involvement.  Furthermore, tolerance develops to the nicotine-induced increase 
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in DA clearance following repeated nicotine administration in both striatum and 
MPFC.  The nicotine-induced increase in DA clearance in striatum is due to an 
increase in the Vmax of DAT without an increase in trafficking of DAT to the cell 
surface.  Finally, the nicotine metabolite and tobacco alkaloid, nornicotine, was 
shown to have an opposite action of nicotine, i.e., nornicotine administration 
decreases DA clearance in striatum.  The current studies are the first to examine 
the effect of nicotine on DAT function in vivo in both the striatum and MPFC.  
Furthermore, these are the first studies examining the mechanism by which 
nicotine modulates DAT function.   
 
II.  Nicotinic receptor modulation of DAT function in striatum and MPFC 
Using in vivo voltammetry, systemic nicotine, in a dose-related manner, 
increases DA clearance in both striatum and MPFC.  In both brain regions, 
nicotine increased DA clearance by 50%.  However, across the same nicotine 
dose range, differential patterns in the nicotine dose-response curve were 
observed in striatum and MPFC. That is, a monophasic dose-response curve 
was observed in striatum, whereas a U-shaped curve was found in MPFC.    
Maximal effect occurred at a lower dose in MPFC than in striatum (0.4 and 0.8 
mg/kg, respectively).  With respect to the time course of the nicotine effect, in 
both brain regions, the onset of a significant effect on DA clearance occurred 10 
to 15 min after nicotine injection.  The time to maximal response was more rapid 
in MPFC compared with striatum (30 and 45 min, respectively). The time course 
of the response to nicotine in both brain regions is in good agreement with 
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pharmacokinetic data showing a maximal nicotine concentration in rat brain at 5 
min after peripheral nicotine injection and a brain t1/2 of 52 min (Ghosheh et al., 
1999).  Nevertheless, the pattern of the nicotine dose-response curve in the 
present study was different between MPFC and striatum, with MPFC showing 
greater sensitivity to nicotine.  α-Conotoxin MII inhibits nicotine-evoked [3H]DA 
overflow by only 50%, implicating involvement of at least two different nicotinic 
receptor subtypes (Zoli et al., 2002; Salminen et al., 2004; Azam and McIntosh 
2005).  Nicotine does not evoke DA release in microdialysis experiments using 
α4-knockout mice (Marubio et al., 2003), indicating that α4 nicotinic receptors are 
critical for DA release, at least in ventral striatum.  Previously, it was reported that 
nicotine was able to enhance amphetamine-evoked [3H]DA release from rat 
MPFC slices, but not from striatal or nucleus accumbens slices via an action at 
nicotinic receptors (Drew et al., 2000).  Thus, it is possible that striatal nicotinic 
receptors modulating DAT function are different between those in MPFC.   
 
The present study also demonstrates that the nicotine-induced 
enhancement of DA clearance in both MPFC and striatum was inhibited by 
pretreatment of the rats with mecamylamine, a nonselective nicotinic receptor 
antagonist (Varanda et al., 1985).  The hallmark of an action at nicotinic 
receptors is its blockade by mecamylamine.  Thus, the current study utilized 
mecamylamine as the first approach to determine nicotinic receptor involvement 
in the nicotine-induced increase in DA clearance.  Further studies are warranted 
examining the effects of subtype selective antagonists to determine if different 
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subtypes are involved in modulating DAT function between striatum and MPFC.  
These results suggest that nicotine stimulates nicotinic receptors to increase 
DAT function in these two brain regions.  The current results are in agreement 
with previous studies showing that peripheral nicotine administration increased 
DA clearance in the nucleus accumbens (Hart and Ksir, 1996).  In the current 
study, mecamylamine had no effect on its own, but inhibited the effect of nicotine 
on DA clearance in both striatum and MPFC.  While mecamylamine has been 
shown to act at NMDA receptors as well as nicotinic receptors (O’Dell and 
Christensen, 1988), the hallmark of an action at nicotinic receptors is blockade by 
mecamylamine.  Thus, mecamylamine was used in the current studies to 
determine involvement of nicotinic receptors on the nicotine-induced increase in 
DA clearance.  Hart and Ksir (1996) also reported no effect of mecamylamine 
alone on DAT function in nucleus accumbens.  It is possible that the nicotinic 
receptors modulating DA release and DAT function are different.  Since 
acetylcholine is the endogenous ligand for the nicotinic receptor, it is likely that 
there is some basal activity of DA release based on nicotinic receptor activation 
by acetylcholine.  The observation that mecamylamine had no effect alone 
suggests that nicotinic receptors, which modulate DAT function in these brain 
regions, are not tonically activated.  These results support the first hypothesis 
that nicotine will increase DA clearance in the striatum and MPFC in a dose-
dependent manner, and this increase in clearance will be mediated by nicotinic 
receptors.   
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Following nicotine-induced DA release DA can be taken back up into the 
terminal by DAT and can also stimulate presynaptic DA D2 autoreceptors.  D2 
autorecepetor activation decreases both DA synthesis and DA release from 
presynaptic terminals (Starke et al., 1989; Langer, 1997).  Importantly stimulation 
of D2 autoreceptors also modulates DAT function.  Uptake of DA into striatal 
minces and synaptosomes is increased following application of a D2 receptor 
agonist, quinpirole (Meiergerd et al., 1993; Batchelor and Schenk, 1998; 
Thompson et al., 2001).  Furthermore, the quinpirole-induced increase in DA 
uptake is inhibited by spiperone, a D2 receptor antagonist (Thompson et al., 
2001).  Local application of the D2 receptor antagonist raclopride decreased DA 
clearance in striatum, nucleus accumbens and prefrontal cortex (Cass and 
Gerhardt, 1994).  In D2 receptor knockout mice, DA clearance is decreased by 
50% compared to wild-type mice (Dickinson et al., 1999).  It is possible that the 
nicotine-induced increase in DA clearance observed in the current studies may 
be influenced by nicotine-induced DA release followed by activation of D2 
receptors, as stimulation of D2 receptors would lead to and increase in DA 
clearance. 
 
III.  Mechanisms Underlying the Different Shaped Dose-Reponse Curves 
observed in Striatum and MPFC. 
IIIa.  Different nicotinic receptors modulating DA clearance in 
striatum and MPFC. 
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Heteromeric α4β2* nicotinic receptors are most abundant in brain, and 
second most abundant are homomeric α7* nicotinic receptors (Whiting and 
Lindstrom, 1986; Wada et al., 1989; Morris et al., 1990; Schoepfer et al., 1990; 
Anand et al., 1991; Flores et al., 1992; Lukas et al., 1999).  The subunits display 
different, but overlapping, patterns of expression in brain (e.g., β2 mRNA 
expression is prominent in the cerebellum, which exhibits no α4 hybridization; 
Wada et al., 1989).  mRNA for nine subunits (α2–α7 and β2–β4) of nicotinic 
receptors have been identified in SN and VTA dopaminergic neurons (Klink et al., 
2001, Zoli et al., 2002; Azam et al., 2002; Wooltorton et al., 2003), indicating that 
potentially a large number of heteromeric nicotinic receptor subtypes of 
pentameric structure may be expressed by these neurons.  
 
Nicotinic receptors are localized on presynaptic terminals and cell bodies 
of VTA and SN DA neurons (Schwartz et al., 1984; Clarke and Pert, 1985; 
McGehee and Role, 1995; Wonnacott, 1997; Quik et al., 2005); and evidence 
indicates that nicotinic receptor subtypes at cell body and terminal locations differ 
pharmacologically (Reuben et al., 2000; Champtiaux et al., 2003).  In striatal 
synaptosomes, nicotine has a lower affinity for nicotinic receptors than 
acetylcholine, and acetylcholine has equal affinity to epibatidine (a nicotinic 
receptor agonist; Reuben et al., 2000).  However, in a dendrosomal preparation, 
nicotine has equal affinity to epibatidine (Reuben et al., 2000), suggesting that 
the nicotinic receptors in the terminal regions differ from those in the cell body 
regions.  Furthermore, α6β2* receptors have been shown to be located on DA 
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terminals, whereas nonα6(α4β2)* receptors represent the majority of functional 
receptors on DA cell bodies (Champtiaux et al., 2003; Salminen et al., 2004).  
Importantly, α-conotoxin MII inhibits nicotine-evoked [3H]DA overflow by only 
50%, implicating involvement of at least two different nicotinic receptor subtypes 
(Zoli et al., 2002; Salminen et al., 2004; Azam and McIntosh 2005).  It is likely 
that the difference in pharmacology between the nicotinic receptors in the cell 
body regions and the nerve terminal regions play different physiological roles. 
 
The involvement of distinct nicotinic receptor subtypes in striatum and 
MPFC provides a likely explanation for the differential nicotine dose-response 
pattern observed in the current study. Recent studies have demonstrated the 
presence of multiple mRNAs for nicotinic receptor subunits (α2-α7 and β2-β4) 
and their respective proteins in DA cell bodies in both substantia nigra and 
ventral tegmental area; however, differences in the relative abundance of these 
subunits in substantia nigra and ventral tegmental area have also been reported 
(Klink et al., 2001; Azam et al., 2002; Zoli et al., 2002; Wooltorton et al., 2003). 
The nicotinic receptors expressed in the nigrostriatal and mesocorticolimbic DA 
systems depend on the specific combinations of subunits forming functional 
nicotinic receptors.  In striatum, the primary subtypes thought to be expressed 
are the α6β2* and α4(non α6)β2* nicotinic receptors (Zoli et al., 2002).  Pairwise 
expression of nicotinic receptor subunits in Xenopus oocytes initially revealed 
characteristic pharmacological profiles, i.e., relative sensitivity and 
responsiveness to a range of nicotinic ligands (Luetje and Patrick, 1991). 
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Inclusion of a third type of subunit (e.g., α5 with β3 and β2 subunits) in similar 
expression systems further altered the physiological response, calcium 
permeability, and desensitization characteristics of the expressed nicotinic 
receptor subtypes (Gerzanich et al., 1998). Characterization of the physiological 
response of individual neurons in midbrain slices revealed four different patterns 
of nicotinic receptor-mediated currents, revealing the complexity of native 
nicotinic receptors, which purportedly contained as many as four different 
subunits (Klink et al., 2001).  More recently, the selective α6 nicotinic receptor 
antagonist, α-conotoxin MII, has been shown to decrease DA release, 
suggesting the involvement of the α6 subunit in nicotine-evoked DA release 
(Salminen et al., 2004).  Importantly, α-conotoxin MII inhibits nicotine-evoked 
[3H]DA overflow by only 50%, implicating involvement of at least two different 
nicotinic receptor subtypes (Zoli et al., 2002; Salminen et al., 2004; Azam and 
McIntosh 2005). Immunoprecipitation of nicotinic receptors from DA terminals as 
well as electrophysiological studies in DA neurons from various nicotinic receptor 
knockout mice suggest the involvement of α4β2*, α6β2*, α6α4β2* nicotinic 
receptors in DA release (Champtiaux et al., 2003).  
 
IIIb.  Neuronal circuitry is different between striatum and MPFC. 
Another potential explanation for the difference in regional dose-response 
is that the local neuronal circuitry is different between these two brain regions, 
i.e., different afferents impinge on the dopaminergic terminals in striatum and 
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MPFC potentially providing differential regulation of DAT function.  In this regard, 
the U-shaped function in MPFC may be the result of nicotine-induced stimulation 
of an additional neurotransmitter system in the MPFC.  The result of activation of 
the additional neurotransmitter may have opposed the nicotinic receptor-
mediated enhancement of DAT function.  For example, high concentrations of 
nicotine have been shown to activate α7 nicotinic receptors, resulting in 
glutamate release in the frontal cortex (Schilstrom et al., 2000; Marchi et al., 
2002).  Stimulation of metabotropic glutamate receptors has been reported to 
decrease DAT function (Page et al., 2001).  Thus, activation of α7 receptors 
indirectly through glutamate neurotransmission could result in the inhibition of 
DAT function, counteracting activation of the high affinity heteromeric nicotinic 
receptors, which enhance DAT function.   
 
Alternatively, nicotinic receptors may modulate DAT function through 
activation of neural circuitry at the cell body level. Local administration of nicotine 
into the substantia nigra and ventral tegmental area has been shown to evoke 
DA release in striatum and nucleus accumbens, respectively, via stimulation of 
nicotinic receptors in the cell body region (Blaha and Winn, 1993; Sziraki et al., 
2002). Additionally, the effect of peripheral administration of nicotine to increase 
DA release in the nucleus accumbens determined using microdialysis was 
inhibited by local administration of mecamylamine into the ventral tegmental area 
(Sziraki et al., 2002). Thus, it seems plausible that in the current study, 
peripherally administered nicotine may be acting at nicotinic receptors at the level 
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of the cell body to modulate DAT function at the terminal. Furthermore, different 
nicotinic receptor subtypes expressed at the cell body may be responsible for the 
different dose-response patterns observed in MPFC and striatum with respect to 
DA clearance. 
 
Due to the lower DAT density and decreased number of DAT per terminal 
in MPFC compared with striatum, metabolism and diffusion likely play a larger 
role in clearing DA from the extracellular space in MPFC under physiological 
conditions.  However, following pharmacological treatment with nicotine, 
enhanced DAT function in MPFC would be predicted to have a large impact on 
dopaminergic transmission.  Nicotine enhancement of DAT function would result 
in more efficient DA clearance from the extracellular space.   
 
IV.  Data Analysis 
Initially the voltammetry data was presented and analyzed as described in 
the literature.  The results of the analysis were problematic and confusing 
because the clearance data were showing a decrease in clearance when actually 
the results showed an increase in clearance (Figure 8).  Further examination of 
the data presented in the literature revealed that previous investigators were not 
using a correct or most appropriate measure of clearance.  Exogenous DA 
clearance has been defined previously as Amax/T80, a parameter with units of 
concentration/time (Zahniser et al., 1999).  In more recent assessments of DAT 
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function by this group of investigators (Sabeti et al., 2002), another parameter for 
DA clearance has been elaborated and referred to as DA clearance efficiency.  
DA clearance efficiency has been defined as a rate constant k, with units of sec−1 
and is determined by fitting the DA signal to a first-order exponential decay 
function (A(t)=Amax*e-k(t-t0); where A is the signal amplitude (µM) at any time t 
(sec) following peak signal amplitude (Amax), and k is the first-order rate constant 
of decay of the DA signal). However, exogenous DA clearance defined by either 
Amax/T80 or k do not represent the classical physiological measure of clearance.  
In the current studies, the classical pharmacokinetic approach has been utilized 
to assess exogenous DA clearance (Ito et al., 1998; Shargel et al., 2005).  Thus, 
the parameter determined in the current study, CLDA, was calculated as the 
amount of DA pressure ejected divided by the AUC for each DA signal, with units 
of volume/time.  CLDA can be directly equated to the physiological process of DA 
elimination from the ejection site, and represents DA transport via DAT.  
Importantly, CLDA is independent of the concentration of DA that is pressure 
ejected and is independent of the volume into which DA distributes under linear 
conditions.  The current work used a more classical approach for the analysis of 
the clearance parameter, which allowed for a more accurate measurement of DA 
clearance.  Thus, the current analysis directly measures the efficiency of DA 
removal after its exogenous application, i.e., the transport process via DAT. 
 
V. Tolerance Develops to the nicotine-induced increase in DAT function 
following repeated nicotine administration. 
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Following repeated nicotine administration tolerance develops to the 
nicotine-induced increase in DAT function in MPFC and striatum.   Following 
repeated injection with saline, an acute challenge with nicotine resulted in an 
increase in DA clearance in MPFC and striatum consistent with the findings 
presented in Chapter Two (Middleton et al., 2004).  Moreover, following repeated 
treatment with nicotine, DA clearance after nicotine challenge was not different 
from that in the control group repeatedly administered saline and challenged with 
saline.  However, in both MPFC and striatum, DA clearance in the group 
repeatedly injected with nicotine and challenged with nicotine on the experiment 
day was decreased compared to the group of rats injected repeatedly with saline 
and challenged with nicotine on the experiment day.  These results demonstrate 
that tolerance develops to the nicotine-induced increase in DA clearance 
following repeated nicotine injection.  The current results extend previous 
findings showing that systemically administered nicotine increases DA clearance, 
via a nicotinic receptor-mediated mechanism, in several dopaminergic terminal 
regions, including MPFC, striatum, and nucleus accumbens (Hart and Ksir, 1996; 
Middleton et al., 2004).  The current results did not support the third hypothesis 
that repeated nicotine administration will further enhance the nicotine-induced 
increase in DA clearance in striatum and MPFC. 
 
Va.  Acute vs. Repeated Nicotine Administration 
It is possible that initially nicotinic receptor activation causes release of DA 
and subsequently increases the clearance of DA from the synapse.  The 
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increase in DA clearance may cause a sharpening of the DA kinetics.  Following 
nicotine pretreatment, using in vitro superfusion and in vivo microdialysis, 
nicotine-evoked DA release was higher than nicotine-evoked DA release from 
rats injected with saline (Yu and Wecker, 1994; Marshall et al., 1997).   A study 
examining the chronic use of tobacco in humans determined that DA levels were 
elevated in the striatum of smokers compared to nonsmokers (Court et al., 1998), 
which would lead to an increase in DA activity.  Acutely, the increase in DA 
clearance coupled with the immediate increase in DA release may sharpen the 
kinetics of the nicotine-mediated increase in extracellular DA concentration.  By 
sharpening the kinetics, the extracellular DA is removed from the synapse more 
rapidly.  In the current study, tolerance that occurs following repeated nicotine 
administration may cause a flattening of the DA kinetics, thus increasing the 
amount of DA in the extracellular space.   
 
Tolerance to chronic nicotine administration has been shown in various 
animal models, i.e., locomotor activity, striatal dopamine metabolism and of 
nicotine-induced antinociception (Stolerman et al., 1973; Marks et al., 1983; 
Marks et al., 1991; McCallum et al., 2000; Pietila and Ahtee, 2000).  Another 
potential explanation for the tolerance of DA clearance to repeated nicotine 
administration may be due to nicotinic receptor desensitization.  Following long-
term stimulation of nicotinic receptor by agonists, nicotinic receptors are no 
longer able to produce an effect, even in the presence of agonist, i.e. 
desensitization.  Furthermore, the EC50 for nicotine to produce desensitization 
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was the same as that required for upregulation, suggesting that upregulation 
occurs as a result of desensitization (Fenster et al., 1999).  Using various doses 
of nicotine and different dosing regimens, Rowell and Li (1997) showed that 
nicotinic receptors were upregulated and that the degree of desensitization was 
dependent on dose and regimen of administration.  Concentrations of nicotine 
that are achieved by smokers desensitize nicotinic receptors located on the 
mesolimbic DA neurons (Pidoplichko et al., 1997).   Tolerance following chronic 
nicotine has been shown in the absence of upregulation of nicotinic receptors 
(Pauly et al., 1992; McCallum et al., 2000).  However, it is also possible that the 
observed tolerance is due to nicotinic receptor upregulation.  Mice chronically 
treated with nicotine have shown and increase in nicotine binding sites in brain 
(Marks et al., 1983; Schwartz and Kellar 1983; Collins et al., 1988; Kassiou et al., 
2001; Nuutinen et al., 2005).  Recently, in β2 knockout mice, following chronic 
nicotine treatment, upregulation of nicotine binding sites is no longer observed 
(McCallum et al., 2005).  Thus, while acute nicotine increases DAT function, 
repeated nicotine decreases DAT function back to control levels.     
 
Tolerance to the nicotine-induced increase in DA clearance may also be 
due to desensitization of DA D2 autoreceptors.  Following repeated nicotine 
injection, dopamine release is enhanced compared to acute nicotine injection (Yu 
and Wecker, 1994; Marshall et al., 1997).  As mentioned above, D2 receptors 
can modulate DAT function.  Thus, it is possible that following repeated nicotine 
injection the increased amount of extracellular DA results in desensitization of D2 
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autoreceptors and therefore DAT function is no longer increased.  This would 
then result in tolerance to the nicotine-induced increase in DAT function. 
 
Previously, it was reported that nicotine was able to enhance 
amphetamine-evoked [3H]DA release from rat MPFC slices, but not from striatal 
or nucleus accumbens slices via an action at nicotinic receptors (Drew et al., 
2000).  More recently, the same group examined the effect of chronic nicotine on 
amphetamine evoked DA release (Drew and Werling, 2003).  Following chronic 
nicotine treatment, nicotine was still able to enhance amphetamine-stimulated 
DA release, suggesting that even after chronic nicotine; nicotinic receptors may 
not be desensitized.  In contrast, the current studies determined that following 
repeated nicotine administration, tolerance develops to the nicotine-induced 
increase in DA clearance.  It is possible that the nicotinic receptors modulating 
DA release and DA transport are different.  Thus, one subtype may desensitize 
(nicotine can still release DA) and one may not (nicotine can no longer modulate 
DAT function).   
 
Tolerance to the nicotine-induced increase in DA clearance may be due to 
an increase in nornicotine production.  Nornicotine decreases DAT function 
(Chapter Three).  Following systemic nicotine injection, nicotine reaches maximal 
brain concentration within 5 min and has a brain t1/2 of 52 min.  However, nicotine 
metabolism results in production of nornicotine (Ghosheh et al., 1999).  Following 
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nicotine injection nornicotine reaches maximal brain concentrations 60 min 
following nicotine injection and has a brain t1/2 of 166 min (Ghosheh et al., 1999).   
Furthermore, following repeated nicotine treatment, nornicotine accumulates in 
brain (Ghosheh et al., 2001).  Therefore, it is possible the nicotine is no longer 
able to increase DAT function following repeated nicotine treatment because 
nornicotine is inhibiting DAT function.  Following repeated nicotine administration 
it is possible that changes in nicotine metabolism also may occur.  Cytochrome 
P450 (CYP) 2B1 is a nicotine metabolizing enzyme found in the brain.  Following 
7 days of nicotine treatment, CYP 2B1 protein was increased in brain, specifically 
in the brain stem, frontal cortex, striatum and olfactory tubercle (Miksys et al., 
2000).  Increases in the CYP 2B1 protein could lead to an increase in nicotine 
metabolism.  Thus, the difference observed between acute and repeated nicotine 
in striatum and MPFC may be due to differences in nicotine metabolism.   
 
VI.  Nornicotine inhibits DA clearance. 
Attention has focused on the N-demethylated nicotine metabolite and 
minor tobacco alkaloid, nornicotine, as contributing to the neuropharmacological 
effects of nicotine exposure and tobacco use (Crooks and Dwoskin, 1997).  
Nornicotine inhibits [3H]nicotine binding to rat brain membranes with a 50-fold 
lower affinity compared with nicotine (Reavill et al., 1988; Copeland et al., 1991; 
Zhang and Nordberg, 1993; Xu et al., 2001).  In contrast, nicotine and nornicotine 
exhibit similar affinities for the [3H]methyllycaconitine binding site in brain.  These 
results indicate interaction of these alkaloids with both α4β2* and α7* nicotinic 
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receptors.  Similar to nicotine, nornicotine evokes a concentration-dependent, 
Ca2+-dependent and mecamylamine-sensitive increase in DA release from rat 
striatal and nucleus accumbens slices (Dwoskin et al., 1993; Teng et al., 1997; 
Green et al., 2001), indicating that nornicotine acts as an agonist at nicotinic 
receptor subtypes modulating DA release.  In the latter studies, whereas nicotine 
and nornicotine were equipotent in releasing DA from striatal slices, nicotine was 
more potent than nornicotine in releasing DA from nucleus accumbens slices.  
Furthermore, nornicotine is a partial agonist whereas nicotine is a full agonist 
(Green et al., 2001).  It is interesting to note that nornicotine has a longer half-life 
than nicotine in plasma and brain (Kyerematen et al., 1990; Crooks et al., 1995, 
1997; Ghosheh et al., 2001); and following chronic treatment with nicotine, 
nornicotine accumulates in brain reaching pharmacologically relevant 
concentrations (Ghosheh et al., 2001).  The current experiments examined the 
ability of nornicotine to modulate striatal DAT function.  Using in vivo 
voltammetry, systemic administration of nornicotine decreased DA clearance in 
striatum in a dose-related manner, demonstrating that nornicotine inhibits striatal 
DAT function.  The nornicotine-induced decrease in DA clearance was inhibited 
completely by mecamylamine, a noncompetitive and nonselective nicotinic 
receptor antagonist, indicating that this effect of nornicotine on DAT function is 
mediated by nicotinic receptors.  In contrast, nornicotine did not inhibit [3H]DA 
uptake into striatal synaptosomes when nornicotine was incubated with 
synaptosomes obtained from drug-naïve rats.  Similar to nornicotine, incubation 
of synaptosomes from drug-naïve rats with nicotine did not inhibit [3H]DA uptake.  
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Taken together, these results suggest that nornicotine and nicotine activate 
nicotinic receptors which are located at sites other than on DA nerve terminals in 
striatum to inhibit DAT function in vivo.  The current results did not support the 
hypothesis that nornicotine would increase DAT function in striatum, however, 
the effect of nornicotine was mediated by nicotinic receptors. 
 
VII.  Potential Mechanism for the Differences Observed between Nicotine 
and Nornicotine. 
VIIa.  Nicotinic receptor subtypes. 
More than one nicotinic receptor subtype has been suggested to mediate 
nicotine-evoked DA release in striatum (Kaiser et al., 1998; Dwoskin et al., 2004).  
α-Conotoxin MII as well as other small molecules is a nicotinic receptor 
antagonist that partially inhibits DA release, i.e., only inhibits DA release by 50% 
(Wilkins et al., 2002; Grinevich et al., 2003; Wei et al., 2005).  This has led to the 
idea that there are more that one nicotinic receptor subtype that modulate DA 
release, α-conotoxin MII sensitive and α-conotoxin MII resistant subtypes 
(Luetje, 2004).  A recent study examined the subunit composition of nicotinic 
receptors modulating α-conotoxin MII sensitive and resistant DA release in 
striatal synaptosomes and slices using knockout mice for various nicotinic 
receptor subunits (Salminen et al., 2004).  Both the α-conotoxin MII sensitive and 
resistant subtypes required the β2 subunit, however only the α-conotoxin MII 
sensitive subtype required the β3; whereas the α-conotoxin MII resistant 
subtypes required α4.  These data suggest that the primary subtypes involved in 
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DA release are the α6β3β2* and α4β2* subtypes (Salminen et al., 2004).  High 
concentrations of nicotine have been shown to activate α7* nicotinic receptors, 
which results in glutamate release in the frontal cortex (Schilstrom et al., 2000; 
Marchi et al., 2002).  Stimulation of metabotropic glutamate receptors has been 
reported to decrease DAT function (Page et al., 2001).   Thus, multiple nicotinic 
receptor subtypes could be involved in modulation of DAT function.  The current 
evidence provides the first report that more than one nicotinic receptor subtype 
may mediate DAT function, since nicotine and nornicotine both mediate DAT 
function but in a different manner. 
 
VIIb.  Neuronal Circuitry 
The current study also shows that incubation of synaptosomes from drug-
naïve rats with both nornicotine and nicotine does not alter [3H]DA uptake into 
striatal synaptosomes, which is consistent with previous reports determining the 
effect of nicotine in vitro (Carr et al., 1989; Zhu et al., 2003).  Taken together with 
the results from the in vivo voltammetry studies, these findings suggest that the 
nicotinic receptors mediating DAT function in vivo are located on dopaminergic 
cell bodies in the substantia nigra or in brain regions other than striatum.   
However, procedural differences between the in vivo and in vitro preparations, 
such as the use of the urethane anesthetic in vivo, may also contribute to the 
differential results obtained.  The anesthetic used in the current in vivo 
voltammetry experiments, urethane, has been shown to not alter striatal DAT 
function (Sabeti et al., 2003).  
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Evidence supporting a critical role for nicotinic receptors at the level of the 
dopaminergic cell body is provided from studies in which local administration of 
nicotine into the substantia nigra or ventral tegmental area evokes DA release in 
striatum and nucleus accumbens, respectively (Blaha and Winn, 1993; Nisell et 
al., 1994; Sziraki et al., 2002).  Additionally, local administration of 
mecamylamine into the ventral tegmental area was shown to inhibit DA release 
in the nucleus accumbens following peripheral administration of nicotine (Sziraki 
et al., 2002).  Thus, as has been suggested for nicotine, nicotinic receptors at the 
level of the substantia nigra may be involved in modulating DAT function in 
striatum following peripheral nornicotine administration. 
 
VIII. Trafficking Independent modulation of DAT function. 
The current project as well as others have examined the effect of nicotine 
on DA uptake/transport by exposing synaptosomes to nicotine in vitro (Carr et al., 
1989; Zhu et al., 2003).  The results of those studies showed that nicotine did not 
alter DA transport.   In the current studies the effect of nicotine administered in 
vivo on DAT function in vitro were examined.  Furthermore, previous studies 
examined the ability to inhibit DAT function.  In the current study, a saturation 
analysis was performed to determine the kinetic parameters of in vivo nicotine 
administration on DAT function measured in vitro.  In rats pretreated with nicotine 
(0.8 mg/kg, s.c.) and killed 10 and 40 min later, a significant 20-25% increase in 
the Vmax for [3H]DA uptake was observed in striatal synaptosomes.  The dose of 
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nicotine was chosen based on previous results showing that nicotine (0.8 mg/kg) 
increased DA clearance in vivo in rats striatum.  Rats killed at 5 min following 
nicotine injection showed a slight but nonsignificant increase in [3H]DA uptake.  
This effect was diminished to control levels by 60 min following nicotine injection.  
This increase in DA uptake was not accompanied by an increase in the total 
amount of DAT protein as measured by [3H]GBR 12935 binding.  Furthermore, 
nicotine pretreatment did not increase the density of DAT on the cell surface 
membrane as measured using biotinylation and subcellular fractionation 
experiments.  These data support and extend previous findings showing that 
systemic nicotine increases DA clearance in vivo in rat striatum (Middleton et al., 
2004).  The increase in DA clearance in striatum observed in vivo is likely due to 
an increase in the Vmax of DAT.  Taken together, these data suggest that nicotine 
increases DA uptake in striatum in vitro through a trafficking-independent 
mechanism.  These data support the hypothesis that nicotine increases DAT 
function by increasing the Vmax for DA uptake, however, the results did not 
validate the hypothesis that the nicotine-induced increase in DAT function was 
due to an increase in the number of transporters on the cell surface. 
 
VIIIa.  DAT Modulation by different proteins/phosphorylation 
DAT localized at the presynaptic membrane reflects functional DAT that is 
involved in the clearance of extracellular DA.  The mechanism by which nicotine 
modulates DAT function may involve regulation of intracellular signaling 
cascades.  Changes in DAT surface expression have been shown to be induced 
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by activation of protein kinase C or exposure to psychostimulants, and such 
changes correlate with alterations in DA uptake in striatum (Copeland et al. 1996; 
Chi and Reith, 2003; Vaughan et al., 1997) and in cell systems expressing DAT 
(Pristupa et al. 1998).  In cells expressing hDAT, application of amphetamine 
results in a decrease in the cell surface expression of DAT (Kahlig et al., 2004).  
Whereas amphetamine decreases cell surface DAT, cocaine has been shown to 
increase trafficking of DAT to the cell surface (Little et al., 2002).   
 
In the current study, nicotine increases DAT function without a change in 
the cell surface localization of DAT, thus acting differently than other 
psychostimulants.  Nitric oxide may play a role in the nicotine-induced increase in 
DAT function.  Nicotine releases nitric oxide from rat hippocampal slices (Smith 
et al., 1998).  Nicotine also activates voltage gated Ca++ channels which increase 
intracellular Ca++ levels and can lead to an increase in the production of reactive 
oxygen species.  Recently, L-arginine has been shown to increase DAT activity 
using rotating disk electrode voltammetry in striatum by a nitric oxide synthase 
pathway (Volz and Schenk, 2004).  Nicotine activates many different second 
messenger pathways that may be involved in modulating DAT.  For example, 
nicotinic receptor activation induces ERK phosphorylation mediated by CaM 
kinase and MAP kinase in PC12 cells (Nakayama et al., 2001).  ERK 
phophorylation then induces CREB phsophorylation.  In hippocampal neurons, 
nicotine has been shown to activate the transcription factor CREB which is 
dependent on calmodulin and MAP kinase (Zhang et al., 2001; Hu et al., 2002).  
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PI-3 kinase and p38 MAP kinase activate a trafficking-independent pathway for 
NET regulation (Apparsundaram et al., 2001), suggesting that neurons likely 
have multiple pathways to modulate NE clearance capacity intrinsically.  Similar 
to insulin regulation of NET, p38 MAP kinase has been shown to have similar 
effects on the serotonin transporter, i.e., an increase in serotonin uptake without 
a change in trafficking of the serotonin transporter (Zhu et al., 2005).  A 
schematic representation of the multiple pathways that may be involved in 
nicotinic receptor modulation of DAT function is shown in Figure 24.  Taken 
together, these results suggest the possibility that nicotine activates neural 
systems in the striatum that subsequently augment the activity of signaling 
cascades leading to an increase in DAT function without altering cell surface 
localization. 
 
One potential explanation could involve the activation of second 
messenger signaling cascades.  A study in hippocampal neurons revealed that 
nicotinic receptor activation resulted in an increase in intracellular calcium (Hu et 
al., 2002).  The calcium then activated MAP kinase and calcium/calmodulin-
dependent protein kinase pathways to activate the cyclic AMP response element 
binding protein producing transcriptional effects (Hu et al., 2002).  Furthermore, 
inhibition of the MAP kinase pathway results in downregulation of DAT from the 
plasma membrane to intracellular pools as measured by biotinylation in human 
embryonic kidney 293 cells (Morón et al., 2003).  Taken together, these data 
suggest a potential role of the MAP kinase pathway to increase DAT levels on 
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the plasma membrane, and thus, increasing DA clearance following acute 
administration of nicotine.  Repeated nicotine may result in an inhibition of the 
MAP kinase pathway resulting in down regulation of DAT, and therefore, a loss in 
the nicotine-induced increase in DA clearance.  Furthermore, it is possible that 
nicotinic receptor activation could lead to phosphorylation of DAT, which would 
decrease DAT function (Copeland et al., 1996; Vrindavanam et al., 1996; Huff et 
al., 1997; Vaughan et al., 1997; Melikian and Buckley, 1999; Chang et al., 2001).  
Therefore, changes in DAT function can be regulated not only by trafficking but 
by modulating the phosphorylation status of DAT.   
 
IX.  Implications: 
Nicotinic receptor agonists have been shown to increase learning and 
memory in both rats and humans (Levin, 1992; Warburton, 1992; Levin and 
Simon, 1998; Levin et al., 1999; Ernst et al., 2001; Houlihan et al., 2001; Uzum et 
al., 2004).  Due to the lower DAT density and decreased number of DAT per 
terminal in MPFC compared with striatum, metabolism and diffusion likely play a 
larger role in clearing DA from the extracellular space in MPFC under 
physiological conditions. However, following pharmacological treatment with 
nicotine, enhanced DAT function in MPFC would be predicted to have a large 
impact on dopaminergic transmission. Nicotine enhancement of DAT function 
would result in more efficient DA clearance from the extracellular space, and 
cortical function would be disinhibited.  Thus, the ability of nicotinic receptors to 
modulate DAT function, and thereby extracellular DA concentration, may have 
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physiological importance with respect to nicotine enhancement of cognitive 
processes such as attention, learning, and memory, as well as important clinical 
relevance with respect to schizophrenia and drug abuse.   
 
 Nicotine is an effective pharmacotherapy for the cessation of tobacco 
smoking when used alone or in combination with other drugs or clinical programs 
(Po, 1993; Rose et al., 1994; Balfour and Fagerstrom, 1996; Glover and Glover, 
2001; Karnath, 2002).  However, despite efficacy with nicotine replacement, the 
majority of smokers continue to relapse, suggesting that more efficacious 
therapeutic agents are needed.  Nornicotine may offer a beneficial alternative to 
nicotine as a tobacco use cessation agent.  The pharmacokinetic profile of 
nornicotine, with its longer half-life and slower clearance compared to nicotine 
(Kyerematen et al., 1990; Crooks and Dwoskin, 1997; Ghosheh et al., 1999), 
may afford additional advantages over nicotine.  Furthermore, since nornicotine 
is significantly less potent than nicotine in increasing blood pressure and heart 
rate (Mattila, 1963; Risner et al., 1988; Stairs et al., submitted 2005), the safety 
index for nornicotine may be greater than that for nicotine, especially among 
smokers with advanced cardiovascular disease.   
 
 The ability of nornicotine to decrease DAT function in vivo, as shown in 
the present study, may afford another advantage over nicotine as a tobacco use 
cessation agent.  In this respect, the antidepressant agent, bupropion, which 
inhibits both DAT and norepinephrine transporter function (Ascher et al., 1995), 
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has been shown to be efficacious as a tobacco smoking cessation agent (Hurt et 
al., 1997; Jorenby et al., 1999; Shiffman et al., 2000).  Thus, nornicotine 
incorporates both inhibition of DAT function and promotion of DA release 
properties into one molecule, and these pharmacological effects have been 
associated with the clinical efficacy of the currently available tobacco cessation 
products, nicotine and bupropion.   
 
Behavioral studies using animal models also provide support for the use of 
nornicotine as a tobacco use cessation agent.  Nornicotine produces nicotine-like 
discriminative stimulus effects (Rosecrans and Meltzer, 1981; Goldberg, et al., 
1989; Bardo et al., 1997; Desai et al., 1999), as well as nicotine-like effects on 
schedule-controlled operant responding (Risner et al., 1985; 1988).  Recent 
results indicate that nornicotine functions as a positive reinforcer (Bardo et al., 
1999); however, under similar experimental conditions, nornicotine is associated 
with a lower rate of responding in comparison with nicotine (Corrigall and Coen, 
1989; Donny et al., 1995; Bardo et al., 1999), suggesting that nornicotine has a 
lower reinforcing efficacy.  Moreover, nornicotine has been shown to decrease 
self-administration of nicotine in rats (Green et al., 2000).  Furthermore, across 
repeated nornicotine pretreatments, tolerance did not develop to nornicotine-
induced decrease in nicotine self-administration.  Thus, a simple structural 
change, i.e., removal of the N-methyl group from the pyrrolidine ring nitrogen of 
nicotine which affords nornicotine, causes a profound change in its effect on DAT 
function, which may be beneficial with respect to its pharmacological profile.  In 
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summary, the current preclinical results suggest that nornicotine could be a 
promising candidate for development as a smoking cessation agent. 
 
X. Future Directions 
 The current series of experiments demonstrate that nicotine, via a nicotinic 
receptor-mediated mechanism, increased DA clearance in striatum and MPFC.  
It is possible that the difference in the response to nicotine between these brain 
regions is due to the involvement of different nicotinic receptor subtypes.  Thus, 
future studies using various subtype selective antagonists to inhibit the effect of 
nicotine on DAT function would help determine which subtypes are involved in 
modulating DAT.    
 
In the current experiments, nicotine was administered systemically.  
Incubation of synaptosomes from drug naïve animals in vitro with nicotine did not 
result in an increase in the Vmax for [3H]DA uptake.  Because systemic 
administration of nicotine increased both the Vmax for DA uptake in vitro and 
increased DA clearance in vivo, to determine if the effect of nicotine is occurring 
in the striatum, nicotine could be locally applied into the striatum and DA 
clearance determined.  Therefore, the effect of nicotine could be localized to the 
striatum.  Conversely, if local application of nicotine did not increase DA 
clearance, it would suggest the role of circuitry in the effect of nicotine.  Another 
potential way to determine if the effect of nicotine is occurring locally, slices from 
the brain region could be removed and voltammetry performed in the slices.  Use 
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of slices would allow determination of the localization of nicotinic receptors either 
on the DA nerve terminals or if other neurotransmitter systems that may alter 
DAT function.     
 
The increase in the Vmax for [3H]DA uptake was observed in the absence 
of an increase in trafficking of DAT to the cell surface membrane.  The increase 
in Vmax was approximately 25%, which is at the limit of detection for biotinylation 
experiments.  It is possible that increasing the dose of nicotine would lead to a 
further increase in the Vmax.  If the Vmax further increases, it is possible that there 
will be a change in DAT trafficking.  If no change in DAT trafficking persists, it is 
likely that the increase in DAT function is due to the involvement of another 
neurotransmitter system or specific second messenger systems.  Use of slices in 
voltammetric experiments would allow determination of the different mechanisms 
involved in nicotine modulation of DAT function.     
 
One major difference between the in vivo and in vitro experiments is the 
use of anesthetic.  While the anesthetic used in the current experiments, 
urethane, does not appear to affect DAT function (Sabeti et al., 2003), it is 
possible that it is altering other systems that could impact the effect of nicotine or 
the DA system.  To rule out the caveat of using an anesthetic, the effect of 
nicotine on DAT function could be measured using voltammetry in awake 
animals.   
 
  
194 
Finally, the effect of nicotine to increase DAT function by increasing the 
Vmax for DA uptake is important to determine in MPFC.  If there is an increase in 
Vmax, then the ability of nicotine to modulate trafficking of DAT would be important 
to determine.  The limiting factor for using MPFC for the in vitro and trafficking 
experiments is that it requires the use of a large number of animals to obtain 
enough protein to see any effects.   
 
XI.  Final Comments 
 The results of the current experiments in this dissertation project are the 
first to examine the effects of nicotine alone on DAT function in striatum and 
MPFC.  Furthermore, this is the first report examining the mechanism by which 
nicotine does modulate DAT.  Nicotine action on the DA system has been well 
studied with regards to DA release.  However the impact of nicotine action on 
DAT will be an important mechanism that has to be considered not only in how 
nicotine acts but in the treatment of nicotine addiction. 
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Figure 24.  Schematic representation of second messenger pathways 
involved in nicotinic receptor modulation of DAT function. 
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